WO2011151436A2 - Novel compounds, method for use them and pharmaceutical composition containing them - Google Patents
Novel compounds, method for use them and pharmaceutical composition containing them Download PDFInfo
- Publication number
- WO2011151436A2 WO2011151436A2 PCT/EP2011/059181 EP2011059181W WO2011151436A2 WO 2011151436 A2 WO2011151436 A2 WO 2011151436A2 EP 2011059181 W EP2011059181 W EP 2011059181W WO 2011151436 A2 WO2011151436 A2 WO 2011151436A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- haloalkyl
- fluoro
- thiazol
- alkoxyalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 300
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 238000000034 method Methods 0.000 title description 41
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 14
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 14
- 230000002496 gastric effect Effects 0.000 claims abstract description 13
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 434
- 125000001153 fluoro group Chemical group F* 0.000 claims description 331
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 282
- -1 haloalkoxyalkoxy Chemical group 0.000 claims description 269
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 232
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 200
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 192
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 188
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims description 188
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 186
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 130
- 125000001188 haloalkyl group Chemical group 0.000 claims description 118
- 125000003545 alkoxy group Chemical group 0.000 claims description 95
- 150000003839 salts Chemical class 0.000 claims description 80
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 73
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 73
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 70
- 125000004043 oxo group Chemical group O=* 0.000 claims description 70
- 125000000623 heterocyclic group Chemical group 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 125000003118 aryl group Chemical group 0.000 claims description 64
- 239000000651 prodrug Substances 0.000 claims description 61
- 229940002612 prodrug Drugs 0.000 claims description 61
- 239000012453 solvate Substances 0.000 claims description 59
- 125000005843 halogen group Chemical group 0.000 claims description 48
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 claims description 34
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 34
- 125000003282 alkyl amino group Chemical group 0.000 claims description 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 28
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 24
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 24
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 24
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 18
- 125000001769 aryl amino group Chemical group 0.000 claims description 16
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 16
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 16
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 16
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims description 16
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 16
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 16
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 16
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 16
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims description 16
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 16
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 15
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 claims description 15
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 14
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 14
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 11
- 239000004031 partial agonist Substances 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- JRGQSQMWPNWILM-LDQXTDLNSA-N 2-[(3s,4s,5r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-5-hydroxy-2-oxo-4-phenylazepan-3-yl]acetic acid Chemical compound C([C@H]([C@@H]([C@H](CC(O)=O)C1=O)C=2C=CC=CC=2)O)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl JRGQSQMWPNWILM-LDQXTDLNSA-N 0.000 claims description 3
- DBKXOROARXFDKF-SQBLYHGDSA-N 2-[(3s,4s,6s,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](C[C@@H]([C@@H](C1)O)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl DBKXOROARXFDKF-SQBLYHGDSA-N 0.000 claims description 3
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 2
- HRLRLZMBNRAFAU-AEFFLSMTSA-N 2-[(3s,4r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-(oxan-4-yl)-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCOCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1Cl HRLRLZMBNRAFAU-AEFFLSMTSA-N 0.000 claims description 2
- DMSADYSOEDUNSY-AEFFLSMTSA-N 2-[(3s,4r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1Cl DMSADYSOEDUNSY-AEFFLSMTSA-N 0.000 claims description 2
- YMWYDKBJFOTLIK-KNQAVFIVSA-N 2-[(3s,4r)-1-[4-[2-(6-methoxypyridin-3-yl)phenyl]-1,3-thiazol-2-yl]-2-oxo-4-propan-2-ylazocan-3-yl]acetic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@@H](C(C)C)CCCC2)=O)=N1 YMWYDKBJFOTLIK-KNQAVFIVSA-N 0.000 claims description 2
- AORMPLXRPZFJGX-QPPBQGQZSA-N 2-[(3s,4r)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-4-propan-2-ylazocan-3-yl]acetic acid Chemical compound O=C1[C@@H](CC(O)=O)[C@@H](C(C)C)CCCCN1C1=NC(C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)=CS1 AORMPLXRPZFJGX-QPPBQGQZSA-N 0.000 claims description 2
- VYJWYJXSJUUEPW-BVAGGSTKSA-N 2-[(3s,4r)-4-cyclopentyl-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O VYJWYJXSJUUEPW-BVAGGSTKSA-N 0.000 claims description 2
- BFBCTDBDUMCSCZ-NUJGCVRESA-N 2-[(3s,4r,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-7-hydroxy-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)O)CCCC1 BFBCTDBDUMCSCZ-NUJGCVRESA-N 0.000 claims description 2
- IDXNTJRYIVPYML-FMKPAKJESA-N 2-[(3s,4r,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-propan-2-ylazocan-3-yl]acetic acid Chemical compound O=C1[C@@H](CC(O)=O)[C@@H](C(C)C)CC[C@@H](O)CN1C1=NC(C=2C(=CC=CC=2)Cl)=CS1 IDXNTJRYIVPYML-FMKPAKJESA-N 0.000 claims description 2
- BFBCTDBDUMCSCZ-JZXOWHBKSA-N 2-[(3s,4r,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-7-hydroxy-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)O)CCCC1 BFBCTDBDUMCSCZ-JZXOWHBKSA-N 0.000 claims description 2
- LBTXWLSTRIQNJO-MSOLQXFVSA-N 2-[(3s,4s)-1-[4-(2,5-dichlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CCCN1C(SC=1)=NC=1C1=CC(Cl)=CC=C1Cl LBTXWLSTRIQNJO-MSOLQXFVSA-N 0.000 claims description 2
- BVHCTICCDWFJED-MJGOQNOKSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2,7-dioxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CC(=O)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl BVHCTICCDWFJED-MJGOQNOKSA-N 0.000 claims description 2
- HIFCURKONYPZMG-VRAFCGOGSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenyl-7-(propan-2-ylamino)azocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CCC(C1)NC(C)C)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl HIFCURKONYPZMG-VRAFCGOGSA-N 0.000 claims description 2
- ZFTJDJJVJIVUCC-AEFFLSMTSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazepan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl ZFTJDJJVJIVUCC-AEFFLSMTSA-N 0.000 claims description 2
- WTVUKACDKDBHHI-MJGOQNOKSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1Cl WTVUKACDKDBHHI-MJGOQNOKSA-N 0.000 claims description 2
- QBCHXFKQFCDTPG-KVJCIMDZSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6-hydroxy-2-oxo-4-phenylazepan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CC(C1)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl QBCHXFKQFCDTPG-KVJCIMDZSA-N 0.000 claims description 2
- LMPBOTCGEIMKNX-VITQDTLGSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6-hydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@H](CC(O)=O)C1=O)C=2C=CC=CC=2)C(O)CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl LMPBOTCGEIMKNX-VITQDTLGSA-N 0.000 claims description 2
- SJHKLTOVMAPWRI-QIONWKSUSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-fluoro-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CC(F)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl SJHKLTOVMAPWRI-QIONWKSUSA-N 0.000 claims description 2
- PUUUMVZRVPHKSA-QIONWKSUSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CCC(C1)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl PUUUMVZRVPHKSA-QIONWKSUSA-N 0.000 claims description 2
- GANHLDGJPGDPBM-QPPBQGQZSA-N 2-[(3s,4s)-1-[4-[2-(6-methoxypyridin-3-yl)phenyl]-1,3-thiazol-2-yl]-2-oxo-4-phenylazepan-3-yl]acetic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@H](CCC2)C=2C=CC=CC=2)=O)=N1 GANHLDGJPGDPBM-QPPBQGQZSA-N 0.000 claims description 2
- XDVYEQCUICNRLD-NUJYYHISSA-N 2-[(3s,4s)-7-(benzylamino)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CC(NCC=2C=CC=CC=2)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl XDVYEQCUICNRLD-NUJYYHISSA-N 0.000 claims description 2
- PUUUMVZRVPHKSA-LMMKCTJWSA-N 2-[(3s,4s,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CC[C@H](C1)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl PUUUMVZRVPHKSA-LMMKCTJWSA-N 0.000 claims description 2
- PUUUMVZRVPHKSA-SCTDSRPQSA-N 2-[(3s,4s,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CC[C@@H](C1)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl PUUUMVZRVPHKSA-SCTDSRPQSA-N 0.000 claims description 2
- KLZQJNRTEJUPKT-IIFCEKJISA-N 2-[(3z,6s,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-8-oxo-6-phenyl-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)\C=C/CN1C(SC=1)=NC=1C1=CC=CC=C1Cl KLZQJNRTEJUPKT-IIFCEKJISA-N 0.000 claims description 2
- MRICGOKABUOYKK-QPPBQGQZSA-N 2-[(5s,6s)-1-[4-[2-(6-methoxypyridin-3-yl)phenyl]-1,3-thiazol-2-yl]-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@H](C=CC2)C=2C=CC=CC=2)=O)=N1 MRICGOKABUOYKK-QPPBQGQZSA-N 0.000 claims description 2
- GCQGMICAJCDECM-UHFFFAOYSA-N 2-[4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-cyclopentyl-3,8-dioxo-1,4-diazocan-2-yl]acetic acid Chemical compound O=C1CCCN(C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)C(=O)C(CC(=O)O)N1C1CCCC1 GCQGMICAJCDECM-UHFFFAOYSA-N 0.000 claims description 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- XELOVLWJBPDZBE-RUZDIDTESA-N 2-[(2r)-1-cyclopentyl-3,8-dioxo-4-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-1,4-diazocan-2-yl]acetic acid Chemical compound N1([C@@H](C(N(C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CCCC1=O)=O)CC(=O)O)C1CCCC1 XELOVLWJBPDZBE-RUZDIDTESA-N 0.000 claims 1
- CAYSFMGHSUINCC-QGZVFWFLSA-N 2-[(2r)-4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-(2-methylpropyl)-3,8-dioxo-1,4-diazocan-2-yl]acetic acid Chemical compound C1CCC(=O)N(CC(C)C)[C@H](CC(O)=O)C(=O)N1C1=NC(C=2C(=CC=CC=2)Cl)=CS1 CAYSFMGHSUINCC-QGZVFWFLSA-N 0.000 claims 1
- CNPIMYFUZSJAGH-LJQANCHMSA-N 2-[(2r)-4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-(cyclopentylmethyl)-3,8-dioxo-1,4-diazocan-2-yl]acetic acid Chemical compound N1([C@@H](C(N(C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CCCC1=O)=O)CC(=O)O)CC1CCCC1 CNPIMYFUZSJAGH-LJQANCHMSA-N 0.000 claims 1
- RDABUATXYWJHJH-QGZVFWFLSA-N 2-[(2r)-4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-1-cyclopentyl-3,7-dioxo-1,4-diazepan-2-yl]acetic acid Chemical compound N1([C@@H](C(N(C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CCC1=O)=O)CC(=O)O)C1CCCC1 RDABUATXYWJHJH-QGZVFWFLSA-N 0.000 claims 1
- MEMLLINOKKYJKT-MRXNPFEDSA-N 2-[(2r)-4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-3,8-dioxo-1-propan-2-yl-1,4-diazocan-2-yl]acetic acid Chemical compound C1CCC(=O)N(C(C)C)[C@H](CC(O)=O)C(=O)N1C1=NC(C=2C(=CC=CC=2)Cl)=CS1 MEMLLINOKKYJKT-MRXNPFEDSA-N 0.000 claims 1
- OPXBAZYJFVUOKA-NOOIUNMQSA-N 2-[(2r,5s,6s)-5-cyclopentyl-2-(hydroxymethyl)-7-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C1([C@H]2C=C[C@@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 OPXBAZYJFVUOKA-NOOIUNMQSA-N 0.000 claims 1
- YTGRTFRPPFJRII-VRPIGFSUSA-N 2-[(2s,3z,6r,7s)-6-cyclopentyl-2-(hydroxymethyl)-8-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C1([C@H]2C\C=C/[C@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 YTGRTFRPPFJRII-VRPIGFSUSA-N 0.000 claims 1
- NJXROSMVRGASBX-SCTDSRPQSA-N 2-[(2s,5s,6s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-(hydroxymethyl)-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](C=C[C@H]1CO)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl NJXROSMVRGASBX-SCTDSRPQSA-N 0.000 claims 1
- OPXBAZYJFVUOKA-FBILRYNDSA-N 2-[(2s,5s,6s)-5-cyclopentyl-2-(hydroxymethyl)-7-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C1([C@H]2C=C[C@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 OPXBAZYJFVUOKA-FBILRYNDSA-N 0.000 claims 1
- CMMZMIIZMHGSBO-ZBFHGGJFSA-N 2-[(3S,4R)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopropyl-2-oxoazocan-3-yl]acetic acid Chemical compound OC(=O)C[C@H]1[C@H](CCCCN(c2nc(cs2)-c2ccccc2Cl)C1=O)C1CC1 CMMZMIIZMHGSBO-ZBFHGGJFSA-N 0.000 claims 1
- KPWMMFNGOUMHLH-OASJLCFRSA-N 2-[(3S,4R,8R)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound OC[C@H]1CCC[C@H](C2CCCC2)[C@H](CC(O)=O)C(=O)N1c1nc(cs1)-c1ccccc1-c1ccc(nc1)N1CCCC1=O KPWMMFNGOUMHLH-OASJLCFRSA-N 0.000 claims 1
- UMNPHRHNKYMWJW-WBVHZDCISA-N 2-[(3s,4r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclobutyl-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1Cl UMNPHRHNKYMWJW-WBVHZDCISA-N 0.000 claims 1
- LRJIDOKKOHFEIN-XLIONFOSSA-N 2-[(3s,4r)-1-[4-[2-(5-methoxypyrazin-2-yl)phenyl]-1,3-thiazol-2-yl]-2-oxo-4-propan-2-ylazocan-3-yl]acetic acid Chemical compound C1=NC(OC)=CN=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@@H](C(C)C)CCCC2)=O)=N1 LRJIDOKKOHFEIN-XLIONFOSSA-N 0.000 claims 1
- ZORSIABRHJJLTE-RDGATRHJSA-N 2-[(3s,4r)-4-cyclobutyl-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O ZORSIABRHJJLTE-RDGATRHJSA-N 0.000 claims 1
- FUVJOJXXPHZEAV-KNQAVFIVSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-(5-methoxypyrazin-2-yl)phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound C1=NC(OC)=CN=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)CCCC2)=O)=N1 FUVJOJXXPHZEAV-KNQAVFIVSA-N 0.000 claims 1
- IQOUQEYXSKYOPR-KNQAVFIVSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-(6-methoxypyridazin-3-yl)phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound N1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)CCCC2)=O)=N1 IQOUQEYXSKYOPR-KNQAVFIVSA-N 0.000 claims 1
- QDIBSAURKQRAOT-ZSQFBXSQSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-[6-[(3r)-3-fluoro-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CC[C@@H](F)C1=O QDIBSAURKQRAOT-ZSQFBXSQSA-N 0.000 claims 1
- PQVJHVRHYYHFPS-DBTWGZIYSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-[6-[(3r)-3-methyl-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound O=C1[C@H](C)CCN1C1=CC=C(C=2C(=CC=CC=2)C=2N=C(SC=2)N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)CCCC2)=O)C=N1 PQVJHVRHYYHFPS-DBTWGZIYSA-N 0.000 claims 1
- QDIBSAURKQRAOT-RZFJZAQRSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-[6-[(3s)-3-fluoro-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CC[C@H](F)C1=O QDIBSAURKQRAOT-RZFJZAQRSA-N 0.000 claims 1
- PQVJHVRHYYHFPS-WBWMCNGVSA-N 2-[(3s,4r)-4-cyclopentyl-1-[4-[2-[6-[(3s)-3-methyl-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound O=C1[C@@H](C)CCN1C1=CC=C(C=2C(=CC=CC=2)C=2N=C(SC=2)N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)CCCC2)=O)C=N1 PQVJHVRHYYHFPS-WBWMCNGVSA-N 0.000 claims 1
- MUNMLSCCNPDWKI-RDGATRHJSA-N 2-[(3s,4r)-4-cyclopentyl-1-[5-fluoro-4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-2-oxoazocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SC=1F)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O MUNMLSCCNPDWKI-RDGATRHJSA-N 0.000 claims 1
- LYLQXYCBZIPAHT-RDGATRHJSA-N 2-[(3s,4r)-4-cyclopentyl-2-oxo-1-[3-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,2,4-thiadiazol-5-yl]azocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCCN1C(SN=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O LYLQXYCBZIPAHT-RDGATRHJSA-N 0.000 claims 1
- GSKAGODUUZUGDT-QPPBQGQZSA-N 2-[(3s,4r)-4-cyclopropyl-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CC2)CCCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O GSKAGODUUZUGDT-QPPBQGQZSA-N 0.000 claims 1
- TXWAAMLBXDXYPD-SUMDDJOVSA-N 2-[(3s,4r,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-7-(hydroxymethyl)-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CO)CCCC1 TXWAAMLBXDXYPD-SUMDDJOVSA-N 0.000 claims 1
- RVCMWBPAAMCHBS-LMMKCTJWSA-N 2-[(3s,4r,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-7-(methanesulfonamido)-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)NS(=O)(=O)C)CCCC1 RVCMWBPAAMCHBS-LMMKCTJWSA-N 0.000 claims 1
- YYWMSCQLCCRYMC-NOOIUNMQSA-N 2-[(3s,4r,7r)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azepan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 YYWMSCQLCCRYMC-NOOIUNMQSA-N 0.000 claims 1
- PIMKFGKXLOAORF-RMXYQJDTSA-N 2-[(3s,4r,7r)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 PIMKFGKXLOAORF-RMXYQJDTSA-N 0.000 claims 1
- JJBDVTSKRULZOM-HYZYYIOASA-N 2-[(3s,4r,7r)-4-cyclopentyl-7-(methanesulfonamido)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)NS(=O)(=O)C)CCCC1 JJBDVTSKRULZOM-HYZYYIOASA-N 0.000 claims 1
- GXZWEDRUOMGLJX-GGPKGHCWSA-N 2-[(3s,4r,7r)-7-acetamido-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)NC(=O)C)CCCC1 GXZWEDRUOMGLJX-GGPKGHCWSA-N 0.000 claims 1
- ACVVNSMRMCHWSB-INOCPDNRSA-N 2-[(3s,4r,7r)-7-acetamido-4-cyclopentyl-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)NC(=O)C)CCCC1 ACVVNSMRMCHWSB-INOCPDNRSA-N 0.000 claims 1
- TXWAAMLBXDXYPD-WDYCEAGBSA-N 2-[(3s,4r,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-7-(hydroxymethyl)-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CO)CCCC1 TXWAAMLBXDXYPD-WDYCEAGBSA-N 0.000 claims 1
- YYWMSCQLCCRYMC-FBILRYNDSA-N 2-[(3s,4r,7s)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azepan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 YYWMSCQLCCRYMC-FBILRYNDSA-N 0.000 claims 1
- PIMKFGKXLOAORF-BBVXACFBSA-N 2-[(3s,4r,7s)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C1([C@H]2CC[C@@H](CN(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 PIMKFGKXLOAORF-BBVXACFBSA-N 0.000 claims 1
- UPFMKXINPNFSNT-LMMKCTJWSA-N 2-[(3s,4r,8r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-8-(hydroxymethyl)-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CCC[C@@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CO)CCCC1 UPFMKXINPNFSNT-LMMKCTJWSA-N 0.000 claims 1
- UPFMKXINPNFSNT-SCTDSRPQSA-N 2-[(3s,4r,8s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-4-cyclopentyl-8-(hydroxymethyl)-2-oxoazocan-3-yl]acetic acid Chemical compound C1([C@H]2CCC[C@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)CO)CCCC1 UPFMKXINPNFSNT-SCTDSRPQSA-N 0.000 claims 1
- KPWMMFNGOUMHLH-XFAFFCHDSA-N 2-[(3s,4r,8s)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]azocan-3-yl]acetic acid Chemical compound C1([C@H]2CCC[C@H](N(C(=O)[C@H]2CC(O)=O)C=2SC=C(N=2)C=2C(=CC=CC=2)C=2C=NC(=CC=2)N2C(CCC2)=O)CO)CCCC1 KPWMMFNGOUMHLH-XFAFFCHDSA-N 0.000 claims 1
- RXWFXYLUUHGLFH-QDKIRNHSSA-N 2-[(3s,4s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-(hydroxymethyl)-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CCC(C1)CO)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl RXWFXYLUUHGLFH-QDKIRNHSSA-N 0.000 claims 1
- MBZXWVOIWYEUEK-VWNXMTODSA-N 2-[(3s,4s)-4-(2-chlorophenyl)-1-[4-(2-methoxyphenyl)phenyl]-2-oxoazocan-3-yl]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=C(N2C([C@@H](CC(O)=O)[C@H](CCCC2)C=2C(=CC=CC=2)Cl)=O)C=C1 MBZXWVOIWYEUEK-VWNXMTODSA-N 0.000 claims 1
- WBVAUVQEIBUVHH-QIONWKSUSA-N 2-[(3s,4s)-7-amino-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CCC(C1)N)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl WBVAUVQEIBUVHH-QIONWKSUSA-N 0.000 claims 1
- DBKXOROARXFDKF-OVQGTLEDSA-N 2-[(3s,4s,6r,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](C[C@H]([C@H](C1)O)O)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl DBKXOROARXFDKF-OVQGTLEDSA-N 0.000 claims 1
- DFBYENQXIUQXFI-GGPKGHCWSA-N 2-[(3s,4s,7r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-(methanesulfonamido)-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CC[C@H](C1)NS(=O)(=O)C)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl DFBYENQXIUQXFI-GGPKGHCWSA-N 0.000 claims 1
- OEBAPNBOQUUCKG-SBHAEUEKSA-N 2-[(3s,4s,7r)-7-acetamido-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenylazocan-3-yl]acetic acid Chemical compound O=C([C@@H](CC(O)=O)[C@H](CC[C@H](C1)NC(=O)C)C=2C=CC=CC=2)N1C(SC=1)=NC=1C1=CC=CC=C1Cl OEBAPNBOQUUCKG-SBHAEUEKSA-N 0.000 claims 1
- JCOBMHPNLBKAQB-MXTKCAFNSA-N 2-[(3z,6r,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6-cyclobutyl-8-oxo-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCC2)\C=C/CN1C(SC=1)=NC=1C1=CC=CC=C1Cl JCOBMHPNLBKAQB-MXTKCAFNSA-N 0.000 claims 1
- NDNPTDJRCPUIOB-ZRBYZBAOSA-N 2-[(3z,6r,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-8-oxo-6-propan-2-yl-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound O=C1[C@@H](CC(O)=O)[C@@H](C(C)C)C\C=C/CN1C1=NC(C=2C(=CC=CC=2)Cl)=CS1 NDNPTDJRCPUIOB-ZRBYZBAOSA-N 0.000 claims 1
- INEWDSUFMPHIMW-TWSMFDHCSA-N 2-[(3z,6r,7s)-6-cyclopentyl-1-[4-[2-[6-[(3r)-3-methyl-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-8-oxo-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound O=C1[C@H](C)CCN1C1=CC=C(C=2C(=CC=CC=2)C=2N=C(SC=2)N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)C\C=C/C2)=O)C=N1 INEWDSUFMPHIMW-TWSMFDHCSA-N 0.000 claims 1
- INEWDSUFMPHIMW-VPODHVIVSA-N 2-[(3z,6r,7s)-6-cyclopentyl-1-[4-[2-[6-[(3s)-3-methyl-2-oxopyrrolidin-1-yl]pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-8-oxo-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound O=C1[C@@H](C)CCN1C1=CC=C(C=2C(=CC=CC=2)C=2N=C(SC=2)N2C([C@@H](CC(O)=O)[C@@H](C3CCCC3)C\C=C/C2)=O)C=N1 INEWDSUFMPHIMW-VPODHVIVSA-N 0.000 claims 1
- KXWJVJLTARCVRE-MGBKSAOESA-N 2-[(3z,6r,7s)-6-cyclopentyl-8-oxo-1-(4-phenyl-1,3-thiazol-2-yl)-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)\C=C/CN1C(SC=1)=NC=1C1=CC=CC=C1 KXWJVJLTARCVRE-MGBKSAOESA-N 0.000 claims 1
- MLOUECFPVUUYCB-KKSLTYSGSA-N 2-[(3z,6s,7s)-1-[4-(2,5-dichlorophenyl)-1,3-thiazol-2-yl]-8-oxo-6-phenyl-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)\C=C/CN1C(SC=1)=NC=1C1=CC(Cl)=CC=C1Cl MLOUECFPVUUYCB-KKSLTYSGSA-N 0.000 claims 1
- VQKNLIXOUQWAMV-FHYYHZITSA-N 2-[(3z,6s,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6-(2-methylpropyl)-8-oxo-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound O=C1[C@@H](CC(O)=O)[C@@H](CC(C)C)C\C=C/CN1C1=NC(C=2C(=CC=CC=2)Cl)=CS1 VQKNLIXOUQWAMV-FHYYHZITSA-N 0.000 claims 1
- GTWAVCXEBLPCOP-RBISFHTESA-N 2-[(5r,6s)-5-cyclopentyl-3,7-dioxo-1-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-1,4-diazepan-6-yl]acetic acid Chemical compound N([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)C(=O)CN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O GTWAVCXEBLPCOP-RBISFHTESA-N 0.000 claims 1
- QSZACIGJZZNJAI-MGPUTAFESA-N 2-[(5s,6s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-3,7-dioxo-5-phenyl-1,4-diazepan-6-yl]acetic acid Chemical compound N([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)C(=O)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl QSZACIGJZZNJAI-MGPUTAFESA-N 0.000 claims 1
- LOBBJOAAHKDBMS-NEKDWFFYSA-N 2-[(6s,7r)-7-cyclopentyl-5-oxo-4-[4-[2-[6-(2-oxopyrrolidin-1-yl)pyridin-3-yl]phenyl]-1,3-thiazol-2-yl]-1,4-oxazepan-6-yl]acetic acid Chemical compound O([C@@H]([C@@H](C1=O)CC(=O)O)C2CCCC2)CCN1C(SC=1)=NC=1C1=CC=CC=C1C(C=N1)=CC=C1N1CCCC1=O LOBBJOAAHKDBMS-NEKDWFFYSA-N 0.000 claims 1
- UFQRNUQZIFHDAK-AEFFLSMTSA-N 2-[(6s,7s)-4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2,5-dioxo-7-phenyl-1,4-diazonan-6-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)CNC(=O)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl UFQRNUQZIFHDAK-AEFFLSMTSA-N 0.000 claims 1
- UFQRNUQZIFHDAK-UHFFFAOYSA-N 2-[4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2,5-dioxo-7-phenyl-1,4-diazonan-6-yl]acetic acid Chemical compound O=C1C(CC(=O)O)C(C=2C=CC=CC=2)CCNC(=O)CN1C(SC=1)=NC=1C1=CC=CC=C1Cl UFQRNUQZIFHDAK-UHFFFAOYSA-N 0.000 claims 1
- QYIWFCSWDIVYDP-UHFFFAOYSA-N 2-[4-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-3,8-dioxo-1-phenyl-1,4-diazocan-2-yl]acetic acid Chemical compound O=C1CCCN(C=2SC=C(N=2)C=2C(=CC=CC=2)Cl)C(=O)C(CC(=O)O)N1C1=CC=CC=C1 QYIWFCSWDIVYDP-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 97
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 94
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 86
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 76
- 238000003786 synthesis reaction Methods 0.000 description 74
- 230000015572 biosynthetic process Effects 0.000 description 73
- 239000000243 solution Substances 0.000 description 70
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- 238000007429 general method Methods 0.000 description 56
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000007787 solid Substances 0.000 description 32
- 101710142059 Free fatty acid receptor 2 Proteins 0.000 description 31
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 31
- 239000004698 Polyethylene Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 0 *C(*)=C(*)N=*C(c1c(-c2c(*)[s]c(*[Al])n2)c(*)c(*)c(*)c1*)=I Chemical compound *C(*)=C(*)N=*C(c1c(-c2c(*)[s]c(*[Al])n2)c(*)c(*)c(*)c1*)=I 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 11
- 125000002757 morpholinyl group Chemical group 0.000 description 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 125000000335 thiazolyl group Chemical group 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 235000021588 free fatty acids Nutrition 0.000 description 9
- 238000005984 hydrogenation reaction Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 7
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 125000000160 oxazolidinyl group Chemical group 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 5
- MXWMFBYWXMXRPD-RXMQYKEDSA-N (2r)-2-azaniumyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)C[C@@H](N)C(O)=O MXWMFBYWXMXRPD-RXMQYKEDSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- KHTYRMNJWARHQK-CABCVRRESA-N (2s,3s)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-phenylhex-5-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@H](CC=C)C1=CC=CC=C1 KHTYRMNJWARHQK-CABCVRRESA-N 0.000 description 3
- MPRHIJJKVGFXRS-AATRIKPKSA-N (e)-3-cyclopentylprop-2-enoic acid Chemical compound OC(=O)\C=C\C1CCCC1 MPRHIJJKVGFXRS-AATRIKPKSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 150000008062 acetophenones Chemical class 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- DKBNVGOWHNOALZ-VOTSOKGWSA-N methyl (e)-3-cyclopentylprop-2-enoate Chemical compound COC(=O)\C=C\C1CCCC1 DKBNVGOWHNOALZ-VOTSOKGWSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CNSCUAYYHRJIRJ-VRAFCGOGSA-N tert-butyl 2-[(3S,4S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](CCC(O)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 CNSCUAYYHRJIRJ-VRAFCGOGSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- TZUSDNJLHZVZMX-SNVBAGLBSA-N (2r)-2-(cyclopentylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)NC1CCCC1 TZUSDNJLHZVZMX-SNVBAGLBSA-N 0.000 description 2
- JWRBSVRDVDBQOA-KRWDZBQOSA-N (4s)-4-benzyl-3-(3-phenylprop-2-enoyl)-1,3-oxazolidin-2-one Chemical compound C([C@@H]1CC=2C=CC=CC=2)OC(=O)N1C(=O)C=CC1=CC=CC=C1 JWRBSVRDVDBQOA-KRWDZBQOSA-N 0.000 description 2
- AGRLRONEERCSGJ-PMACEKPBSA-N (4s)-4-benzyl-3-[(3s)-3-phenylhex-5-enoyl]-1,3-oxazolidin-2-one Chemical compound C([C@@H]1N(C(OC1)=O)C(=O)C[C@H](CC=C)C=1C=CC=CC=1)C1=CC=CC=C1 AGRLRONEERCSGJ-PMACEKPBSA-N 0.000 description 2
- IUSFLWRQSGVDDY-AATRIKPKSA-N (e)-3-cyclopentylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1CCCC1 IUSFLWRQSGVDDY-AATRIKPKSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- QKIMOGJXYIHKBY-UHFFFAOYSA-N 2-[4-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]amino]butanoyl-cyclopentylamino]-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound N=1C(C=2C(=CC=CC=2)Cl)=CSC=1NCCCC(=O)N(C(CC(=O)OC(C)(C)C)C(O)=O)C1CCCC1 QKIMOGJXYIHKBY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- HWJRGSBTVDMYBC-LLVKDONJSA-N 4-o-tert-butyl 1-o-methyl (2r)-2-(cyclopentylamino)butanedioate Chemical compound CC(C)(C)OC(=O)C[C@H](C(=O)OC)NC1CCCC1 HWJRGSBTVDMYBC-LLVKDONJSA-N 0.000 description 2
- CAXDOLCVRMCKFS-CQSZACIVSA-N 4-o-tert-butyl 1-o-methyl (2r)-2-[cyclopentyl(4-oxobutanoyl)amino]butanedioate Chemical compound CC(C)(C)OC(=O)C[C@H](C(=O)OC)N(C(=O)CCC=O)C1CCCC1 CAXDOLCVRMCKFS-CQSZACIVSA-N 0.000 description 2
- DJNCIACWVSMYGK-OAHLLOKOSA-N 4-o-tert-butyl 1-o-methyl (2r)-2-[cyclopentyl(pent-4-enoyl)amino]butanedioate Chemical compound CC(C)(C)OC(=O)C[C@H](C(=O)OC)N(C(=O)CCC=C)C1CCCC1 DJNCIACWVSMYGK-OAHLLOKOSA-N 0.000 description 2
- CMRVIYSFXFDEBJ-UHFFFAOYSA-N 4-o-tert-butyl 1-o-methyl 2-[4-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]amino]butanoyl-cyclopentylamino]butanedioate Chemical compound N=1C(C=2C(=CC=CC=2)Cl)=CSC=1NCCCC(=O)N(C(CC(=O)OC(C)(C)C)C(=O)OC)C1CCCC1 CMRVIYSFXFDEBJ-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 2
- 102100040136 Free fatty acid receptor 3 Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 2
- 101000890662 Homo sapiens Free fatty acid receptor 3 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003243 anti-lipolytic effect Effects 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 2
- 150000005347 biaryls Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 150000005363 heterobiaryls Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000002794 lymphocyte assay Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FCSCCYPHWDWTSB-IRLDBZIGSA-N tert-butyl 2-[(3S,4S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2,7-dioxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](CCC(=O)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 FCSCCYPHWDWTSB-IRLDBZIGSA-N 0.000 description 2
- XGIPHAWWQKCZBL-WXPBMIAQSA-N tert-butyl 2-[(3S,4S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6-hydroxy-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](CC(O)CCN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 XGIPHAWWQKCZBL-WXPBMIAQSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- LLJFNWVJKMVHIL-UHFFFAOYSA-N (2-methoxy-2-oxoethyl)phosphonic acid Chemical compound COC(=O)CP(O)(O)=O LLJFNWVJKMVHIL-UHFFFAOYSA-N 0.000 description 1
- CIVBTRHLYKWPOI-LLVKDONJSA-N (2r)-2-anilino-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)NC1=CC=CC=C1 CIVBTRHLYKWPOI-LLVKDONJSA-N 0.000 description 1
- DZWMOIJNVNDEIX-UONOGXRCSA-N (2r,3r)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-phenylpent-4-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@@H](C(O)=O)[C@@H](C=C)C1=CC=CC=C1 DZWMOIJNVNDEIX-UONOGXRCSA-N 0.000 description 1
- DZWMOIJNVNDEIX-ZIAGYGMSSA-N (2r,3s)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-phenylpent-4-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@@H](C(O)=O)[C@H](C=C)C1=CC=CC=C1 DZWMOIJNVNDEIX-ZIAGYGMSSA-N 0.000 description 1
- SJADWXWTERNMNA-KGLIPLIRSA-N (2s,3r)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-(oxan-4-yl)hex-5-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@H](CC=C)C1CCOCC1 SJADWXWTERNMNA-KGLIPLIRSA-N 0.000 description 1
- DZWMOIJNVNDEIX-KBPBESRZSA-N (2s,3r)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-phenylpent-4-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@@H](C=C)C1=CC=CC=C1 DZWMOIJNVNDEIX-KBPBESRZSA-N 0.000 description 1
- VLKBSVCQSSNGPP-NEPJUHHUSA-N (2s,3r)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-propan-2-ylhex-5-enoic acid Chemical compound C=CC[C@H](C(C)C)[C@@H](C(O)=O)CC(=O)OC(C)(C)C VLKBSVCQSSNGPP-NEPJUHHUSA-N 0.000 description 1
- GEZAJXOHWUEPBG-KGLIPLIRSA-N (2s,3r)-3-cyclopentyl-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]hex-5-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@H](CC=C)C1CCCC1 GEZAJXOHWUEPBG-KGLIPLIRSA-N 0.000 description 1
- YAPNFRDQXZPYLG-NEPJUHHUSA-N (2s,3r)-3-cyclopropyl-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]hex-5-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@H](CC=C)C1CC1 YAPNFRDQXZPYLG-NEPJUHHUSA-N 0.000 description 1
- MLHAVSGIESMOGJ-OLZOCXBDSA-N (2s,3s)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-(2-methylpropyl)hex-5-enoic acid Chemical compound CC(C)C[C@@H](CC=C)[C@@H](C(O)=O)CC(=O)OC(C)(C)C MLHAVSGIESMOGJ-OLZOCXBDSA-N 0.000 description 1
- HETWKGPDWLBBHK-RTWAWAEBSA-N (2s,3s)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-(4-phenylphenyl)hex-5-enoic acid Chemical compound C1=CC([C@@H](CC=C)[C@H](CC(=O)OC(C)(C)C)C(O)=O)=CC=C1C1=CC=CC=C1 HETWKGPDWLBBHK-RTWAWAEBSA-N 0.000 description 1
- DZWMOIJNVNDEIX-KGLIPLIRSA-N (2s,3s)-2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-3-phenylpent-4-enoic acid Chemical compound CC(C)(C)OC(=O)C[C@H](C(O)=O)[C@H](C=C)C1=CC=CC=C1 DZWMOIJNVNDEIX-KGLIPLIRSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000004815 1,2-dimethylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([*:2])C([H])([H])[H] 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- XUKOPQAHBZWVFI-BFUGUPBASA-N 2-[(3z,6s,7s)-1-[4-[2-(6-methoxypyridin-3-yl)phenyl]-1,3-thiazol-2-yl]-8-oxo-6-phenyl-2,5,6,7-tetrahydroazocin-7-yl]acetic acid Chemical compound C1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N2C([C@@H](CC(O)=O)[C@H](C\C=C/C2)C=2C=CC=CC=2)=O)=N1 XUKOPQAHBZWVFI-BFUGUPBASA-N 0.000 description 1
- NQEIXEUHGORMAD-PGGFHSQXSA-N 2-[(4z,7s,8s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-9-oxo-7-phenyl-3,6,7,8-tetrahydro-2h-azonin-8-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)\C=C/CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl NQEIXEUHGORMAD-PGGFHSQXSA-N 0.000 description 1
- BUSSFLGFRXQVGF-FUHWJXTLSA-N 2-[(5r,6r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C([C@H]([C@H](C1=O)CC(=O)O)C=2C=CC=CC=2)=CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl BUSSFLGFRXQVGF-FUHWJXTLSA-N 0.000 description 1
- BUSSFLGFRXQVGF-WMZOPIPTSA-N 2-[(5r,6s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C([C@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)=CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl BUSSFLGFRXQVGF-WMZOPIPTSA-N 0.000 description 1
- BUSSFLGFRXQVGF-SJLPKXTDSA-N 2-[(5s,6r)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C([C@@H]([C@H](C1=O)CC(=O)O)C=2C=CC=CC=2)=CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl BUSSFLGFRXQVGF-SJLPKXTDSA-N 0.000 description 1
- BUSSFLGFRXQVGF-AEFFLSMTSA-N 2-[(5s,6s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-oxo-5-phenyl-5,6-dihydro-2h-azepin-6-yl]acetic acid Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)O)C=2C=CC=CC=2)=CCN1C(SC=1)=NC=1C1=CC=CC=C1Cl BUSSFLGFRXQVGF-AEFFLSMTSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WZWWEVCLPKAQTA-UHFFFAOYSA-N 2-bromo-1-(2-chlorophenyl)ethanone Chemical compound ClC1=CC=CC=C1C(=O)CBr WZWWEVCLPKAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- XIZXADDGOCJZAL-UHFFFAOYSA-N 3h-dioxole-5-carboxylic acid Chemical class OC(=O)C1=CCOO1 XIZXADDGOCJZAL-UHFFFAOYSA-N 0.000 description 1
- HBAOQMFTWSDKDV-UHFFFAOYSA-N 4-(2-bromophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=CC=2)Br)=C1 HBAOQMFTWSDKDV-UHFFFAOYSA-N 0.000 description 1
- GWXQQHVBVMLZLU-UHFFFAOYSA-N 4-(2-chlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=CC=2)Cl)=C1 GWXQQHVBVMLZLU-UHFFFAOYSA-N 0.000 description 1
- MYAAMOSMVGVCBY-UHFFFAOYSA-N 4-(2-fluorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=CC=2)F)=C1 MYAAMOSMVGVCBY-UHFFFAOYSA-N 0.000 description 1
- WNRZCGGMNRPFDK-UHFFFAOYSA-N 4-[2-(6-methoxypyridin-3-yl)phenyl]-1,3-thiazol-2-amine Chemical compound C1=NC(OC)=CC=C1C1=CC=CC=C1C1=CSC(N)=N1 WNRZCGGMNRPFDK-UHFFFAOYSA-N 0.000 description 1
- DYPOEZITRKQUGB-UHFFFAOYSA-N 4-methoxy-4-oxo-3-[4-oxobutanoyl(propan-2-yl)amino]butanoic acid Chemical compound COC(=O)C(CC(O)=O)N(C(C)C)C(=O)CCC=O DYPOEZITRKQUGB-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- CAXDOLCVRMCKFS-UHFFFAOYSA-N 4-o-tert-butyl 1-o-methyl 2-[cyclopentyl(4-oxobutanoyl)amino]butanedioate Chemical compound CC(C)(C)OC(=O)CC(C(=O)OC)N(C(=O)CCC=O)C1CCCC1 CAXDOLCVRMCKFS-UHFFFAOYSA-N 0.000 description 1
- JYBAIHMFQFITNQ-UHFFFAOYSA-N 4-o-tert-butyl 1-o-methyl 2-[n-(4-oxobutanoyl)anilino]butanedioate Chemical compound CC(C)(C)OC(=O)CC(C(=O)OC)N(C(=O)CCC=O)C1=CC=CC=C1 JYBAIHMFQFITNQ-UHFFFAOYSA-N 0.000 description 1
- FREHXEYAZAQJFE-UHFFFAOYSA-N 4-phenyl-n-prop-2-enyl-1,3-thiazol-2-amine Chemical compound S1C(NCC=C)=NC(C=2C=CC=CC=2)=C1 FREHXEYAZAQJFE-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N 4-thiomorpholin-4-ylsulfinylthiomorpholine Chemical compound C1CSCCN1S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N 4-thiomorpholin-4-ylsulfonylthiomorpholine Chemical compound C1CSCCN1S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- SWICXAJWFSOBKJ-UHFFFAOYSA-N 5-(2-chlorophenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC=C1C1=CC=CC=C1Cl SWICXAJWFSOBKJ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- BJESOMSWQYFSPW-VIFPVBQESA-N C=C[C@@H](CO)Nc1nc(-c2ccccc2Cl)c[s]1 Chemical compound C=C[C@@H](CO)Nc1nc(-c2ccccc2Cl)c[s]1 BJESOMSWQYFSPW-VIFPVBQESA-N 0.000 description 1
- PNJXYVJNOCLJLJ-MRVPVSSYSA-N CC(C)(C)OC(N1C(C)(C)OC[C@H]1C=O)=O Chemical compound CC(C)(C)OC(N1C(C)(C)OC[C@H]1C=O)=O PNJXYVJNOCLJLJ-MRVPVSSYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- XDDFSGQCTAMHGZ-UHFFFAOYSA-N Clc1ccccc1-c1c[s]c(Br)n1 Chemical compound Clc1ccccc1-c1c[s]c(Br)n1 XDDFSGQCTAMHGZ-UHFFFAOYSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 206010052402 Gastrointestinal hypermotility Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N O=C(c1ccccc1)N=C=S Chemical compound O=C(c1ccccc1)N=C=S CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- KBZZHUDLCWWLTF-WQKGLNPUSA-N OCC(C=CC(C1)[C@]1([C@@H]1CC(O)=O)c2ccccc2)N(c2nc(-c(cccc3)c3Cl)c[s]2)C1=O Chemical compound OCC(C=CC(C1)[C@]1([C@@H]1CC(O)=O)c2ccccc2)N(c2nc(-c(cccc3)c3Cl)c[s]2)C1=O KBZZHUDLCWWLTF-WQKGLNPUSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HTKFORQRBXIQHD-UHFFFAOYSA-N allylthiourea Chemical compound NC(=S)NCC=C HTKFORQRBXIQHD-UHFFFAOYSA-N 0.000 description 1
- 229960001748 allylthiourea Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- DQEUYIQDSMINEY-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C=C DQEUYIQDSMINEY-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- JDKQTIKEGOOXTJ-UHFFFAOYSA-N pent-4-enoyl chloride Chemical compound ClC(=O)CCC=C JDKQTIKEGOOXTJ-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 208000024981 pyrosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- NNTYBUBZPCVRJL-VXNXHJTFSA-N tert-butyl (3s,4s)-3-[(4s)-4-benzyl-2-oxo-1,3-oxazolidine-3-carbonyl]-4-phenylhept-6-enoate Chemical compound C1([C@@H](CC=C)[C@H](CC(=O)OC(C)(C)C)C(=O)N2C(OC[C@@H]2CC=2C=CC=CC=2)=O)=CC=CC=C1 NNTYBUBZPCVRJL-VXNXHJTFSA-N 0.000 description 1
- NNTYBUBZPCVRJL-XAGPSQNTSA-N tert-butyl (4s)-3-[(4s)-4-benzyl-2-oxo-1,3-oxazolidine-3-carbonyl]-4-phenylhept-6-enoate Chemical compound C1([C@@H](CC=C)C(CC(=O)OC(C)(C)C)C(=O)N2C(OC[C@@H]2CC=2C=CC=CC=2)=O)=CC=CC=C1 NNTYBUBZPCVRJL-XAGPSQNTSA-N 0.000 description 1
- DJJIXKYZANDHOZ-OMQKAAQBSA-N tert-butyl 2-[(3S,4S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-2-oxo-4-phenyl-7-(propan-2-ylamino)azocan-3-yl]acetate Chemical compound CC(C)NC1CC[C@@H]([C@H](CC(=O)OC(C)(C)C)C(=O)N(C1)c1nc(cs1)-c1ccccc1Cl)c1ccccc1 DJJIXKYZANDHOZ-OMQKAAQBSA-N 0.000 description 1
- RZBLCXAXAZEJJZ-VRAFCGOGSA-N tert-butyl 2-[(3S,4S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-fluoro-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](CCC(F)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 RZBLCXAXAZEJJZ-VRAFCGOGSA-N 0.000 description 1
- JNXAGWCUBYJEMM-JDBUVZGPSA-N tert-butyl 2-[(3S,4S,6R,7S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](C[C@@H](O)[C@@H](O)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 JNXAGWCUBYJEMM-JDBUVZGPSA-N 0.000 description 1
- JNXAGWCUBYJEMM-CDPNLFKUSA-N tert-butyl 2-[(3S,4S,6S,7R)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](C[C@H](O)[C@H](O)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 JNXAGWCUBYJEMM-CDPNLFKUSA-N 0.000 description 1
- CNSCUAYYHRJIRJ-VWPQPMDRSA-N tert-butyl 2-[(3S,4S,7S)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-7-hydroxy-2-oxo-4-phenylazocan-3-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1[C@H](CC[C@H](O)CN(c2nc(cs2)-c2ccccc2Cl)C1=O)c1ccccc1 CNSCUAYYHRJIRJ-VWPQPMDRSA-N 0.000 description 1
- KMOLTTRBEWZKOS-ZTQYDYAKSA-N tert-butyl 2-[(3z,6s,7s)-1-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-8-oxo-6-phenyl-2,5,6,7-tetrahydroazocin-7-yl]acetate Chemical compound C([C@@H]([C@@H](C1=O)CC(=O)OC(C)(C)C)C=2C=CC=CC=2)\C=C/CN1C(SC=1)=NC=1C1=CC=CC=C1Cl KMOLTTRBEWZKOS-ZTQYDYAKSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FYZXEMANQYHCFX-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O FYZXEMANQYHCFX-UHFFFAOYSA-K 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to novel compounds including their pharmaceutically acceptable salts, solvates, and prodrugs, which are modulators of G- protein coupled receptor 43 (GPR43) and are useful as therapeutic compounds, particularly in the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
- GPR43 G- protein coupled receptor 43
- GPR43 (also named FFA2R) belongs to a subfamily of G-Protein-Coupled Receptors (GPCRs), including GPR40 and GPR41 that have been identified as receptor for Free Fatty Acids (FFAs) (Le Poul et al, J. Biol Chem. 278, 25481-489, 2003; Covington et al., Biochemical Society transaction 34, 770-773, 2006).
- GPCRs G-Protein-Coupled Receptors
- FFAs Free Fatty Acids
- the 3 family members share 30 to 40% sequences identity with specificity toward different fatty acids carbon chain lengths, with short chain fatty acids (SCFAs: six carbons molecules or shorter) activating GPR41 and GPR43 and medium and long chain fatty acids activating GPR40 (Rayasam et al., Expert Opinion on therapeutic targets, 1 1 661-671 , 2007 ).
- SCFAs short chain fatty acids
- GPR40 medium and long chain fatty acids activating GPR40 (Rayasam et al., Expert Opinion on therapeutic targets, 1 1 661-671 , 2007 ).
- C2 acetate and C3 propionate are the most potent activators of GPR43.
- GPR43 by immune cells (neutrophils, monocytes, peripheral blood mononuclear cells, B-lymphocytes and polymorphonuclear cells), in part of the gastro-intestinal tract and by white adipocytes cells as well as pancreatic ⁇ cells strongly suggested its potential as target in inflammatory, gastrointestinal and/or metabolic disorders (Milligan et al. BJP 158, ppl46-153, 2009; Regard et al, J. Clin. Inv., 117, pp40344043, 2007; Ahren Bo, Nature Reviews, 8, pp369-385, 2009). This potential is well supported by recent data. Using a GPR43 knockout mouse, Ge et al, (Endocrinology, 149, pp4519-
- GPR43 the major receptor for acetate and propionate
- new agonists or partial agonists of GPR43 may be of therapeutic value for the treatment and/or prevention of the above-mentioned disorders.
- the invention encompasses compounds of general Formula I, their pharmaceutically acceptable salts, solvates, and prodrugs as well as methods of use of such compounds or compositions comprising such compounds as modulators of GPR43 activity.
- the invention provides compounds of general formula I:
- Ar 1 is a C3-C6 alkyl, C3-C6 cycloalkyl, C4-C6 heterocyclyl, 6-membered aryl or 5 to 6- membered heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl or haloalkoxy;
- L 1 is a single bond, -CH 2 -, -CHCH3 or -C(CH 3 ) 2 ;
- Ar 2 is a 6-membered aryl group or a 5 to 6-membered heteroaryl group, each of which being optionally substituted by one or more halo or alkyl group(s);
- Ar 3 is a 5 to 6-membered aryl optionally substituted by one or more halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy group(s), by one aryl or heteoaryl group, each of said aryl or heteroaryl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, amino, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N-(aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the aryl or heteroaryl group may
- R is a 7 to 9-membered heterocyclyl ring selected from the group consisting of:
- L 1 is attached to the ring at position a and Ar 2 is attached to the nitrogen atom at position b; the bonds represented by the dotted lines are independently a single bond, a double bond or a triple bond; at least one of the bonds represented by the dotted lines depicted as "c" and "d” in ring- VII is a single bond;
- R 1 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, Ci- C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl
- R 1 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl
- R 2 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclyl
- R 6 and R 6' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 haloalkoxyalky
- R 8 is H or C1-C4 alkyl
- R 9 and R 9 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 10 and R 10' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in ring-V is a single bond, R 11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R 11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl,
- R 16 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci- C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl;
- R 16 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl, or R 16 forms together with R 16 an oxo moiety;
- R 17 and R 17' are independently selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl; when the dotted lines depicted by "c" and "d” in ring- VII are both single bonds, R 18 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl; R 18 is selected from H, fluoro, chloro, C 1
- L 3 is a single bond, or L 3 is a C 1 -C3 alkylene optionally substituted by one or more group(s) selected from fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl;
- R 21 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci- C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl;
- R 21 is selected from H, fluoro
- R 23 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci- C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl;
- R 23 is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl, or R 23 forms together with R 23 an oxo moiety;
- R 24 is H or Ci-C 4 alkyl
- R 25 and R 25 are independently selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl;
- L 2 is a C 1 -C 2 alkylene optionally substituted by one or more methyl group(s);
- Z is selected from the group consisting of-COOR°, wherein R° is H or linear or branched alkyl, aryl, acyloxyalkyl, dioxolene, R is H, methyl or ethyl, and R" is hydroxyl -S0 2 CH 3i -S0 2 cyclopropyl or -S0 2 CF 3 .
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound according to the invention or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- the invention also relates to the use of the above compounds or their pharmaceutically acceptable salts and solvates or prodrugs as modulators of GPR43, preferably as agonists or partial agonists of GPR43.
- the invention further provides methods of treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders comprising the administration of a therapeutically effective amount of a compound or pharmaceutically acceptable salt, solvate, or prodrug of formula (I), to a patient in need thereof.
- the patient is a warm-blooded animal, more preferably a human.
- the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof as a medicament.
- the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
- the invention relates to compounds of formula I, as well as their pharmaceutically acceptable salts, solvates, and prodrugs.
- Preferred compounds of formula I and pharmaceutically acceptable salts, solvates, and prodrugs thereof are those wherein
- Ar 1 is C 3 -C 6 alkyl, C 3 -C 6 cycloalkyl, tetrahydropyran-4-yl, 6-membered aryl or 5 membered heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, alkyl, haloalkyl, alkoxy or haloalkoxy, preferably Ar 1 is C 3 -C 6 alkyl preferably isopropyl, isobutyl, C 3 -C 6 cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, more preferably cyclopentyl, tetrahydropyran-4-yl, 6-membered aryl preferably phenyl, or 5 membered heteroaryl preferably thiazolyl group; and/or L 1 is a single bond or -CH 2 -, preferably L 1 is a single bond; and/or
- Ar 2 is a 5 to 6-membered heteroaryl group optionally substituted by one or more halo or alkyl group(s), preferably Ar 2 is a thiazolyl, thiadiazolyl or pyridinyl group, more preferably Ar 2 is a thiazolyl group; and/or
- Ar 3 is a 5 to 6-membered aryl optionally substituted by one or more halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy group(s), by one aryl or heteoaryl group, each of said aryl or heteroaryl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, amino, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N-(aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the aryl or heteroaryl group may
- R is selected from ring-I, ring-V, ring- VI and ring-VII, preferably R is ring-V or ring -VI, more preferably R is ring -V; wherein preferably when the dotted line in ring-I is a single bond, R 1 is selected from H, fluoro, Ci-C 3 alkyl, preferably methyl, Ci-C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, Ci-C 3 alkoxy, preferably methoxy, Ci-C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 1 is H; R 1 is selected from H, fluoro, Ci-C 3 alkyl preferably methyl, more preferably R 1 is H; R 2 is selected from H, fluoro, chloro, Ci-C 6 al
- R 3 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 3 is H; and/or
- R 3 is selected from H, fluoro, C 1 -C 3 alkyl preferably methyl, more preferably R 3 is H; and/or
- R 10 and R 10 ' are independently selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 10 and R 10 are H; and/or when the dotted line in ring-V is a single bond, R 11 is selected from H, fluoro, C 1 -C 3 alkyl, preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 3 alkoxy, preferably
- R 13 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 13 is H; and/or
- R 13 is selected from H, fluoro, Ci-C 3 alkyl preferably methyl, more preferably R 13 is H; and/or when the dotted line in ring- VI is a single bond, R 14 is selected from H, fluoro, chloro, Ci-C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 14 is H; R 14 is selected from H, fluoro, Ci-C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxy-Ci-C 3 alkyl preferably
- R 16 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 16 is H; and/or
- R 16 is selected from H, fluoro, C 1 -C 3 alkyl preferably methyl, more preferably R 16 is H; and/or
- R 17 and R 17 ' are independently selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 17 and R 17 are H; and/or when the dotted lines depicted by "c" and "d" in ring- VII are both single bonds, R 18 is selected from H, fluoro, chloro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl,
- R is H; R is absent; R and R are independently selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C3 alkoxyalkyl preferably methoxymethyl; more preferably R and R 20 are independently selected from H, fluoro, methyl, -CHF 2 , hydroxymethyl, methoxymethyl; still more preferably R 19 and R 20 are H; R 19 is absent; R 20 is selected from H, fluoro, chloro, C 1 -C4 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, Ci-C 3 alkoxyalkyl preferably methoxymethyl, or R 20 forms
- R 21 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -
- Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 21 is selected from H, fluoro, -CHF 2 , hydroxyl, hydroxymethyl, methoxy, methoxymethy, still more preferably R 21 is H; and/or
- R 21 is selected from H, fluoro, Ci-C 3 alkyl preferably methyl, more preferably R 21 is H; and/or
- L 3 is a single bond; and/or when R is selected from ring-II, ring III, ring IV and ring VIII
- R 4 , R 4' , R 5 and R 5 are H; and/or
- R 6 , R 6' , R 7 and R 7' are H; and/or R 8 , R 9 and R 9' are H; and/or
- R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 are H; and/or
- L 2 is a methylene optionally substituted by one or more methyl group(s), preferably L 2 is CH 2 ; and/or
- Z is selected from the group consisting of -COOR 0 , wherein R° is H or linear or branched alkyl, preferably Z is -COOH.
- preferred compounds of Formula I are those of formula
- R is as defined above in respect to formula I, preferably R is selected from ring-I, ring-II, ring-V, ring- VI, ring- VII and ring- VIII, more preferably R is selected from ring-I, ring-V, ring VI and ring- VII, still more preferably R is ring-V or ring VI, even more preferably R is ring-V;
- Ar 1 is as defined above in respect to formula I, preferably Ar 1 is is isopropyl, butyl, tert-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-difluorocyclohexan-l-yl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, furanyl, thiophenyl or thiazolyl, each of which being optionally substituted by one or more group(s) selected from hal
- Y is CH or N, preferably Y is CH;
- heterocyclic group is substituted with Ar either in position 4 or 5 , preferably in position 4;
- R is H, methyl, F, CI, or CF 3 , more preferably R.
- o is H or F, still more R is preferably H; if Y is N, R 2b is absent.
- Preferred compounds of formula la are those of formula Ia-1
- R, Ar 1 , Ar 3 and R 26 are as defined above in respect to formula la, preferably R 26 is H or F, more preferably R 26 is H.
- Preferred compounds of formula Ia-1 are those of formula Ia-2
- R 27 is H, halo preferably chloro or fluoro, cyano, alkyl preferably methyl or isopropyl, haloalkyl preferably -CHF 2 or -CF 3 , hydroxyl, alkoxy preferably methoxy, haloalkoxy preferably -OCHF 2 or -OCF 3 , phenyl, pyridinyl, pyridazinyl or pyrazinyl, each of said phenyl, pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably -CHF 2 or -CF 3 , hydroxyl, alkoxy preferably methoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy, aralkyloxy preferably benzyloxy, alk
- R 27' is H
- R 28 is H, halo, cyano, alkyl preferably methyl, haloalkyl, hydroxyl, alkoxy preferably methoxy, haloalkoxy, preferably R 28 is H, fluoro, chloro, cyano, -CHF 2 , -CF 3 or -OCF 3 more preferably R 28 is H;
- R 28' is H, halo, cyano, alkyl preferably methyl, haloalkyl, hydroxyl, alkoxy preferably methoxy, haloalkoxy, preferably R 28 is H, fluoro, chloro, -CF 3 , -OCHF 2 or -OCF 3 more preferably R 28 is H;
- R 29 is H, halo, cyano, alkyl, alkoxy, preferably R 29 is H, chloro, fluoro, methyl or methoxy more preferably R 29 is H.
- Preferred compounds of formula Ia-2 are those of formula Ia-3
- R 28 is as defined above in respect to formula Ia-2, preferably R 28 is H or fluoro, more preferably R 28 is H;
- R is as defined above in respect to formula Ia-2, preferably R is H, chloro or fluoro, more preferably R 28 is H;
- R 29 is as defined above in respect to formula Ia-2, preferably R 29 is H, chloro or fluoro, more preferably R 29 is H;
- R 30 is H, halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably - CHF 2 or -CF 3 , hydro xyl, alkoxy preferably methoxy, preferably R 30 is H, chloro;
- R 31 is alkoxy preferably methoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy, aralkyloxy preferably benzyloxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, (2-ethoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, (3- methoxybutan-2-yl) o xy , (1 -methoxy-2-methylpropan-2-yl)oxy, ((3 S)-3 -methoxybutan-2- yl)o xy , ( (3 R)-3-methoxybutan-2-yl)oxy, haloalkoxyalkoxy preferably (2-(2,2,2- trifluoroethoxy)ethyl) o x y , (2-(2-ethoxyethoxy)ethyl)oxy, alkylamino preferably dimethylamino, N
- R 30 and R 31 together form a heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, or heteroaryl preferably pyrrolyl, pyrazolyl or triazolyl ring, thus forming a fused bicyclic system which may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s);
- X 1 is N or C-R 32 wherein R 32 is H;
- X is N or C-R wherein R is H or alkoxy preferably R is H or methoxy, more preferably R 32 is H, preferably X 2 is N or CH, more preferably X 2 is CH.
- Preferred compounds of formula Ia-3 are those wherein the moiety is selected from: H, X 2 is CH and R 31 is methoxy or 2-oxopyrrolidin-l-yl.
- R" and R i0 are as defined above in respect to formula Ia-2, preferably R and R are independently selected from H, halo, haloalkyl, haloalkoxy, preferably chloro, fluoro, -CF 3 , -CHF 2 , -OCF 3 or -OCHF 2 , more preferably R 27 is H, chloro or fluoro and R 28 is selected from H, halo, -CF 3 , -CHF 2 , -OCF 3 or -OCHF 2 , preferably chloro and fluoro, even more preferably R 27 is chloro or fluoro and R 28 is H, or R 27 is H and R 28' is -OCF 3 or -OCHF 2 , even more preferably R 27 is chloro or fluoro and R 28 is H.
- preferred compounds of Formula I are those of formula lb:
- R 33 and R 33' are independently selected from H, halo, cyano, hydro xyl, linear or branched C1-C 3 alkyl, C1-C 3 haloalkyl, preferably R 33 and R 33 are independently selected from H, F, CI, or CF 3 , more preferably R 33 and R 33' are H;
- preferred compounds of Formula I are those formula Ic:
- R, Ar 1 , Ar R ⁇ and R ⁇ are as defined above in respect to formula lb.
- preferred compounds of Formula I are those of formulae Id-1, Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8:
- R 3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R 3 forms together with R 3 an oxo moiety; when the dotted line in formula Id-2 is absent, R 4 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl
- R 6 and R 6' are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 7 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 7 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 haloalkoxyalkyl, or R 7 forms together with R 7 an oxo moiety;
- R 8 is H or C1-C4 alkyl
- R 9 and R 9 are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
- R 10 and R 10' are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in formula Id-5 is absent, R 11 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R 11 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl,
- R 13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R 13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R 13 forms together with R 13 an oxo moiety; when the dotted line in formula Id-6 is absent, R 14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C
- R 16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R 16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R 16 forms together with R 16 an oxo moiety;
- R 17 and R 17' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted lines depicted by "c" and "d” in formula Id-7 are both absent, R is selected from H, fluoro, chloro, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, hydroxy-Ci-C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkoxyalkyl or C 1 -C 4 haloalkoxyalkyl; R 18 is selected from H, fluoro, chloro, C 1 -C 4 al
- R 21 is selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C 1 -C4 alkoxy, C 1 -C4 haloalkoxy, C 1 -C4 alkoxyalkyl or C 1 -C4 haloalkoxyalkyl;
- R 21 is selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxy-Ci-C4 alkyl, C 1 -C4 alkoxyalkyl or C 1 -C4 haloalkoxyalkyl, or R 21 forms together with R 21 an oxo moiety;
- R 22 and R 22' are independently selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C 1 -C4 haloalkoxyalkyl;
- R 23 is selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C 1 -C4 alkoxy, C 1 -C4 haloalkoxy, C 1 -C4 alkoxyalkyl or C 1 -C4 haloalkoxyalkyl;
- R 23 is selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxy-Ci-C4 alkyl, C 1 -C4 alkoxyalkyl or C 1 -C4 haloalkoxyalkyl, or R 23 forms together with R 23 an oxo moiety;
- R 24 is H or Ci-C 4 alkyl
- R 25 and R 25 are independently selected from H, fluoro, chloro, C 1 -C4 alkyl, C 1 -C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl.
- compounds of formula Id-6 are those wherein the bond linking carbon to which L 2 -Z is attached and D is drawn as a solid wedge:
- Preferred compounds of formulae Id-1 , Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8 are those of formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8 respectively:
- le-7 le-8 harmaceutically acceptable salts, and solvates, or prodrugs thereof, wherein
- Ar 1 and Ar 3 are as defined above in respect to formula la;
- Ar 2 is as defined above in respect to formula I, preferably Ar 2 is a 5 to 6-membered heteroaryl group, preferably thiazolyl, thiadiazolyl or pyridinyl, each of which being optionally substituted by one or more halo, preferably fluoro, or alkyl, preferably methyl, group(s) preferably Ar 2 is a thiazolyl connected to the ring nitrogen at position 2 and to Ar 3 at position 4 and optionally substituted by a fluoro at position 5, preferably unsubstituted at position 5, or Ar 2 is a thiadiazolyl connected to the ring nitrogen at position 2 and to Ar 3 at position 5, more preferably Ar 2 is a thiazolyl connected to the ring nitrogen at position 2 and to Ar 3 at position 4;
- R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 , R 25 , and the dotted lines are as defined above in respect to formulae Id-1, Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8, preferably: when the dotted line in formula Ie-1 is absent, R 1 is selected from H, fluoro, C 1 -C 3 alkyl, preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 3 alkoxy, preferably methoxy, Ci-C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 1 is H; R 1 is selected from H, fluoro, C
- R 3 is selected from H, fluoro, Ci-C 3 alkyl preferably methyl, more preferably R 3 is H;
- R 4 , R 4' , R 5 and R 5 are H;
- R 6 , R 6' , R 7 and R 7' are H;
- R 8 , R 9 and R 9' are H;
- R 10 and R 10' are independently selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 10 and R 10 are H; when the dotted line in formula Ie-5 is absent, R 11 is selected from H, fluoro, Ci-C 3 alkyl, preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, Ci-C 3 alkoxy, preferably methoxy, C 1 -C 2 halo
- R 13 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 13 is H;
- R 13 is selected from H, fluoro, C 1 -C 3 alkyl preferably methyl, more preferably R 13 is H; when the dotted line in formula Ie-6 is absent, R 14 is selected from H, fluoro, chloro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , C 1 -C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 14 is H; R 14 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxy-Ci-C 3 alkyl preferably
- R 16 is selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 16 is H; R 16 is selected from H, fluoro, C 1 -C3 alkyl preferably methyl, more preferably R 16 is H;
- R 17 and R 17 ' are independently selected from H, fluoro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2 alkoxy preferably methoxy, C 1 -C 2 haloalkoxy preferably -OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 17 and R 17 are H; when the dotted lines depicted by "c" and "d” in formula Ie-7 are both absent, R 18 is selected from H, fluoro, chloro, C 1 -C 2 alkyl preferably methyl, C 1 -C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, C 1 -C 2
- R 21 is selected from H, fluoro, Ci-C 2 alkyl preferably methyl, Ci-C 2 haloalkyl preferably -CF 3 or -CHF 2 , hydroxyl, hydroxy-Ci-C 3 alkyl preferably hydroxymethyl, Ci-C 2 alkoxy preferably methoxy, Ci-C 2 haloalkoxy preferably - OCF 3 or -OCHF 2 , Ci-C 3 alkoxyalkyl preferably methoxymethyl, more preferably R 21 is selected from H, fluoro, -CHF 2 , hydroxyl, hydroxymethyl, methoxy, methoxymethy, still more preferably R 21 is H; R 21 is selected from H, fluoro, Ci-C 3 alkyl preferably methyl, more preferably R 21 is H;
- compounds of formula Ie-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
- Preferred compounds of formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8 are those formulae If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 respectively:
- Ar 1 , Ar 3 , R 26 , X and Y are as defined above in respect to formula la;
- R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 and the dotted lines are as defined above in respect to formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8.
- compounds of formula If-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid0 wedge:
- Preferred compounds of formulae If-l , If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those of formulae Ig-1 , Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 respectively:
- R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 and the dotted lines are as defined above in respect to formulae If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8.
- compounds of formula Ig-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
- Preferred compounds of formulae Ig-1 , Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 are those of formulae Ih-1, Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 respectively: 52
- R 12 R 12' R 13 R 13' R 14 R 14' R 15 R 15' R 16 R 16' R 17 R 17' R 18 R 18' R 19 R 19' R 20 R 20' IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV , R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 and the dotted lines are as defined above in respect to formulae Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8.
- compounds of formula Ih-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
- Preferred compounds of formulae Ih-1 , Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 are those of formulae Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 respectively: 54
- Ar 1 , R 26 , R 27' , R 28 , R 28 , R 29 , R 30 , R 31 , X 1 and X 2 are as defined above in respect to formula Ia-3;
- R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 and the dotted lines are as defined above in respect to formulae Ih-1, Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8.
- compounds of formula Ii-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid 0 wedge:
- Preferred c mpounds of formulae Ii-l, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 are those
- Ar 1 , R 26 , R 27 and R 28' are as defined above in respect to formula Ia-4;
- R 21 , R 21' , R 22 , R 22' , R 23 , R 23' , R 24 , R 25 and R 25 and the dotted lines are as defined above in respect to formulae Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8.
- the compounds of formula I can be prepared by different ways with reactions known by the person skilled in the art. Reaction schemes as described in the example section illustrate by way of example different possible approaches.
- the invention further provides the use of the compounds of the invention or pharmaceutically acceptable salts, solvates, or prodrugs thereof as agonists or partial agonists of G-protein coupled receptor 43 (GPR43).
- GPR43 G-protein coupled receptor 43
- the invention relates to the use of compounds of formula I and subformulae in particular those of table 1 above, or pharmaceutically acceptable salts solvates, and prodrugs thereof, as GPR43 agonists or partial agonists.
- the compounds of the invention are therefore useful in the prevention and/or treatment of inflammatory, gastrointestinal and/or metabolic disorders.
- the invention also provides for a method for delaying in patient the onset of inflammatory, gastrointestinal and/or metabolic disorders comprising the administration of a pharmaceutically effective amount of a compound of formula (I) or pharmaceutically acceptable salt thereof to a patient in need thereof.
- the patient is a warm-blooded animal, more preferably a human.
- the invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvates or prodrug thereof for treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.
- the patient is a warm-blooded animal, more preferably a human.
- a method for modulating GPR43 receptor activity in a patient, preferably a warm blooded animal, and even more preferably a human, in need of such treatment, which comprises administering to said animal an effective amount of compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- the compounds of the invention, their pharmaceutical acceptable salts or solvates, or prodrugs may be administered as part of a combination therapy.
- a combination therapy comprising coadministration of, and compositions and medicaments which contain, in addition to a compound of the present invention, a pharmaceutically acceptable salt, solvate or prodrug thereof as active ingredient, additional therapeutic agents and/or active ingredients.
- Such multiple drug regimens often referred to as combination therapy, may be used in the treatment and/or prevention of any of the diseases or conditions mediated by or associated with GPR43 receptor modulation, particularly inflammatory, gastrointestinal and/or metabolic disorders.
- the use of such combinations of therapeutic agents is especially pertinent with respect to the treatment of the above-mentioned list of disorders within a patient in need of treatment or one at risk of becoming such a patient.
- Suitable supplementary therapeutic agents used for the purpose of auxiliary treatment include drugs which, instead of directly treating or preventing a disease or condition mediated by or associated with GPR43 receptor modulation, treat diseases or conditions which directly result from or indirectly accompany the basic or underlying GPR43 receptor modulated disease or condition.
- the methods of treatment and pharmaceutical compositions of the present invention may employ the compounds of Formula I or their pharmaceutical acceptable salts, solvates, or prodrugs thereof in the form of monotherapy, but said methods and compositions may also be used in the form of multiple therapy in which one or more compounds of Formula I or their pharmaceutically acceptable salts, solvates, or prodrugs are coadministered in combination with one or more other therapeutic agents.
- the compound of Formula I, a pharmaceutically acceptable salt or solvate thereof and other therapeutic active agents may be administered in terms of dosage forms either separately or in conjunction with each other, and in terms of their time of administration, either serially or simultaneously.
- the administration of one component agent may be prior to, concurrent with, or subsequent to the administration of the other component agent(s).
- the invention also provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.
- the invention also covers pharmaceutical compositions which contain, in addition to a compound of the present invention, a pharmaceutically acceptable salt, solvate or prodrug thereof as active ingredient, additional therapeutic agents and/or active ingredients.
- Another object of this invention is a medicament comprising at least one compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, as active ingredient.
- the invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament.
- the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
- a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for modulating GPR43 receptor activity, in a patient, in need of such treatment, which comprises administering to said patient an effective amount of compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- the patient is a warm-blooded animal, more preferably a human.
- the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders
- the compounds of the invention, their pharmaceutically acceptable salts, solvates, or prodrugs may be used in monotherapy or in combination therapy.
- the invention provides the use of a compound of the invention for the manufacture of a medicament for at least one of the purposes described above, wherein said medicament is administered to a patient in need thereof, preferably a warm-blooded animal, and even more preferably a human, in combination with at least one additional therapeutic agent and/or active ingredient.
- a multiple drug regimen, possible administration regimens as well as suitable additional therapeutic agents and/or active ingredients are those described above.
- the compounds of the invention may be formulated as a pharmaceutical preparation comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant, and optionally one or more further pharmaceutically active compound(s).
- a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration (including ocular), for administration by inhalation, by a skin patch, by an implant, by a suppository, etc.
- Such suitable administration forms - which may be solid, semi-solid or liquid, depending on the manner of administration - as well as methods and carriers, diluents and excipients for use in the preparation thereof, will be clear to the skilled person; reference is made to the latest edition of Remington's Pharmaceutical Sciences.
- Such preparations include tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, cremes, lotions, soft and hard gelatin capsules, suppositories, drops, sterile injectable solutions and sterile packaged powders (which are usually reconstituted prior to use) for administration as a bolus and/or for continuous administration, which may be formulated with carriers, excipients, and diluents that are suitable per se for such formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, micro crystalline cellulose, polyvinylpyrrolidone, polyethylene glycol, cellulose, (sterile) water, methylcellulose, methyl- and prop
- the formulations can optionally contain other substances that are commonly used in pharmaceutical formulations, such as lubricating agents, wetting agents, emulsifying and suspending agents, dispersing agents, desintegrants, bulking agents, fillers, preserving agents, sweetening agents, flavoring agents, flow regulators, release agents, etc..
- the compositions may also be formulated so as to provide rapid, sustained or delayed release of the active compound(s) contained therein.
- the pharmaceutical preparations of the invention are preferably in a unit dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which may be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use.
- unit dosages will contain between 0,05 and 1000 mg, and usually between 1 and 500 mg, of the at least one compound of the invention, e.g. about 10, 25, 50, 100, 200, 300 or 400 mg per unit dosage.
- the active compound of the invention will usually be administered between 0.01 to 100 mg per kilogram, more often between 0.1 and 50 mg, such as between 1 and 25 mg, for example about 0.5, 1, 5, 10, 15, 20 or 25 mg, per kilogram body weight of the patient per day, which may be administered as a single daily dose, divided over one or more daily doses, or essentially continuously, e.g. using a drip infusion.
- groups may be substituted, such groups may be substituted with one or more substituents, and preferably with one, two or three substituents.
- Substituents may be selected from but not limited to, for example, the group comprising halogen, hydroxyl, oxo, nitro, amido, carboxy, amino, cyano haloalkoxy, and haloalkyl.
- alkyl, aryl, or cycloalkyl each being optionally substituted with -- or "alkyl, aryl, or cycloalkyl, optionally substituted with -- encompasses “alkyl optionally substituted with?”, “aryl optionally substituted with?” and “cycloalkyl optionally substituted with... ".
- alkyl by itself or as part of another substituent refers to a hydrocarbyl radical of Formula C n H2 n +i wherein n is a number greater than or equal to 1.
- alkyl groups of this invention comprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2 carbon atoms.
- Alkyl groups may be linear or branched and may be substituted as indicated herein.
- Suitable alkyl groups include methyl, ethyl, n-propyl, /-propyl, n-butyl, /- butyl, 5-butyl and /-butyl, pentyl and its isomers (e.g. n-pentyl, iso-pentyl), and hexyl and its isomers (e.g. n-hexyl, /so-hexyl).
- Preferred alkyl groups include methyl, ethyl, n-propyl, /-propyl, n-butyl, /-butyl, s-butyl and /-butyl.
- alkylene When the suffix "ene” (“alkylene”) is used in conjunction with an alkyl group, this is intended to mean the alkyl group as defined herein having two single bonds as points of attachment to other groups.
- alkylene includes methylene, ethylene, methylmethylene, propylene, ethylethylene, and 1,2-dimethylethylene.
- alkenyl as used herein refers to an unsaturated hydrocarbyl group, which may be linear or branched, comprising one or more carbon-carbon double bonds. Suitable alkenyl groups comprise between 2 and 6 carbon atoms, preferably between 2 and 4 carbon atoms, still more preferably between 2 and 3 carbon atoms.
- alkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2- hexenyl and its isomers, 2,4-pentanedienyl and the like.
- alkynyl refers to a class of monovalent unsaturated hydrocarbyl groups, wherein the unsaturation arises from the presence of one or more carbon-carbon triple bonds.
- Alkynyl groups typically, and preferably, have the same number of carbon atoms as described above in relation to alkenyl groups.
- Non limiting examples of alkynyl groups are ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl and its isomers, 2-hexynyl and its isomers-and the like.
- alkenylene and alkynylene respectively mean an alkenyl group or an alkinyl group as defined above having two single bonds as points of attachment to other groups.
- haloalkyl alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen as defined above.
- Non-limiting examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1- trifluoro ethyl and the like.
- cycloalkyl as used herein is a cyclic alkyl group, that is to say, a monovalent, saturated, or unsaturated hydrocarbyl group having 1 or 2 cyclic structures.
- Cycloalkyl includes monocyclic or bicyclic hydrocarbyl groups. Cycloalkyl groups may comprise 3 or more carbon atoms in the ring and generally, according to this invention comprise from 3 to 10, more preferably from 3 to 8 carbon atoms still more preferably from 3 to 6 carbon atoms. Examples of cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, with cyclopropyl being particularly preferred.
- heterocycloalkyl where at least one carbon atom in a cycloalkyl group is replaced with a heteroatom, the resultant ring is referred to herein as "heterocycloalkyl” or “heterocyclyl”.
- heterocyclyl refers to non-aromatic, fully saturated or partially unsaturated cyclic groups (for example, 3 to 7 member monocyclic, 7 to 11 member bicyclic, or containing a total of 3 to 10 ring atoms) which have at least one heteroatom in at least one carbon atom-containing ring.
- Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
- heterocyclic group may be substituted by oxo (for example piperidone, pyrrolidinone).
- the heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system, where valence allows.
- the rings of multi-ring heterocycles may be fused, bridged and/or joined through one or more spiro atoms.
- Non limiting exemplary heterocyclic groups include oxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinyl imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, 3H- indolyl, indolinyl, isoindolinyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl, 2- pyrazolinyl, 3-pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro- 2H-pyranyl, 3-dioxolanyl, 1 ,4-dioxanyl, 2,5-dioximidazolidinyl, 2-oxopiperidiny
- aryl refers to a polyunsaturated, aromatic hydrocarbyl group having a single ring (i.e. phenyl) or multiple aromatic rings fused together (e.g. naphtyl) or linked covalently, typically containing 5 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic.
- the aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocyclyl or heteroaryl) fused thereto.
- Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein.
- Non-limiting examples of aryl comprise phenyl, biphenylyl, biphenylenyl, 5- or 6-tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1- 2-, 3-, 4- or 5-acenaphtylenyl, 3-, 4- or 5-acenaphtenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl, 1-, 2-, 3-, 4- or 5- pyrenyl.
- arylene as used herein is intended to include divalent carbocyclic aromatic ring systems such as phenylene, biphenylylene, naphthylene, indenylene, pentalenylene, azulenylene and the like.
- Arylene is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthylene, 1,4- dihydronaphthylene and the like.
- heteroaryl ring where at least one carbon atom in an aryl group is replaced with a heteroatom, the resultant ring is referred to herein as a heteroaryl ring.
- heteroaryl refers but is not limited to 5 to 12 carbon-atom aromatic rings or ring systems containing 1 to 2 rings which are fused together or linked covalently, typically containing 5 to 6 atoms; at least one of which is aromatic, in which one or more carbon atoms in one or more of these rings is replaced by oxygen, nitrogen and/or sulfur atoms where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
- Such rings may be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl ring.
- Non-limiting examples of such heteroaryl include: furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, imidazo[2,l-b][l,3]thiazolyl, thieno [3, 2-b] furanyl, thieno[3,2- b]thiophenyl, thieno[2,3-d][l,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[
- heteroarylene as used herein means divalent carbocyclic aromatic ring systems including pyridinylene and the like.
- X is selected from: X is selected from: X is selected from: Y is selected from:
- X is selected from: X is selected from:
- biaryl designates two aryl moieties as defined herein linked via a single bond.
- Non-limiting examples of such biaryl moieties include biphenyl.
- heteroaryl designates two heteroaryl moieties as defined herein or a heteroaryl moiety and an aryl moity as defined herein linked via a single bond.
- heterobiaryl moieties include pyridinylphenyl which is meant to include (2-pyridinyl)phenyl, (3-pyridinyl)phenyl and (4-pyridinyl)phenyl, bipyridinyl.
- alkylamino as used herein means an amino group substituted with one or two alkyl groups. This includes monoalkylamino and dialkylamino groups.
- the compounds of Formula I and subformulae thereof contain at least one asymmetric center and thus may exist as different stereoisomeric forms. Accordingly, the present invention includes all possible stereoisomers and includes not only racemic compounds but the individual enantiomers and their non racemic mixtures as well. When a compound is desired as a single enantiomer, such may be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods as each are known in the art.
- Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley- Interscience, 1994), incorporated by reference with regard to stereochemistry.
- the bonds from an asymmetric carbon in compounds of the present invention may be depicted herein using a solid line (— ), a zigzag line ( ⁇ ww ), a solid wedge ( ), or a dotted wedge ( ).
- the compounds of the invention may also contain more than one asymmetric carbon atom.
- the use of a solid line to depict bonds from asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included, unless it is clear from the context that a specific stereoisomer is intended.
- the compounds of the invention may be in the form of pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts of the compounds of formula I include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2- (diethylamino)ethanol, ethanolamine, morpholine, 4-(2-hydroxyethyl)morpholine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
- Preferred, pharmaceutically acceptable salts include hydrochloride/chloride, hydrobromide/bromide, bisulphate/sulphate, nitrate, citrate, and acetate.
- the compounds of the invention may also form internal salts, and such compounds are within the scope of the invention.
- the compounds of the invention contain a hydrogen-donating heteroatom (e.g. NH, OH)
- the invention also covers salts and/or isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule.
- compositions of Formula I may be prepared by one or more of these methods:
- solvate is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- solvent molecules for example, ethanol.
- 'hydrate' is employed when said solvent is water.
- the compounds of the invention include compounds of formula I as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) and iso topically- labeled compounds of formula I.
- salts of the compounds of the invention are preferred, it should be noted that the invention in its broadest sense also included non-pharmaceutically acceptable salts, which may for example be used in the isolation and/or purification of the compounds of the invention.
- non-pharmaceutically acceptable salts which may for example be used in the isolation and/or purification of the compounds of the invention.
- salts formed with optically active acids or bases may be used to form diastereo isomeric salts that can facilitate the separation of optically active isomers of the compounds of Formula I above.
- the invention also generally covers all pharmaceutically acceptable predrugs and prodrugs of the compounds of Formula I.
- prodrug means the pharmacologically acceptable derivatives of compounds of formula I such as esters whose in vivo biotransformation product is the active drug.
- Prodrugs are characterized by increased bio-availability and are readily metabolized into the active compounds in vivo.
- Suitable prodrugs for the purpose of the invention include carboxylic esters, in particular alkyl esters, aryl esters, acyloxyalkyl esters, and dioxolene carboxylic esters; ascorbic acid esters as well as compounds of formula I in which Z is a substituent selected from the table 2 below.
- predrug means any compound that will be modified to form a drug species, wherein the modification may take place either inside or outside of the body, and either before or after the predrug reaches the area of the body where administration of the drug is indicated.
- patient refers to a warm-blooded animal, more preferably a human, who/which is awaiting or receiving medical care or is or will be the object of a medical procedure.
- human refers to suject of both genders and at any stage of development (i.e. neonate, infant, juvenile, adolescent, adult).
- treat means to include alleviating or abrogating a condition or disease and/or its attendant symptoms.
- prevent refers to a method of delaying or precluding the onset of a condition or disease and/or its attendant symptoms, barring a patient from acquiring a condition or disease, or reducing a patient's risk of acquiring a condition or disease.
- terapéuticaally effective amount means the amount of active agent or active ingredient (e. g. GPR43 agonist or partial agonist) which is sufficient to achieve the desired therapeutic or prophylactic effect in the individual to which it is administered.
- administration means providing the active agent or active ingredient (e. g. a GPR43 agonist or partial agonist), alone or as part of a pharmaceutically acceptable composition, to the patient in whom/which the condition, symptom, or disease is to be treated or prevented.
- active agent or active ingredient e. g. a GPR43 agonist or partial agonist
- pharmaceutically acceptable is meant that the ingredients of a pharmaceutical composition are compatible with each other and not deleterious to the patient thereof.
- agonist means a ligand that activates an intracellular response when it binds to a receptor.
- An agonist according to the invention may promote internalization of a cell surface receptor such that the cell surface concentration of a receptor is decreased or remove.
- partial agonist means an agonist which is unable to induce maximal activation of a receptor, regardless of the amount of compound applied on the receptor.
- pharmaceutical vehicle means a carrier or inert medium used as solvent or diluent in which the pharmaceutically active agent is formulated and/or administered.
- pharmaceutical vehicles include creams, gels, lotions, solutions, and liposomes.
- inflammatory disorders are those pertaining to, characterized by, causing, resulting from or becoming affected by inflammation.
- inflammatory diseases include but are not limited to rheumatoid arthritis; inflammatory bowel disease (IBD) including but not limited to Crohn's disease, ulcerative colitis and colitis; Pagets disease; osteoporosis; multiple myeloma; uveitilis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; rheumatoid spondylitis, osteoarthritis; gouty arthritis and other arthritis conditions; gout; adult respiratory distress syndrome (ARDS); chronic pulmonary inflammation diseases; silicosis; pulmonary sarcoidosis; psoriasis; allergic rhinitis; anaphylaxis; contact dermatitis; pancreatitis; non-alcoholic steatohepatitis (NASH); asthma; muscle degeneration; cachexia such as cachexia secondary to infection or malign
- metabolic disorders includes but is not limited to type I and type II diabetes, obesity, dyslipidemia such as mixed or diabetic dyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia hypertension, hyperlipoproteinemia, metabolic syndrome, syndrome X, thrombotic disorders, cardiovascular disease, atherosclerosis and its sequelae including angina, claudication, heart attack, stroke and others, kidney diseases, ketoacidosis, nephropathy, diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liver diseases such as steatosis or nonalcoholic steatohepatitis (NASH).
- dyslipidemia such as mixed or diabetic dyslipidemia
- hypercholesterolemia low HDL cholesterol, high LDL cholesterol
- hyperlipidemia hypertriglyceridemia
- hypoglycemia hyperglycemia
- glucose intolerance insulin resistance
- gastrointestinal disorders means diseases selected from the group consisting of gastrointestinal hypermotility disorders, including but not limited to any type of diarrhea, such as, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease and other types of diarrhea; Irritable Bowel Syndrome (IBS); intestinal injury disorders such as short-bowel syndrome; diseases involving intestinal barrier dysfunction such as pancreatitis, proctitis and pouchitis.
- IBS Irritable Bowel Syndrome
- TLC thin layer chromatography
- the Agilent instrument includes an Autosampler 1200, a binary pump 1100, a 5 wave length detector 1100 and a 6100 Single Quad.
- the column used was an XBridge CI 8.
- Eluent was a mixture of solution A (0.1% TFA in H 2 0) and solution B (0.1% TFA in MeCN).
- Gradients used are as follows: gradient A (intermediates characterization): held the initial conditions of 5% solution B for 1 min, increased linearly to 95% solution B in 4 min, held at 95% during 1 min, returned to initial conditions in 0.5 min and maintained for 1 min; gradient B (examples characterization): held the initial conditions of 5% solution B for 1 min, increased linearly to 60% in 10 min, increased linearly to 95% in 0.5 min, held at 95% during 3 min, returned to initial conditions in 0.5 min and maintained for 1 min.
- enantiomeric excess was performed on an Agilent 1100 (binary pump and 5 wavelengths detector) with manual or automatic (Autosampler 1100) injection. Columns used were CHIRALPAK IA CHIRALPAK IB or CHIRALPAK IC in isocratic mode. Mixtures of eluents were selected depending on the separation obtained of enantiomers or diastereosiomers. Usual mixtures were:
- Solvents, reagents and starting materials were purchased from well known chemical suppliers such as for example Sigma Aldrich, Acros Organics, VWR Int., Sopachem or Polymer labs and the following abbreviations are used:
- HATU 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tretramethyluronium hexafluorophosphate
- HMDS Hexamethyldisilazane
- NMM N-methylmorpholine
- NMO N-methylmorpholine-N-oxide
- PE Petroleum ether
- SIBX Stabilized 2-iodoxybenzoic acid
- R a is chloro and R b is isopropyl, isobutyl, cyclopropyl, cyclopentyl, tetrahydropyran-4-yl, phenyl, or biphen-4-yl; or
- R a is 2-methoxypyridin-5-yl and R b is isopropyl, cyclopentyl or phenyl; or
- R a is 2-methoxypyrazin-5-yl and R b is isopropyl; or
- R a is 2-(2-oxopyrrolidin-l-yl)pyridin-5-yl and R b is isopropyl, cyclopentyl or phenyl.
- Scheme 2 Selected methods to achieve ring substitutions for the compounds containg ring I, ring V or ring VII.
- Scheme 4 Suggested synthetic route for the compounds containing ring II.
- a suggested method for the synthesis of compounds of the invention containing ring III is outlined in scheme 5.
- Scheme 5 Suggested synthetic route for the compounds containing ring III.
- Scheme 6 Suggested method for the preparation of the compounds of the invention containg ring IV.
- R c is chloro and R d is cyclopentyl or phenyl; or R c is 2-methoxypyridin-5-yl and R d is isopropyl or cyclopentyl.
- Scheme 8 Suggested method for the preparation of the compounds of the invention containg ring VIII.
- Scheme 10 General scheme for the preparation of biaryl- or heterobiaryl-thiazole amine intermediates 10.3 using Suzuki approach.
- Scheme 11 Alternative general scheme for the preparation of biaryl- or heterobiaryl- thiazole amine intermediates 10.3 using Suzuki approach.
- Scheme 13 General scheme for the preparation of 4-aryl-2-amino-thiazole intermediates using Rudolph's synthetic approach.
- Acetophenone intermediates 12.1 can be prepared as described in Scheme 14.
- Step 1 synthesis of (S)-4-benzyl-3-cinnamoyloxazolidin-2-one.
- Step 3 synthesis of (3S,4S)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3- carbonyl)-4-phenylhept-6-enoate.
- Step 4 synthesis of (2S,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylhex-5-enoic acid, intermediate la.
- Step 2 synthesis of (E)-3-cyclopentylacrylic acid.
- Step 3 synthesis of (E)-3-cyclopentylacryloyl chloride.
- Step 1 synthesis of 2-(2-(allylamino)thiazol-4-yl)phenylboronic acid.
- Step 2 synthesis of l-(5-(2-(2-(allylamino)thiazol-4-yl)phenyl)pyridin-2- yl)pyrrolidin-2-one, intermediate 2d.
- intermediate 2g N-allyl-4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-amine
- intermediate 21 4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-amine from intermediate 2j.
- Example 1 This general method is depicted with the synthesis of Example 1: compound n°6: 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid.
- Step 1 synthesis of (3S,4S)-tert-butyl 3-(allyl(4-(2-chlorophenyl)thiazol-2- yl)carbamoyl)-4-phenylhept-6-enoate.
- Step 2 synthesis of tert-butyl 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2- oxo-4-phenyl-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetate.
- Step 3 synthesis of 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-1,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid, compound n°6.
- Step 1 synthesis of (R)-4-(tert-butoxy)-2-(cyclopentylamino)-4-oxobutanoic acid
- Step 2 synthesis of (R)-4-tert-butyl 1 -methyl 2-(cyclopentylamino)succinate.
- Preparation of the diazomethane solution (Organic Syntheses, Coll. Vol. 2, p.165 (1943); Vol. 15, p.3 (1935))
- Step 4 synthesis of (R)-4-tert-butyl 1-methyl 2-(N-cyclopentyl-4- oxobutanamido)succinate, intermediate 3a.
- intermediate 3b 4-tert-butyl 1 -methyl 2-(4-oxo-N-phenylbutanamido)succinate which was obtained from (R)-4-tert-butoxy-4-oxo-2-(phenylamino)butanoic acid which was synthesized as follows from (R)-2-amino-4-tert-butoxy-4-oxobutanoic acid:
- Example 2 compound n°32 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,8- dioxo- 1 ,4-diazocan-2-yl)acetic acid.
- Step 1 synthesis of 4-tert-butyl 1 -methyl 2-(4-((4-(2-chlorophenyl)thiazol-2- yl)amino)-N-cyclopentylbutanamido)succinate.
- Step 2 synthesis of 4-(tert-butoxy)-2-(4-((4-(2-chlorophenyl)thiazol-2- yl)amino)-N-cyclopentylbutanamido)-4-oxobutanoic acid.
- Step 3 synthesis of tert-buty l 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l- cyclopentyl-3,8-dioxo-l,4-diazocan-2-yl)acetate.
- Step 4 synthesis of 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,8- dioxo-l,4-diazocan-2-yl)acetic acid, compound n°32.
- Example 3 compound n°l : 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lb and 2a using general method D.
- Example 4 compound n°2: 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lc and 2a using general method D.
- Example 5 compound n°3: 2-((3R,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates Id and 2a using general method D.
- Example 6 compound n°4: 2-((3R,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates le and 2a using general method D.
- Example 7 compound n°5: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazepan-3-yl)acetic acid:
- Example 8 compound n°7: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2- oxo-4-phenylazocan-3-yl)acetic acid:
- Step 1 synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetate.
- Step 2 synthesis of compound n°7.
- Example 9 c o m p o u n d n ° 9 : 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2a using general method D.
- Example 10 compound n°l l : 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-2,3,4,5,8,9-hexahydro-lH-azonin-3-yl)acetic acid was synthesized from intermediates la and 2b using general method D.
- Example 11 compound n°12: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid was synthesized from compound n°6 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 12 compound n°13: 2-((3S,4S,Z)-l-(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo- 4-phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates la and 2e using general method D.
- Example 13 compound n°14: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2- oxo-4-phenylazepan-3-yl)acetic acid was synthesized from compound n°l using the hydroboration and TFA deprotection steps as described for the synthesis of compound n°7. 73 ⁇ 4rt-butyl 2-((3S,4S,5R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-5-hydroxy-2-oxo-4- phenylazepan-3-yl)acetate was also recovered during the chromatography.
- Example 14 compound n°16: 2-((3S,4S)-l-(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid was synthesized from compound n°13 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 15 compound n°17: 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- (tetrahydro-2H-pyran-4-yl)-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates lg and 2a using general method D.
- Example 16 compound n°18: 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- (tetrahydro-2H-pyran-4-yl)azocan-3-yl)acetic acid was synthesized from compound n°17 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 17 compound n°19: 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-3,8-dioxo-l-phenyl- l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3b and 2f using general method F.
- Example 18 compound n°20: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2- oxo-4-phenylazocan-3-yl)acetic acid:
- Example 19 c omp ound n°21 : 2-((3S,4S,5R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-5- hydroxy-2-oxo-4-phenylazepan-3-yl)acetic acid:
- Example 20 compound n°22: 2-((3S,4S)-l-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol- 2-yl)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lb and 2g using general method D.
- Example 21 compound n°23: 2-((3S,4S)-l-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol- 2-yl)-2-oxo-4-phenylazepan-3-yl)acetic acid was synthesized from compound n°22 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 22 compound n°24: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-fluoro-2- oxo-4-phenylazocan-3-yl)acetic acid:
- step 1 synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-fluoro-2-oxo- 4-phenylazocan-3-yl)acetate
- Step 2 synthesis of compound n°24
- Example 23 compound n°25: 2-((3S,4S,6S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7- dihydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid and compound n°26: 2-((3S,4S,6S,7R)- l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid: A solution of 4-methylmorpholine (1.336 mmol, 135 mg) and a catalytic amount of a 4wt% solution osmium tetroxide in distilled water (0.039 mmol, 0.240 mL) in distilled water (0.3 M, 230 ⁇ ) at RT was added slowly to a solution of tert-butyl 2-((3S,4S,Z)- 1 -(
- Example 24 c o m p o u n d n ° 2 7 : 2-((3S,4S,Z)-4-([l,l'-biphenyl]-4-yl)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo- 1,2,3,4,5 , 8-hexahydroazocin-3 -y l) acetic acid was synthesized from intermediates lh and 2a using general method D.
- Example 25 compound n°29: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2,7-dioxo- 4-phenylazocan-3-yl)acetic acid:
- Example 26 compound n°30: 2-((3S,4S,Z)-2-oxo-l-(4-(2-(6-(2-oxopyrrolidin-l- yl)pyridin-3-yl)phenyl)thiazol-2-yl)-4-phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates la and 2d using general method D.
- Example 27 c omp o und n°31 : 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- (isopropylamino)-2-oxo-4-phenylazocan-3-yl)acetic acid:
- step 1 synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- (isopropylamino)-2-oxo-4-phenylazocan-3-yl)acetate
- step 1 Intermediate obtained in step 1 was treated with TFA and DCM, as described in step 3 of general method D which provided title product.
- Example 28 compound n° 33 : 2-((3S,4S,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid
- Example 29 compound n°34 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- isopropyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2a using general method D.
- Example 30 compound n°36: 2-((3S,4S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid was obtained using the same procedure as for compound n°33.
- Example 31 compound n°37: 2-((3S,4R,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-7-hydroxy-2-oxoazocan-3-yl)acetic acid and compound n° 38 : 2- ((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7-hydroxy-2-oxoazocan- 3-yl)acetic acid were synthesized from compound n°9 using the methodology described for the synthesis of compound n°7.
- Example 32 compound n°39 : 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- isobutyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates lj and 2a using general method D.
- Example 33 compound n°40 : 2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-4-isopropyl-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°34 using the methodology described for the synthesis of compound n°7.
- Example 34 compound n°41 : 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°9 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 35 compound n°42 : 2-((3S,4R,Z)-4-cyclopentyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid was synthesized from intermediates If and 2d using general method D.
- Example 36 compound n°43: 2-((3S,4R)-4-cyclopentyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid was
- Example 37 compound n°44: 2-((3S,4R,Z)-4-cyclopentyl-2-oxo-l-(4-phenylthiazol-2- yl)-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2h using general method D.
- Example 38 c omp ound n ° 45 : 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2- fluorophenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2i using general method D.
- Example 39 compound n°46: 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-methoxypyridin- 3-yl)phenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2g using general method D.
- Example 40 compound n°47: 2-((3S,4S)-7-(benzylamino)-l-(4-(2-chlorophenyl)thiazol-2- yl)-2-oxo-4-phenylazocan-3-yl)acetic acid was synthesized using the methodology used for the synthesis of compound n°31 , replacing isopropylamine with benzylamine.
- Example 41 compound n°48: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2g using general method D.
- Example 42 compound n°49 : 2-((3S,4R,Z)-4-isopropyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid was synthesized from intermediates li and 2d using general method D.
- Example 43 compound n°50 : 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopropyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates lk and 2a using general method D.
- Example 44 compound n° 62 : 2-((3S,4S,Z)-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-4-phenyl- 1 ,2,3 ,4,5 ,8-hexahydroazocin-3-y l)acetic acid was synthesized from intermediates la and 2g using general method D.
- Example 45 compound n° 63 : 2-((3S,4R)-4-isopropyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid was synthesized from compound n°49 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 46 compound n°64: 2-((3S,4R)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°62 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 47 c o m p o u n d n °116: 2-(l-isopropyl-4-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3c and 2g using general method F.
- Example 48 compound n°117: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2k using general method D.
- Example 49 compound n°118: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°l 17 using the hydrogenation procedure detailed for the synthesis of compound n°5.
- Example 50 c o m p o u n d n °119: 2-(l-cyclopentyl-4-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3a and 2g using general method F. BIOLOGY EXAMPLES
- Figure 1 represents the effect of compound 9 on GLP-1 release from rat lower intestinal GLP-1 secreting cells.
- Figure 2 represents the inhibition of in-vitro TNFa release from LPS-stimulated PBMC following the activation by the compounds of the invention.
- Figure 3 represents the inhibition of in-vivo lipolysis following the injection of compound 42 in mice.
- Membrane binding assay GTPyS binding assay.
- the following assay can be used for determination of GPR43 activation.
- a GPCR When a GPCR is in its active state, either as a result of ligand binding or constitutive activation, the receptor couples to a G protein and stimulates the release of GDP and subsequent binding of GTP to the G protein.
- the alpha subunit of the G protein-receptor complex acts as a GTPase and slowly hydrolyses the GTP to GDP, at which point the receptor normally is deactivated. Activated receptors continue to exchange GDP for GTP.
- the non- hydro lysable GTP analog, [ 35 S]GTPyS was used to demonstrate enhance binding of [ 35 S]GTPyS to membranes expressing receptors.
- the assay uses the ability of GPCR to stimulate [ 35 S]GTPyS binding to membranes expressing the relevant receptors.
- the assay can, therefore, be used in the direct identification method to screen candidate compounds to endogenous or not endogenous GPCR. Preparation of membrane extracts:
- Membrane extracts were prepared from cells expressing the human GPR43 receptor (hGPR43) as follows: the medium was aspirated and the cells were scraped from the plates in Ca ++ and Mg ++ -free Phosphate-buffered saline (PBS). The cells were then centrifuged for 3 min at 1500 g and the pellets were resuspended in buffer A (15 mM Tris-HCl pH 7.5, 2 mM MgCl 2 , 0.3 mM EDTA, 1 mM EGTA) and homogenized in a glass homogenizer. The crude membrane fraction was collected by two consecutive centrifugation steps at 40.000 x g for 25 min separated by a washing step in buffer A.
- buffer A 15 mM Tris-HCl pH 7.5, 2 mM MgCl 2 , 0.3 mM EDTA, 1 mM EGTA
- the final pellet was resuspended in 500 ⁇ . of buffer B (75 mM Tris-HCl pH 7.5, 12.5 mM MgCl 2 , 0.3 mM EDTA, lmM EGTA, 250 mM sucrose) and flash frozen in liquid nitrogen. Protein content was assayed by the Folin method.
- the assay was performed in the presence of SCFA, and was used to determine the activity of the compounds of the invention.
- the [ 35 S]GTPyS assay was incubated in 20 mM HEPES pH 7.4, 100 mM NaCl, 10 ⁇ g/ml saponin, 30 mM of MgCl 2 , 10 ⁇ of GDP, 5 ⁇ g membrane-expressing hGPR43, 250 ⁇ g of wheatgerm agglutinin beads (Amersham, ref: RPNQ001), a range concentration of compounds of the invention (from 30 ⁇ to 1 nM) in a final volume of 100 ⁇ for 30 min at room temperature.
- the SCFA propionate was used at 1 mM final concentration as positive control.
- Rat lower intestinal GLP-1 secreting cells were prepared from eight- week-old male Sprague-Dawley rat. Each well contained 5x 10 4 cells stimulated in assay buffer (DMEM- based medium) containing 5.6 mM glucose with increasing concentration of the compounds of the invention for 1 hour at 37°C in cell incubator. The supernatants were harvested and assessed for GLP-1 using an ELISA (Wako).
- assay buffer DMEM- based medium
- the blood glucose area under the curve (AUC) between time t-15 min and time tl20 min was calculated (GraphPad Prism software).
- preferred compounds of the invention When tested in the above-described assay, preferred compounds of the invention showed a % of AUC inhibition > 13%, indicating that the compounds of invention are able to significantly reduce the level of blood glucose.
- PBMC Peripheral blood mononuclear cells
- PBMC Peripheral blood mononuclear cells
- LPS 100 ng/ml
- Cell supernatants are recovered after centrifugation and human soluble TNFa .is quantified using ELISA assay (R&D system) according manufacturer's recommendation.
- mice Male C57BL/6N wild-type are housed one per cage in a room maintained on a 12h light/dark cycle under constant temperature (22-25°C) with ad libitum access to food and water.
- the anti-lipolytic effects of the compounds of the invention are studied in awake mice. Animals are fasted overnight before experimental use. On the day of the experiment, animals are put in metabolic cages and left undisturbed to acclimate to the environment for l-2h. Blood samples are taken at indicated time points from the intraorbital retrobulbar plexus. A 1% sodium citrate saline solution is used to flush the lines. A pre-treatment blood sample is obtained from each animal to determine baseline values for free fatty acids (FFA) and triglycerides (TG).
- FFA free fatty acids
- TG triglycerides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to novel compounds of formula (I) Ar1__L1__R__Ar2__Ar3 and their use in treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.
Description
NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
The present invention relates to novel compounds including their pharmaceutically acceptable salts, solvates, and prodrugs, which are modulators of G- protein coupled receptor 43 (GPR43) and are useful as therapeutic compounds, particularly in the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
[BACKGROUND OF THE INVENTION]
GPR43 (also named FFA2R) belongs to a subfamily of G-Protein-Coupled Receptors (GPCRs), including GPR40 and GPR41 that have been identified as receptor for Free Fatty Acids (FFAs) (Le Poul et al, J. Biol Chem. 278, 25481-489, 2003; Covington et al., Biochemical Society transaction 34, 770-773, 2006). The 3 family members share 30 to 40% sequences identity with specificity toward different fatty acids carbon chain lengths, with short chain fatty acids (SCFAs: six carbons molecules or shorter) activating GPR41 and GPR43 and medium and long chain fatty acids activating GPR40 (Rayasam et al., Expert Opinion on therapeutic targets, 1 1 661-671 , 2007 ). C2 acetate and C3 propionate are the most potent activators of GPR43.
The expression of GPR43 by immune cells (neutrophils, monocytes, peripheral blood mononuclear cells, B-lymphocytes and polymorphonuclear cells), in part of the gastro-intestinal tract and by white adipocytes cells as well as pancreatic β cells strongly suggested its potential as target in inflammatory, gastrointestinal and/or metabolic disorders (Milligan et al. BJP 158, ppl46-153, 2009; Regard et al, J. Clin. Inv., 117, pp40344043, 2007; Ahren Bo, Nature Reviews, 8, pp369-385, 2009). This potential is well supported by recent data. Using a GPR43 knockout mouse, Ge et al, (Endocrinology, 149, pp4519-
4526, 2008) found that neither acetate nor propionate was able to inhibit lipolysis in primary adipocytes isolated from the GPR43-/- mouse, suggesting that GPR43 is able to inhibit lipolysis and therefore, regulate plasma free fatty acid levels. Several data have shown that GPR43 is implicated in the regulation of plasma free fatty acid and glucose
homeostasis, indicating that GPR43 could be an emerging target for the treatment of type 2 diabetes, obesity, dyslipidemia and insulin resistance (Tiwari, Current Opinion in Investigational Drugs, 11(4), pp385-393, 2010).
Recent studies have shown that both acetate and proprionate decreased LPS- stimulated TNF-a release from neutrophils. In addition proprionate dose-dependently suppressed IL-6 mRNA and protein release from colitis mouse colon organ cultures. TNF- α and members of the interleukin family are known to play role in the pathogenesis of IBD (Fuss, Curr Drug Targets Inflamm allergy 2003, 2: 101-112; Tedelind et al, World J. Gastroenterol 2007, 13(20): 2826-2832). Further, GPR43 has been described to regulate the anti-inflammatory responses by short chain fatty acids in various in vivo models such as colitis, rheumatoid arthritis and asthma through a regulation of the neutrophil physio lo logy. SCFA-mediated GPR43 activation decreased TNF-a and ΜΙΡ-Ια levels in mouse DSS colitis model, as well as neutrophil chemotactic responsiveness (Maslowski et al, Nature, 2009, 461(7268): 1282-1286).
Taken together these results suggest that therapeutic strategies based on GPR43, the major receptor for acetate and propionate, could be useful in treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders. On this basis, new agonists or partial agonists of GPR43 may be of therapeutic value for the treatment and/or prevention of the above-mentioned disorders.
[SUMMARY OF THE INVENTION]
The invention encompasses compounds of general Formula I, their pharmaceutically acceptable salts, solvates, and prodrugs as well as methods of use of such compounds or compositions comprising such compounds as modulators of GPR43 activity. In a general aspect, the invention provides compounds of general formula I:
Ar1— L1— R Ar2— Ar3
I and pharmaceutically acceptable salts , solvates, and prodrugs thereof, wherein:
Ar1 is a C3-C6 alkyl, C3-C6 cycloalkyl, C4-C6 heterocyclyl, 6-membered aryl or 5 to 6- membered heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl or haloalkoxy; L1 is a single bond, -CH2-, -CHCH3 or -C(CH3)2;
Ar2 is a 6-membered aryl group or a 5 to 6-membered heteroaryl group, each of which being optionally substituted by one or more halo or alkyl group(s);
Ar3 is a 5 to 6-membered aryl optionally substituted by one or more halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy group(s), by one aryl or heteoaryl group, each of said aryl or heteroaryl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, amino, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N-(aralkyl)(alkyl)amino, heterocyclyl,
heterocyclylcarbonyl, heteroaryl, or fused to the aryl or heteroaryl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo or oxo group(s);
R is a 7 to 9-membered heterocyclyl ring selected from the group consisting of:
ring-VII ring-VIII wherein:
L1 is attached to the ring at position a and Ar2 is attached to the nitrogen atom at position b; the bonds represented by the dotted lines are independently a single bond, a double bond or a triple bond;
at least one of the bonds represented by the dotted lines depicted as "c" and "d" in ring- VII is a single bond;
D is C=0; when the dotted line in ring-I is a single bond, R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R2 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and R2 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R2 forms together with R2 a =CH2 or oxo moiety; when the dotted line in ring-I is a double bond R1 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is absent; R2 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R2 is absent; when the dotted line in ring-I is a triple bond R1, R1 , R2 and R2 are absent;
R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R3 forms together with R3 an oxo moiety; when the dotted line in ring-II is a single bond, R4 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R5 forms together with R5 an oxo moiety; when the dotted line in ring-II is a double bond, R4 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is absent; R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is absent; when the dotted line in ring- II is a triple bond R4, R4', R5 and R5 are absent;
R6 and R6' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 haloalkoxyalkyl, or R7 forms together with R7 an oxo moiety;
R8 is H or C1-C4 alkyl; R9 and R9 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R10 and R10' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4
haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in ring-V is a single bond, R11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R12 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R12 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R12 forms together with R12 a =CH2 or oxo moiety; when the dotted line in ring-V is a double bond, R11 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is absent; R12 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R12 is absent when the dotted line in ring- V is a triple bond, R11, R11', R12, and R12' are absent;
R is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R13 forms together with R13 an oxo moiety; when the dotted line in ring- VI is a single bond, R14 is selected from H, fluoro, chloro, Ci- C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R15 is H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino, heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alkyloxycarbonylamino , heterocyclyloxycarbonylamin o , a ry loxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R15 is selected from H, fluoro, chloro, Ci- C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl or R15 forms together with R15 a =CH2 or oxo moiety; when the dotted line in ring- VI is a double bond, R14 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is absent; R15 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R15 is absent;
when the dotted line in ring- VI is a triple bond, R14, R14', R15, and R15 are absent;
R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R16 forms together with R16 an oxo moiety;
R17 and R17' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted lines depicted by "c" and "d" in ring- VII are both single bonds, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; one of R19 or R20 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and the other one is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R19 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R19 forms together with R19 a =CH2 or oxo moiety and R20 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R20 forms together with R20 a =CH2 or oxo moiety and R19 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; when the dotted line depicted by a "c" in ring- VII is a single bond and the dotted line depicted by a "d" in ring- VII is a double bond, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19 and R20 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 and R20 are absent; when the dotted line depicted by a "c" in ring- VII is a single bond and the dotted line depicted by a "d" in ring- VII is a triple bond, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19, R19', R20 and R20' are absent; when the dotted line depicted by a "c" in ring- VII is a double bond and the dotted line depicted by a "d" in ring- VII is a single bond, R18 and R19 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 and R19 are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or Ci- C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky;
when the dotted line depicted by a "c" in ring- VII is a triple bond and the dotted line depicted by a "d" in ring- VII is a single bond, R18, R18 , R19 and R19' are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky;
L3 is a single bond, or L3 is a C1-C3 alkylene optionally substituted by one or more group(s) selected from fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R21 forms together with R21 an oxo moiety; R22 and R22' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R23 forms together with R23 an oxo moiety;
R24 is H or Ci-C4 alkyl;
R25 and R25 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
L2 is a C1-C2 alkylene optionally substituted by one or more methyl group(s);
Z is selected from the group consisting of-COOR°,
wherein R° is H or linear or branched alkyl, aryl, acyloxyalkyl, dioxolene, R is H, methyl or ethyl, and R" is hydroxyl -S02CH3i -S02cyclopropyl or -S02CF3.
In another aspect, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
The invention also relates to the use of the above compounds or their pharmaceutically acceptable salts and solvates or prodrugs as modulators of GPR43, preferably as agonists or partial agonists of GPR43. The invention further provides methods of treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders comprising the administration of a therapeutically effective amount of a compound or pharmaceutically acceptable salt, solvate, or prodrug of formula (I), to a patient in need thereof. Preferably the patient is a warm-blooded animal, more preferably a human.
The invention also provides the use of a compound of formula (I) or a
pharmaceutically acceptable salt, solvate, or prodrug thereof as a medicament. Preferably, the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
[DETAILED DESCRIPTION OF THE INVENTION] As noted above, the invention relates to compounds of formula I, as well as their pharmaceutically acceptable salts, solvates, and prodrugs.
Preferred compounds of formula I and pharmaceutically acceptable salts, solvates, and prodrugs thereof are those wherein
Ar1 is C3-C6 alkyl, C3-C6 cycloalkyl, tetrahydropyran-4-yl, 6-membered aryl or 5 membered heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, alkyl, haloalkyl, alkoxy or haloalkoxy, preferably Ar1 is C3-C6 alkyl preferably isopropyl, isobutyl, C3-C6 cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, more preferably cyclopentyl, tetrahydropyran-4-yl, 6-membered aryl preferably phenyl, or 5 membered heteroaryl preferably thiazolyl group; and/or L1 is a single bond or -CH2-, preferably L1 is a single bond; and/or
Ar2 is a 5 to 6-membered heteroaryl group optionally substituted by one or more halo or alkyl group(s), preferably Ar2 is a thiazolyl, thiadiazolyl or pyridinyl group, more preferably Ar2 is a thiazolyl group; and/or
Ar3 is a 5 to 6-membered aryl optionally substituted by one or more halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy group(s), by one aryl or heteoaryl group, each of said aryl or heteroaryl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, amino, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N-(aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the aryl or heteroaryl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo or oxo group(s), preferably Ar3
is a phenyl optionally substituted by one or more chloro, fluoro, -CF3 or -CF2H, methoxy, -OCF3 or -OCF2H group(s), or by one pyridinyl, pyridazinyl or pyrazinyl group, each of said pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected chloro, fluoro, methyl, -CF3 or -CF2H, methoxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, dimethylamino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo or oxo group(s); and/or
D is C=0; and/or
R is selected from ring-I, ring-V, ring- VI and ring-VII, preferably R is ring-V or ring -VI, more preferably R is ring -V; wherein preferably when the dotted line in ring-I is a single bond, R1 is selected from H, fluoro, Ci-C3 alkyl, preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxy, preferably methoxy, Ci-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R1 is H; R1 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R1 is H; R2 is selected from H, fluoro, chloro, Ci-C6 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxy preferably methoxy, Ci-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R2 is selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, still more preferably R2 is H; R2 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, or R2 forms together with R2 a =CH2 or oxo moiety, more
preferably R2 is H; when the dotted line in ring-I is a double bond, R1 is selected from H, fluoro, C1-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably metho xymethyl, more preferably R1 is H; R1 is absent; R2 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably metho xymethyl, more preferably R2 is H; R2 is absent;
R3 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R3 is H; and/or
R3 is selected from H, fluoro, C1-C3 alkyl preferably methyl, more preferably R3 is H; and/or
R10 and R10' are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R10 and R10 are H; and/or when the dotted line in ring-V is a single bond, R11 is selected from H, fluoro, C1-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy, preferably methoxy, Ci-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl; more preferably R11 is H; R11 is selected from H, fluoro, C1-C3 alkyl preferably methyl; more preferably R11 is H; R12 is selected from H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl
preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R12 is H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, still more preferably R12 is H, fluoro, hydroxyl, even more preferably R12 is H, hydroxyl and the bond linking R12 to R is drawn as a solid wedge or a dotted wedge, preferably as a solid wedge when R11 is H or as a dotted wedge when R11 is hydroxyl, even more preferably R12 is H, hydroxyl and the bond linking R12 to R is drawn as a solid wedge; R12 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, or R12 forms together with R12 a =CH2 or oxo moiety, more preferably R12 is H; when the dotted line in ring-V is a double bond, R11 is selected from H, fluoro, Ci- C3 alkyl, preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy- Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R11 is H; R11 is absent; R12 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R12 is H; R12 is absent; and/or
R13 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R13 is H; and/or
R13 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R13 is H; and/or when the dotted line in ring- VI is a single bond, R14 is selected from H, fluoro, chloro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably
methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R14 is H; R14 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl; more preferably R14 is selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl, still more preferably R14 is H; R15 is selected from H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R15 is H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, still more preferably R15 is H, fluoro, hydroxyl, even more preferably R15 is H, hydroxyl and the bond linking R15 to R is drawn as a solid wedge or a dotted wedge, preferably as a solid wedge when R14 is H or as a dotted wedge when R14 is hydroxyl, even more preferably R15 is H, hydroxyl and the bond linking R15 to R is drawn as a solid wedge; R15 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R15 is H; when the dotted line in ring- VI is a double bond R14 is selected from H, fluoro, Ci- C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci- C3 alkyl preferably hydroxymethyl, C1-C2 alkoxyalkyl preferably methoxymethyl; more preferably R14 is selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl; still more preferably R14 is H; R14 is absent; R15 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or - CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, more preferably R15 is H; R15 is absent; and/or
R16 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably
hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R16 is H; and/or
R16 is selected from H, fluoro, C1-C3 alkyl preferably methyl, more preferably R16 is H; and/or
R17 and R17' are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R17 and R17 are H; and/or when the dotted lines depicted by "c" and "d" in ring- VII are both single bonds, R18 is selected from H, fluoro, chloro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R18 is selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl; still preferably R18 is H; R18 is selected from H, fluoro, C1-C3 alkyl preferably methyl preferably R18 is H; one of R19 or R20 is selected from H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or - CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, and the other one is selected from H, fluoro, chloro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably - CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl; more preferably one of R19 or R20 IS selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, and the other one is selected from H, fluoro, chloro,
methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl; still more preferably R19 and R20 are independently selected from H, fluoro and hydroxyl; even more preferably R19 and R20 are independently selected from H and hydroxyl and the bonds linking R19 and R20 to R are independently drawn as a solid wedge or a dotted wedge, preferably as a solid wedge when only one of R19 and R20 is hydroxyl, preferably as a dotted wedge when both R19 and R20 are hydroxyl; R19 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl more preferably R19 is H; R20 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl preferably - CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R20 is H; when the dotted line depicted by a "c" in ring- VII is a single bond and the dotted line depicted by a "d" in ring- VII is a double bond, R18 is selected from H, fluoro, chloro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R18 is selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl; still more preferably R18 is H; R18 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R18 is H; R19 and R20 are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl; more preferably R19 and R20 are H; R19 and R20 are absent; when the dotted line depicted by a "c" in ring- VII is a double bond and the dotted line depicted by a "d" in ring- VII is a single bond, R18 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy- Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably
18 18' 19 20 methoxymethyl, more preferably R is H; R is absent; R and R are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably
hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl; more preferably R and R20 are independently selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl; still more preferably R19 and R20 are H; R19 is absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, or R20 forms together with R20 a =CH2 or oxo moiety, preferably R20 is H; and/or
R21 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -
OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R21 is selected from H, fluoro, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethy, still more preferably R21 is H; and/or
R21 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R21 is H; and/or
L3 is a single bond; and/or when R is selected from ring-II, ring III, ring IV and ring VIII
R4, R4', R5 and R5 are H; and/or
R6, R6', R7 and R7' are H; and/or R8, R9 and R9' are H; and/or
R22, R22', R23, R23', R24, R25 and R25 are H; and/or
L2 is a methylene optionally substituted by one or more methyl group(s), preferably L2 is CH2; and/or
Z is selected from the group consisting of -COOR0, wherein R° is H or linear or branched alkyl, preferably Z is -COOH.
In one embodiment preferred compounds of Formula I are those of formula
R is as defined above in respect to formula I, preferably R is selected from ring-I, ring-II, ring-V, ring- VI, ring- VII and ring- VIII, more preferably R is selected from ring-I, ring-V, ring VI and ring- VII, still more preferably R is ring-V or ring VI, even more preferably R is ring-V; Ar1 is as defined above in respect to formula I, preferably Ar1 is isopropyl, butyl, tert-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-difluorocyclohexan-l-yl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, furanyl, thiophenyl or thiazolyl, each of which being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy, more preferably Ar1 is isopropyl, isobutyl, cyclopropyl, cyclopentyl, tetrahydrofuran-2-yl, tetrahydropyran-4-yl, phenyl , 2- fluorophenyl, 4-chlorophenyl, 4-tolyl, 4-methoxyphenyl, furan-2-yl, thiophen-2-yl, thiazol- 2-yl or thiazol-4-yl, still more preferably Ar1 is isopropyl, isobutyl, cyclopropyl, cyclopentyl, tetrahydropyran-4-yl, or phenyl, even more preferably Ar1 is cyclopropyl, cyclopentyl; Ar3 is as defined above in respect to formula I, preferably Ar3 is a phenyl optionally substituted by one or more halo preferably chloro or fluoro, cyano, alkyl preferably methyl or isopropyl, haloalkyl preferably -CHF2 or -CF3, hydroxyl, alkoxy preferably methoxy, haloalkoxy preferably -OCHF2 or -OCF3 group(s), by one phenyl, pyridinyl, pyridazinyl or pyrazinyl group, each of said phenyl, pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo preferably chloro or
fluoro, alkyl preferably methyl, haloalkyl preferably -CHF2 or -CF3, hydroxyl, alkoxy preferably methoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy, aralkyloxy preferably benzyloxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, (2-ethoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, (3-methoxybutan-2- yl)oxy, (l-methoxy-2-methylpropan-2-yl)oxy, ((3S)-3-methoxybutan-2-yl)oxy, ((3R)-3- methoxybutan-2-yl)oxy, haloalkoxyalkoxy preferably (2-(2,2,2-trifluoroethoxy)ethyl)oxy, (2-(2-ethoxyethoxy)ethyl)oxy, alkylamino preferably dimethylamino, N,N- (cycloalkyl)(alkyl)amino preferably N,N-(cyclohexyl)(methyl)amino, N,N- (aralkyl)(alkyl)amino preferably N,N-(benzyl)(methyl)amino, heterocyclyl preferably azetidinyl, pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin- lyl)carbonyl, heteroaryl preferably furan-2-yl, thiophen-2-yl, 3,5-dimethyl-lH-pyrazol-l- yl, pyrazol-l-yl, 2-methyltetrazol-5-yl, 1,3,4-triazol-l-yl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,3-oxazinyl or heteroaryl preferably pyrrolyl, pyrazolyl, triazolyl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), more preferably Ar3 is a phenyl optionally substituted by one or more halo preferably chloro, fluoro, by one pyridinyl, pyridazinyl or pyrazinyl group, each of said pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably -CHF2 or -CF3, alkoxy preferably methoxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, ((3S)-3-methoxybutan-2-yl)oxy, ((3R)-3-methoxybutan-2-yl)oxy, alkylamino preferably dimethylamino, heterocyclyl preferably pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin-lyl)carbonyl, heteroaryl preferably 3,5-dimethyl-lH-pyrazol-l-yl, pyrazol-l-yl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, or heteroaryl preferably pyrrolyl, pyrazolyl, triazolyl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), even more preferably Ar3 is phenyl, 2- chlorophenyl, 2-fluorophenyl, 2,5-dichlorophenyl, 2-(6-methoxypyridin-3-yl)phenyl, 2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl, 2-(6-(3 -methyl-2-oxopyrrolidin- 1 -yl)pyridin-3 -
yl)phenyl, 2-(6-methoxypyrazin-3-yl)phenyl, 2-(6-(2-oxopyrrolidin- 1 -yl)pyrazin-3- yl)phenyl, 2-(6-methoxypyridazin-3-yl)phenyl, even more preferably Ar3 is phenyl, 2- chlorophenyl, 2-fluorophenyl, 2,5-dichlorophenyl, 2-(6-methoxypyridin-3-yl)phenyl, 2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl, 2-(6-methoxypyrazin-3 -yl)phenyl. X is S or O, preferably X is S;
Y is CH or N, preferably Y is CH;
the heterocyclic group
is substituted with Ar either in position 4 or 5 , preferably in position 4; and
H, halo, cyano, hydro xyl, linear or branched C1-C3 alkyl, C1-C3 hydro xyalkyl, Ci-
26
C3 haloalkyl, preferably R is H, methyl, F, CI, or CF3, more preferably R. o is H or F, still more R is preferably H; if Y is N, R2b is absent.
Preferred compounds of formula la are those of formula Ia-1
Ia-1 harmaceutically acceptable salts, solvates, and prodrugs thereof, wherein
R, Ar1, Ar3 and R26 are as defined above in respect to formula la, preferably R26 is H or F, more preferably R26 is H.
Preferred compounds of formula Ia-1 are those of formula Ia-2
Ia-2 and pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein R, Ar1 and R26 are as defined above in respect to formula Ia-1;
R27 is H, halo preferably chloro or fluoro, cyano, alkyl preferably methyl or isopropyl, haloalkyl preferably -CHF2 or -CF3, hydroxyl, alkoxy preferably methoxy, haloalkoxy preferably -OCHF2 or -OCF3, phenyl, pyridinyl, pyridazinyl or pyrazinyl, each of said phenyl, pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably -CHF2 or -CF3, hydroxyl, alkoxy preferably methoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy, aralkyloxy preferably benzyloxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, (2-ethoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, (3-methoxybutan-2-yl)oxy, (l-methoxy-2- methylpropan-2-yl) o xy , ((3 S)-3 -methoxybutan-2-yl)oxy, ((3R)-3 -methoxybutan-2-yl)oxy, h a l o a l k o x y a l k o x y p r e fe r a b l y (2-(2,2,2-trifluoroethoxy)ethyl)oxy, (2-(2- ethoxyethoxy)ethyl)oxy, alkylamino preferably dimethylamino, N,N- (cycloalkyl)(alkyl)amino preferably N,N-(cyclohexyl)(methyl)amino, N,N- (aralkyl)(alkyl)amino preferably N,N-(benzyl)(methyl)amino, heterocyclyl preferably azetidinyl, pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin- lyl)carbonyl, heteroaryl preferably furan-2-yl, thiophen-2-yl, 3,5-dimethyl-lH-pyrazol-l- yl, pyrazol-l-yl, 2-methyltetrazol-5-yl, 1,3,4-triazol-l-yl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,3-oxazinyl or heteroaryl preferably pyrrolyl, pyrazolyl, triazolyl ring, thus forming a fused bicyclic system, each of said substituents may be
substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), preferably R27 is H, halo preferably chloro or fluoro, pyridinyl, pyridazinyl or pyrazinyl, each of said pyridinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably -CHF2 or -CF3, alkoxy preferably methoxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, ((3S)-3-methoxybutan-2-yl)oxy, ((3R)-3-methoxybutan-2-yl)oxy, alkylamino preferably dimethylamino, heterocyclyl preferably pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin-lyl)carbonyl, heteroaryl preferably 3,5-dimethyl-lH-pyrazol-l-yl, pyrazol-l-yl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, or heteroaryl preferably pyrrolyl, pyrazolyl, triazolyl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), more preferably R27 is H, chloro, fluoro, 6- methoxypyridin-3 -yl, 6-(2-oxopyrrolidin- 1 -yl)pyridin-3 -yl, 6-(3 -methyl-2-oxopyrrolidin- 1 - yl)pyridin-3-yl, 6-(3-fluoro-2-oxopyrrolidin-l-yl)pyridin-3-yl, 6-methoxypyrazin-3-yl, 6- (2-oxopyrrolidin-l-yl)pyrazin-3-yl, 6-methoxypyridazin-3-yl, even more preferably R27 is chloro, fluoro, 6-methoxypyridin-3-yl, 6-(2-oxopyrrolidin-l-yl)pyridin-3-yl, 6- methoxypyrazin-3 -yl;
R27' is H;
R28 is H, halo, cyano, alkyl preferably methyl, haloalkyl, hydroxyl, alkoxy preferably methoxy, haloalkoxy, preferably R28 is H, fluoro, chloro, cyano, -CHF2, -CF3 or -OCF3 more preferably R28 is H;
R28' is H, halo, cyano, alkyl preferably methyl, haloalkyl, hydroxyl, alkoxy preferably methoxy, haloalkoxy, preferably R28 is H, fluoro, chloro, -CF3 , -OCHF2 or -OCF3 more preferably R28 is H;
R29 is H, halo, cyano, alkyl, alkoxy, preferably R29 is H, chloro, fluoro, methyl or methoxy more preferably R29 is H.
Preferred compounds of formula Ia-2 are those of formula Ia-3
Ia-3 and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein R, Ar1 and R26 are as defined above in respect to formula Ia-2; R27' is H;
R28 is as defined above in respect to formula Ia-2, preferably R28 is H or fluoro, more preferably R28 is H;
28' 28'
R is as defined above in respect to formula Ia-2, preferably R is H, chloro or fluoro, more preferably R28 is H;
R29 is as defined above in respect to formula Ia-2, preferably R29 is H, chloro or fluoro, more preferably R29 is H;
R30 is H, halo preferably chloro or fluoro, alkyl preferably methyl, haloalkyl preferably - CHF2 or -CF3, hydro xyl, alkoxy preferably methoxy, preferably R30 is H, chloro;
R31 is alkoxy preferably methoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy, aralkyloxy preferably benzyloxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, (2-ethoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, (3- methoxybutan-2-yl) o xy , (1 -methoxy-2-methylpropan-2-yl)oxy, ((3 S)-3 -methoxybutan-2- yl)o xy , ( (3 R)-3-methoxybutan-2-yl)oxy, haloalkoxyalkoxy preferably (2-(2,2,2- trifluoroethoxy)ethyl) o x y , (2-(2-ethoxyethoxy)ethyl)oxy, alkylamino preferably dimethylamino, N,N-(cycloalkyl)(alkyl)amino preferably N,N-(cyclohexyl)(methyl)amino,
N,N-(aralkyl)(alkyl)amino preferably N,N-(benzyl)(methyl)amino, heterocyclyl preferably azetidinyl, pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin- lyl)carbonyl, heteroaryl preferably furan-2-yl, thiophen-2-yl, 3,5-dimethyl-lH-pyrazol-l- yl, pyrazol-l-yl, 2-methyltetrazol-5-yl, 1,3,4-triazol-l-yl, each of said substituents may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), preferably R31 is alkoxy preferably methoxy, alkoxyalkoxy optionally substituted by an alkoxy group preferably (2-methoxyethyl)oxy, 2-(isopropyloxyethyl)oxy, ((3S)-3- methoxybutan-2-yl) o x y , ( ( 3 R)-3-methoxybutan-2-yl)oxy, alkylamino preferably dimethylamino, heterocyclyl preferably pyrrolidinyl, morpholinyl, heterocyclylcarbonyl preferably (pyrrolidin-lyl)carbonyl, heteroaryl preferably 3,5-dimethyl-lH-pyrazol-l-yl, pyrazol-l-yl, each of said substituents may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s), more preferably R31 is methoxy, 2-oxopyrrolidin-l-yl, 3-methyl-2-oxopyrrolidin-l-yl, 3-fluoro-2-oxopyrrolidin-l-yl even more preferably R31 is methoxy, 2-oxopyrrolidin-l-yl; or
R30 and R31 together form a heterocyclyl preferably pyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, or heteroaryl preferably pyrrolyl, pyrazolyl or triazolyl ring, thus forming a fused bicyclic system which may be substituted by one or more alkyl preferably methyl, halo preferably chloro or fluoro, or oxo group(s);
X1 is N or C-R32 wherein R32 is H;
2 32' 32' 32'
X is N or C-R wherein R is H or alkoxy preferably R is H or methoxy, more preferably R32 is H, preferably X2 is N or CH, more preferably X2 is CH.
Preferred compounds of formula Ia-3 are those wherein the
moiety is selected from:
H, X2 is CH and R31 is methoxy or 2-oxopyrrolidin-l-yl.
Other preferred compounds of formula Ia-2 are those of formula Ia-4
Ia-4 and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein R and Ar1 are as defined above in respect to formula Ia-2;
27 28' 27 28'
R" and Ri0 are as defined above in respect to formula Ia-2, preferably R and R are independently selected from H, halo, haloalkyl, haloalkoxy, preferably chloro, fluoro, -CF3, -CHF2, -OCF3 or -OCHF2, more preferably R27 is H, chloro or fluoro and R28 is selected from H, halo, -CF3, -CHF2, -OCF3 or -OCHF2, preferably chloro and fluoro, even more preferably R27 is chloro or fluoro and R28 is H, or R27 is H and R28' is -OCF3 or -OCHF2, even more preferably R27 is chloro or fluoro and R28 is H.
In another embodiment, preferred compounds of Formula I are those of formula lb:
lb
and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein R, Ar1 and Ar3 are as defined above in respect to formula la; X3 is CH or N;
R33 and R33' are independently selected from H, halo, cyano, hydro xyl, linear or branched C1-C3 alkyl, C1-C3 haloalkyl, preferably R33 and R33 are independently selected from H, F, CI, or CF3, more preferably R33 and R33' are H;
In another embodiment, preferred compounds of Formula I are those formula Ic:
1 3 33 33'
R, Ar1, Ar R~ and R^ are as defined above in respect to formula lb.
In another embodiment, preferred compounds of Formula I are those of formulae Id-1, Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8:
ld-7 ld-8 and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein
Ar1, Ar2, Ar3, L1, L2, D, and Z are as defined above in respect to formula I; the bonds represented by the dotted lines are independently either absent or present thus making the bonds represented by = independently a single bond or a double bond respectively, preferably the dotted lines are absent; at least one of the bonds represented by the dotted lines depicted as "c" and "d" in formula Id-7 is a single bond;
when the dotted line in formula Id-1 is absent, R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R2 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and R2 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R2 forms together with R2 a =CH2 or oxo moiety; when the dotted line in formula Id-1 is present, R1 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is absent; R2 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R2 is absent;
R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R3 forms together with R3 an oxo moiety; when the dotted line in formula Id-2 is absent, R4 is selected from H, fluoro, chloro, C1-C4
alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R5 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R5 forms together with R5 an oxo moiety; when the dotted line in formula Id-2 is present, R4 is selected from H, fiuoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is absent; R5 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is absent;
R6 and R6' are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R7 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R7 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 haloalkoxyalkyl, or R7 forms together with R7 an oxo moiety;
R8 is H or C1-C4 alkyl;
R9 and R9 are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R10 and R10' are independently selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in formula Id-5 is absent, R11 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is selected from H, fiuoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R is H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino, heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alkyloxycarbonylamino , hetero cycly lo xycarbony lamino , arylo xycarbony lamino , hetero arylo xycarbonylamino , alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R12 is selected from H, fluoro, chloro, Ci- C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R12 forms together with R12 a =CH2 or oxo moiety; when the dotted line in formula Id-5 is present, R11 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is absent; R12 is H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R12 is absent
R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R13 forms together with R13 an oxo moiety; when the dotted line in formula Id-6 is absent, R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R15 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R15 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl or R15 forms together with R15 a =CH2 or oxo moiety; when the dotted line in formula Id-6 is present, R14 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is absent; R15 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R15 is absent;
R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R16 forms together with R16 an oxo moiety;
R17 and R17' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
when the dotted lines depicted by "c" and "d" in formula Id-7 are both absent, R is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; one of R19 or R20 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and the other one is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R19 forms together with R19 a =CH2 or oxo moiety and R20 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R20 forms together with R20 a =CH2 or oxo moiety and R19 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; when the dotted line depicted by a "c" in formula Id-7 is absent and the dotted line depicted
by a "d" in formula Id-7 is present, R is selected from H, fluoro, chloro, C1-C4 alkyl, Ci- C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19 and R20 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 and R20 are absent; when the dotted line depicted by a "c" in formula Id-7 is present and the dotted line depicted by a "d" in formula Id-7 is absent, R18 and R19 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 and R19 are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or Ci- C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky;
R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R21 forms together with R21 an oxo moiety;
R22 and R22' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R23 forms together with R23 an oxo moiety;
R24 is H or Ci-C4 alkyl; and
R25 and R25 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4
haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl.
In one embodiment, compounds of formula Id-6 are those wherein the bond linking carbon to which L2-Z is attached and D is drawn as a solid wedge:
Among the compounds of formulae Id-1 , Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8 those of formulae Id-1, Id-2, Id-5, Id-6, Id-7 and Id-8 are preferred.
Among the compounds of formulae Id-1 , Id-2, Id-5, Id-6, Id-7 and Id-8 those of formulae Id-1, Id-5, Id-6 and Id-7 are preferred.
Among the compounds of formulae Id-1 , Id-5, Id-6 and Id-7 those of formula Id-5 and Id-6 are preferred.
Among the compounds of formulae Id-5 and Id-6, those of formula Id-5 are preferred.
Preferred compounds of formulae Id-1 , Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8 are those of formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8 respectively:
le-7 le-8 harmaceutically acceptable salts, and solvates, or prodrugs thereof, wherein
Ar1 and Ar3 are as defined above in respect to formula la;
Ar2 is as defined above in respect to formula I, preferably Ar2 is a 5 to 6-membered heteroaryl group, preferably thiazolyl, thiadiazolyl or pyridinyl, each of which being optionally substituted by one or more halo, preferably fluoro, or alkyl, preferably methyl, group(s) preferably Ar2 is a thiazolyl connected to the ring nitrogen at position 2 and to Ar3 at position 4 and optionally substituted by a fluoro at position 5, preferably unsubstituted at position 5, or Ar2 is a thiadiazolyl connected to the ring nitrogen at position 2 and to Ar3 at
position 5, more preferably Ar2 is a thiazolyl connected to the ring nitrogen at position 2 and to Ar3 at position 4;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' ,
R12 R12' R13 R13' R14 R14' R15 R15' R16 R16' R17 R17' R18 R18' R19 R19' R20 R20' IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV ,
R21, R21', R22, R22', R23, R23', R24, R25, R25 , and the dotted lines are as defined above in respect to formulae Id-1, Id-2, Id-3, Id-4, Id-5, Id-6, Id-7 and Id-8, preferably: when the dotted line in formula Ie-1 is absent, R1 is selected from H, fluoro, C1-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy, preferably methoxy, Ci-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R1 is H; R1 is selected from H, fluoro, C1-C3 alkyl preferably methyl, more preferably R1 is H; R2 is H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy- C1-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R2 is H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino still more preferably R2 is H; R2 is selected from H, fluoro, C1-C2 alkyl preferably methyl, Ci- C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl, or R2 forms together with R2 a =CH2 or oxo moiety, more preferably R2 is H; when the dotted line in formula Ie-1 is present, R1 is selected from H, fluoro, C1-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R1 is H; R1 is absent; R2 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R2 is H; R2 is absent;
R3 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R3 is H;
R3 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R3 is H;
R4, R4', R5 and R5 are H; R6, R6', R7 and R7' are H; R8, R9 and R9' are H;
R10 and R10' are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R10 and R10 are H; when the dotted line in formula Ie-5 is absent, R11 is selected from H, fluoro, Ci-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxy, preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl; more preferably R11 is H; R11 is selected from H, fluoro, Ci-C3 alkyl preferably methyl; more preferably R11 is H; R12 is H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R12 is H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, still more
preferably R is H, fluoro, hydroxyl, even more preferably R is H, hydroxyl and the bond linking R12 to R is drawn as a solid wedge or a dotted wedge, preferably as a solid wedge when R11 is H or as a dotted wedge when R11 is hydroxyl, even more preferably R12 is H, hydroxyl and the bond linking R12 to R is drawn as a solid wedge; R12 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydro xymethyl, C1-C3 alkoxyalkyl preferably metho xymethyl, or R12 forms together with R12 a =CH2 or oxo moiety, preferably R12 is H; when the dotted line in formula Ie-5 is present, R11 is selected from H, fluoro, C1-C3 alkyl, preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydro xymethyl, C1-C3 alkoxyalkyl preferably metho xymethyl, more preferably R11 is H; R11 is absent; R12 is H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydro xymethyl, C1-C3 alkoxyalkyl preferably metho xymethyl, more preferably R12 is H; R12 is absent;
R13 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R13 is H;
R13 is selected from H, fluoro, C1-C3 alkyl preferably methyl, more preferably R13 is H; when the dotted line in formula Ie-6 is absent, R14 is selected from H, fluoro, chloro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, C1-C3 alkoxyalkyl preferably methoxymethyl, more preferably R14 is H; R14 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C3 alkoxyalkyl preferably
methoxymethyl; more preferably R14 is selected from H, fluoro, methyl, -CHF2, hydro xymethyl, methoxymethyl, still more preferably R14 is H; R15 is H, fluoro, chloro, Ci-C6 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydro xyl, hydroxy-Ci-C3 alkyl preferably hydro xymethyl, Ci-C3 alkoxy preferably methoxy, Ci-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, more preferably R15 is H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, still more preferably R15 is H, fluoro, hydroxyl, even more preferably R15 is H, hydroxyl and the bond linking R15 to R is drawn as a solid wedge or a dotted wedge, preferably as a solid wedge when R14 is H or as a dotted wedge when R14 is hydroxyl, even more preferably R15 is H, hydroxyl and the bond linking R15 to R is drawn as a solid wedge; R15 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R15 is H; when the dotted line in formula Ie-6 is present, R14 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C2 alkoxyalkyl preferably methoxymethyl; more preferably R14 is selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl; still more preferably R14 is H; R14 is absent; R15 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or - CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, more preferably R15 is H; R15 is absent;
R16 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R16 is H;
R16 is selected from H, fluoro, C1-C3 alkyl preferably methyl, more preferably R16 is H;
R17 and R17' are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R17 and R17 are H; when the dotted lines depicted by "c" and "d" in formula Ie-7 are both absent, R18 is selected from H, fluoro, chloro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably - OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R18 is selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl; more preferably R18 is H; R18 is selected from H, fluoro, Ci-C3 alkyl preferably methyl more preferably R18 is H; one of R19 or R20 is selected from H, fluoro, chloro, Ci-C6 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, aralkyloxy preferably benzyloxy, aralkylamino preferably benzylamino, alkylcarbonylamino preferably acetylamino, alkylsulfonylamino preferably methylsulfonylamino, and the other one is selected from H, fluoro, chloro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably - CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl; more preferably one of R19 or R20 IS selected from H, fluoro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, benzylamino, and the other one is selected from H, fluoro, chloro, methyl, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethyl; still more preferably R19 and R20 are independently selected from H, fluoro and hydroxyl; even more preferably R19 and R20 are independently selected from H and hydroxyl and the bonds linking R19 and R20 to R are independently drawn as a solid wedge or
a dotted wedge, preferably as a solid wedge when only one of R and R is hydroxyl, preferably as a dotted wedge when both R19 and R20 are hydroxyl; R19 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R19 is H; R20 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl preferably - CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R20 is H; when the dotted line depicted by a "c" in ring-VII absent and the dotted line depicted by a "d" in formula Ie-7 is present, R18 is selected from H, fluoro, chloro, Ci-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, C1-C2 alkoxy preferably methoxy, C1-C2 haloalkoxy preferably -OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R18 is H; R18 is selected from H, fluoro, Ci-C3 alkyl preferably methyl more preferably R18' is H; R19 and R20 are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl; more preferably R19 and R20 are H; R19 and R20 are absent; when the dotted line depicted by a "c" in formula Ie-7 is present and the dotted line depicted by a "d" in formula Ie-7 is absent R18 is selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R18 is selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl; still more preferably R 18 is H; R 18' is absent; R 19 and R 20 are independently selected from H, fluoro, C1-C2 alkyl preferably methyl, C1-C2 haloalkyl preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl; more preferably R19 and R20 are independently selected from H, fluoro, methyl, -CHF2, hydroxymethyl, methoxymethyl; still more preferably R19 and R20 are H; R19 is absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl preferably methyl, C1-C2 haloalkyl
preferably -CF3 or -CHF2, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C3 alkoxyalkyl preferably methoxymethyl, or R20 forms together with R20 a =CH2 or oxo moiety, more preferably R20 is H;
R21 is selected from H, fluoro, Ci-C2 alkyl preferably methyl, Ci-C2 haloalkyl preferably -CF3 or -CHF2, hydroxyl, hydroxy-Ci-C3 alkyl preferably hydroxymethyl, Ci-C2 alkoxy preferably methoxy, Ci-C2 haloalkoxy preferably - OCF3 or -OCHF2, Ci-C3 alkoxyalkyl preferably methoxymethyl, more preferably R21 is selected from H, fluoro, -CHF2, hydroxyl, hydroxymethyl, methoxy, methoxymethy, still more preferably R21 is H; R21 is selected from H, fluoro, Ci-C3 alkyl preferably methyl, more preferably R21 is H;
R22 R22 R23 R23 R24 R25 ^ R25 ^ R
In one embodiment, compounds of formula Ie-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
Among the compounds of formulae Ie-1 , Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8 those of formulae Ie-1, Ie-2, Ie-5, Ie-6, Ie-7 and Ie-8 are preferred.
Among the compounds of formulae Ie-1, Ie-2, Ie-5, Ie-6, Ie-7 and Ie-8 those of formulae Ie- 1, Ie-5, Ie-6 and Ie-7 are preferred.
Among the compounds of formulae Ie-1 , Ie-5, Ie-6 and Ie-7 those of formula Ie-5 and Ie-6 are preferred.
Among the compounds of formulae Ie-5 and Ie-6, those of formula Ie-5 are preferred.
Preferred compounds of formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8 are those formulae If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 respectively:
and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein
Ar1, Ar3, R26, X and Y are as defined above in respect to formula la;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' , cr R12 r12' r13 r13' r14 r14' r15 r15' r16 r16' r17 r17' r18 r18' r19 r19' r20 r20' D IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV ,
R21, R21', R22, R22', R23, R23', R24, R25 and R25 and the dotted lines are as defined above in respect to formulae Ie-1, Ie-2, Ie-3, Ie-4, Ie-5, Ie-6, Ie-7 and Ie-8.
In one embodiment, compounds of formula If-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid0 wedge:
Among the compounds of formulae If-l , If-2, If-3, If-4, If-5, If-6, If-7 and If-8 those of formulae If-l , If-2, If-5, If-6, If-7 and If-8 are preferred.
Among the compounds of formulae If-l , If-2, If-5, If-6, If-7 and If-8 those of formulae If-l , If-5, If-6 and If-7 are preferred.
Among the compounds of formulae If-l , If-5 , If-6 and If-7 those of formula If-5 and If-6 are preferred.
Among the compounds of formulae If-5 and If-6, those of formula If-5 are preferred.
Preferred compounds of formulae If-l , If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those of formulae Ig-1 , Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 respectively:
harmaceutically acceptable salts, solvates, and prodrugs thereof, wherein
Ar1, Ar3 and R26 are as defined above in respect to formula Ia-1;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' ,
R12 R12' R13 R13' R14 R14' R15 R15' R16 R16' R17 R17' R18 R18' R19 R19' R20 R20' IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV ,
R21, R21', R22, R22', R23, R23', R24, R25 and R25 and the dotted lines are as defined above in respect to formulae If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8.
In one embodiment, compounds of formula Ig-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
Among the compounds of formulae Ig-1 , Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 those of formulae Ig-1, Ig-2, Ig-5, Ig-6, Ig-7 and Ig-8 are preferred.
Among the compounds of formulae Ig-1 , Ig-2, Ig-5, Ig-6, Ig-7 and Ig-8 those of formulae Ig-1, Ig-5, Ig-6 and Ig-7 are preferred.
Among the compounds of formulae Ig-1 , Ig-5, Ig-6 and Ig-7 those of formula Ig-5 and Ig-6 are preferred.
Among the compounds of formulae Ig-5 and Ig-6, those of formula Ig-5 are preferred.
Preferred compounds of formulae Ig-1 , Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 are those of formulae Ih-1, Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 respectively:
52
and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein Ar1, R26, R27, R27 , R28, R28 and R29 are as defined above in respect to formula Ia-2;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' ,
R12 R12' R13 R13' R14 R14' R15 R15' R16 R16' R17 R17' R18 R18' R19 R19' R20 R20' IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV , R21, R21', R22, R22', R23, R23', R24, R25 and R25 and the dotted lines are as defined above in respect to formulae Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8.
In one embodiment, compounds of formula Ih-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid wedge:
Among the compounds of formulae Ih-1 , Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 those of formulae Ih-1, Ih-2, Ih-5, Ih-6, Ih-7 and Ih-8 are preferred.
Among the compounds of formulae Ih-1 , Ih-2, Ih-5, Ih-6, Ih-7 and Ih-8 those of formulae Ih-1, Ih-5, Ih-6 and Ih-7 are preferred. Among the compounds of formulae Ih-1 , Ih-5, Ih-6 and Ih-7 those of formula Ih-5 and Ih-6 are preferred.
Among the compounds of formulae Ih-5 and Ih-6, those of formula Ih-5 are preferred.
Preferred compounds of formulae Ih-1 , Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 are those of formulae Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 respectively:
54
Ar1, R26, R27', R28, R28 , R29, R30, R31, X1 and X2 are as defined above in respect to formula Ia-3;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' , cr R12 r12' r13 r13' r14 r14' r15 r15' r16 r16' r17 r17' r18 r18' r19 r19' r20 r20' D IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV ,
R21, R21', R22, R22', R23, R23', R24, R25 and R25 and the dotted lines are as defined above in respect to formulae Ih-1, Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8.
In one embodiment, compounds of formula Ii-6 are those wherein the bond linking the carbon to which the carboxymethyl is attached and the adjacent carbonyl is drawn as a solid 0 wedge:
Preferred c mpounds of formulae Ii-l, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 are those
Further preferred compounds of formulae Ii-l , Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 are those wherein R27', R28, R28 , R29, R30 are H, X2 is CH and R31 is methoxy or 2-
oxopyrrolidin- 1 -yl.
Among the compounds of formulae Ii-l , Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8 those of formulae Ii-l , Ii-2, Ii-5, Ii-6, Ii-7 and Ii-8 are preferred.
Among the compounds of formulae Ii-l , Ii-2, Ii-5, Ii-6, Ii-7 and Ii-8 those of formulae Ii-l , Ii-5, Ii-6 and Ii-7 are preferred.
Among the compounds of formulae Ii-l , Ii-5, Ii-6 and Ii-7 those of formula Ii-5 and Ii-6 are preferred.
Among the compounds of formulae Ii-5 and Ii-6, those of formula Ii-5 are preferred.
Other preferred compounds of formulae Ih-1 , Ih-2, Ih-3, Ih-4, Ih-5, Ih-6, Ih-7 and Ih-8 are those of formulae Ij-1 , Ij-2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7 and Ij-8 respectively:
lj-4
and pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein
Ar 1 , R 26 , R 27 and R 28' are as defined above in respect to formula Ia-4;
R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . R IV4. R IV4' . R IV5. R IV5' . R IV6. R IV6' . R IV7. R IV7' . R IV8. R IV9. R IV9' . RIV10. R IV10' . RIV11. RIV11' , cr R12 r12' r13 r13' r14 r14' r15 r15' r16 r16' r17 r17' r18 r18' r19 r19' r20 r20' D IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV . IV ,
R21, R21', R22, R22', R23, R23', R24, R25 and R25 and the dotted lines are as defined above in respect to formulae Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7 and Ii-8.
Among the compounds of formulae Ij-l, Ij-2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7 and Ij-8 those of formulae Ij-l, Ij-2, Ij-5, Ij-6, Ij-7 and Ij-8 are preferred. 0 Among the compounds of formulae Ij-l, Ij-2, Ij-5, Ij-6, Ij-7 and Ij-8 those of formulae Ij-l, Ij-5, Ij-6 and Ij-7 are preferred.
Among the compounds of formulae Ij-l, Ij-5, and Ij-7 those of formula Ij-5 and Ij-6 are preferred.
Among the compounds of formulae Ij-5 and Ij-6, those of formula Ij-5 are preferred.
Particularly preferred compounds of the invention are those listed in Table 1 hereafter:
Table 1 :
Compd Structure
n° Compound name (M+H)+
2-((3S,4S)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo-
1 4-phenyl-2,3 ,4,7-tetrahydro- 1 H- 439.9 azepin-3-yl)acetic acid
2-((3S,4R)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo-
2 4-phenyl-2, 3 ,4,7-tetrahydro- 1 H- 439.9 azepin-3-yl)acetic acid
2-((3R,4S)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo-
3 4-phenyl-2, 3 ,4,7-tetrahydro- 1 H- 439.9 azepin-3-yl)acetic acid
2-((3R,4R)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo-
and pharmaceutically acceptable salts, solvates, and prodrugs thereof.
The compounds of table 1 were named using ChemDraw Ultra purchased from CambridgeSoft (Cambridge, MA, USA).
The compounds of formula I can be prepared by different ways with
reactions known by the person skilled in the art. Reaction schemes as described in the example section illustrate by way of example different possible approaches.
The invention further provides the use of the compounds of the invention or pharmaceutically acceptable salts, solvates, or prodrugs thereof as agonists or partial agonists of G-protein coupled receptor 43 (GPR43).
Accordingly, in a particularly preferred embodiment, the invention relates to the use of compounds of formula I and subformulae in particular those of table 1 above, or pharmaceutically acceptable salts solvates, and prodrugs thereof, as GPR43 agonists or partial agonists.
[APPLICATIONS]
The compounds of the invention are therefore useful in the prevention and/or treatment of inflammatory, gastrointestinal and/or metabolic disorders.
The invention also provides for a method for delaying in patient the onset of inflammatory, gastrointestinal and/or metabolic disorders comprising the administration of a pharmaceutically effective amount of a compound of formula (I) or pharmaceutically acceptable salt thereof to a patient in need thereof.
Preferably, the patient is a warm-blooded animal, more preferably a human.
The invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvates or prodrug thereof for treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.
Preferably, the patient is a warm-blooded animal, more preferably a human.
According to a further feature of the present invention there is provided a method for modulating GPR43 receptor activity, in a patient, preferably a warm blooded animal, and even more preferably a human, in need of such treatment, which comprises administering to said animal an effective amount of compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
According to one embodiment, the compounds of the invention, their pharmaceutical acceptable salts or solvates, or prodrugs may be administered as part of a combination therapy. Thus, are included within the scope of the present invention embodiments comprising coadministration of, and compositions and medicaments which contain, in addition to a compound of the present invention, a pharmaceutically acceptable salt, solvate or prodrug thereof as active ingredient, additional therapeutic agents and/or active ingredients. Such multiple drug regimens, often referred to as combination therapy, may be used in the treatment and/or prevention of any of the diseases or conditions mediated by or associated with GPR43 receptor modulation, particularly inflammatory, gastrointestinal and/or metabolic disorders. The use of such combinations of therapeutic
agents is especially pertinent with respect to the treatment of the above-mentioned list of disorders within a patient in need of treatment or one at risk of becoming such a patient.
In addition to the requirement of therapeutic efficacy, which may necessitate the use of active agents in addition to the GPR43 agonist or partial agonist compounds of Formula I or their pharmaceutical acceptable salts, solvates, or prodrugs thereof, there may be additional rationales which compel or highly recommend the use of combinations of drugs involving active ingredients which represent adjunct therapy, i.e., which complement and supplement the function performed by the GPR43 receptor agonist or partial agonist compounds of the present invention. Suitable supplementary therapeutic agents used for the purpose of auxiliary treatment include drugs which, instead of directly treating or preventing a disease or condition mediated by or associated with GPR43 receptor modulation, treat diseases or conditions which directly result from or indirectly accompany the basic or underlying GPR43 receptor modulated disease or condition.
Thus, the methods of treatment and pharmaceutical compositions of the present invention may employ the compounds of Formula I or their pharmaceutical acceptable salts, solvates, or prodrugs thereof in the form of monotherapy, but said methods and compositions may also be used in the form of multiple therapy in which one or more compounds of Formula I or their pharmaceutically acceptable salts, solvates, or prodrugs are coadministered in combination with one or more other therapeutic agents. In the above-described embodiment combinations of the present invention, the compound of Formula I, a pharmaceutically acceptable salt or solvate thereof and other therapeutic active agents may be administered in terms of dosage forms either separately or in conjunction with each other, and in terms of their time of administration, either serially or simultaneously. Thus, the administration of one component agent may be prior to, concurrent with, or subsequent to the administration of the other component agent(s).
The invention also provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. As indicated above, the invention also covers pharmaceutical compositions which contain, in
addition to a compound of the present invention, a pharmaceutically acceptable salt, solvate or prodrug thereof as active ingredient, additional therapeutic agents and/or active ingredients.
Another object of this invention is a medicament comprising at least one compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, as active ingredient.
The invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament. Preferably, the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders.
According to a further feature of the present invention there is provided the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for modulating GPR43 receptor activity, in a patient, in need of such treatment, which comprises administering to said patient an effective amount of compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Preferably, the patient is a warm-blooded animal, more preferably a human.
Preferably, the medicament is used for the treatment and/or prevention of inflammatory, gastrointestinal and/or metabolic disorders As set forth above, the compounds of the invention, their pharmaceutically acceptable salts, solvates, or prodrugs may be used in monotherapy or in combination therapy. Thus, according to one embodiment, the invention provides the use of a compound of the invention for the manufacture of a medicament for at least one of the purposes described above, wherein said medicament is administered to a patient in need thereof, preferably a warm-blooded animal, and even more preferably a human, in combination with at least one additional therapeutic agent and/or active ingredient. The benefits and advantages of such a multiple drug regimen, possible administration regimens as well as suitable additional therapeutic agents and/or active ingredients are those described above.
Generally, for pharmaceutical use, the compounds of the invention may be formulated as a pharmaceutical preparation comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant, and optionally one or more further pharmaceutically active compound(s). By means of non-limiting examples, such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration (including ocular), for administration by inhalation, by a skin patch, by an implant, by a suppository, etc. Such suitable administration forms - which may be solid, semi-solid or liquid, depending on the manner of administration - as well as methods and carriers, diluents and excipients for use in the preparation thereof, will be clear to the skilled person; reference is made to the latest edition of Remington's Pharmaceutical Sciences.
Some preferred, but non-limiting examples of such preparations include tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, cremes, lotions, soft and hard gelatin capsules, suppositories, drops, sterile injectable solutions and sterile packaged powders (which are usually reconstituted prior to use) for administration as a bolus and/or for continuous administration, which may be formulated with carriers, excipients, and diluents that are suitable per se for such formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, micro crystalline cellulose, polyvinylpyrrolidone, polyethylene glycol, cellulose, (sterile) water, methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate, edible oils, vegetable oils and mineral oils or suitable mixtures thereof. The formulations can optionally contain other substances that are commonly used in pharmaceutical formulations, such as lubricating agents, wetting agents, emulsifying and suspending agents, dispersing agents, desintegrants, bulking agents, fillers, preserving agents, sweetening agents, flavoring agents, flow regulators, release agents, etc.. The compositions may also be formulated so as to provide rapid, sustained or delayed release of the active compound(s) contained therein. The pharmaceutical preparations of the invention are preferably in a unit
dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which may be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use. Generally, such unit dosages will contain between 0,05 and 1000 mg, and usually between 1 and 500 mg, of the at least one compound of the invention, e.g. about 10, 25, 50, 100, 200, 300 or 400 mg per unit dosage.
Usually, depending on the condition to be prevented or treated and the route of administration, the active compound of the invention will usually be administered between 0.01 to 100 mg per kilogram, more often between 0.1 and 50 mg, such as between 1 and 25 mg, for example about 0.5, 1, 5, 10, 15, 20 or 25 mg, per kilogram body weight of the patient per day, which may be administered as a single daily dose, divided over one or more daily doses, or essentially continuously, e.g. using a drip infusion.
[DEFINITIONS]
The definitions and explanations below are for the terms as used throughout the entire application, including both the specification and the claims.
When describing the compounds of the invention, the terms used are to be construed in accordance with the following definitions, unless indicated otherwise.
Where groups may be substituted, such groups may be substituted with one or more substituents, and preferably with one, two or three substituents. Substituents may be selected from but not limited to, for example, the group comprising halogen, hydroxyl, oxo, nitro, amido, carboxy, amino, cyano haloalkoxy, and haloalkyl.
As used herein the terms such as "alkyl, aryl, or cycloalkyl, each being optionally substituted with..." or "alkyl, aryl, or cycloalkyl, optionally substituted with..." encompasses "alkyl optionally substituted with...", "aryl optionally substituted with..." and "cycloalkyl optionally substituted with... ".
The term "halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred halo groups are fluoro and chloro.
The term "alkyl" by itself or as part of another substituent refers to a hydrocarbyl radical of Formula CnH2n+i wherein n is a number greater than or equal to 1. Generally, alkyl groups of this invention comprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2 carbon atoms. Alkyl groups may be linear or branched and may be substituted as indicated herein.
Suitable alkyl groups include methyl, ethyl, n-propyl, /-propyl, n-butyl, /- butyl, 5-butyl and /-butyl, pentyl and its isomers (e.g. n-pentyl, iso-pentyl), and hexyl and its isomers (e.g. n-hexyl, /so-hexyl). Preferred alkyl groups include methyl, ethyl, n-propyl, /-propyl, n-butyl, /-butyl, s-butyl and /-butyl.
When the suffix "ene" ("alkylene") is used in conjunction with an alkyl group, this is intended to mean the alkyl group as defined herein having two single bonds as points of attachment to other groups. The term "alkylene" includes methylene, ethylene, methylmethylene, propylene, ethylethylene, and 1,2-dimethylethylene. The term "alkenyl" as used herein refers to an unsaturated hydrocarbyl group, which may be linear or branched, comprising one or more carbon-carbon double bonds. Suitable alkenyl groups comprise between 2 and 6 carbon atoms, preferably between 2 and 4 carbon atoms, still more preferably between 2 and 3 carbon atoms. Examples of alkenyl groups are ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2- hexenyl and its isomers, 2,4-pentanedienyl and the like.
The term "alkynyl" as used herein refers to a class of monovalent unsaturated hydrocarbyl groups, wherein the unsaturation arises from the presence of one or more carbon-carbon triple bonds. Alkynyl groups typically, and preferably, have the same number of carbon atoms as described above in relation to alkenyl groups. Non limiting examples of alkynyl groups are ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl and its isomers, 2-hexynyl and its isomers-and the like.
The terms "alkenylene" and "alkynylene" respectively mean an alkenyl group or an alkinyl group as defined above having two single bonds as points of attachment to other groups.
The term "haloalkyl" alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen as defined above. Non-limiting examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1- trifluoro ethyl and the like.
The term "cycloalkyl" as used herein is a cyclic alkyl group, that is to say, a monovalent, saturated, or unsaturated hydrocarbyl group having 1 or 2 cyclic structures. Cycloalkyl includes monocyclic or bicyclic hydrocarbyl groups. Cycloalkyl groups may comprise 3 or more carbon atoms in the ring and generally, according to this invention comprise from 3 to 10, more preferably from 3 to 8 carbon atoms still more preferably from 3 to 6 carbon atoms. Examples of cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, with cyclopropyl being particularly preferred.
When the suffix "ene" is used in conjunction with a cyclic group, this is intended to mean the cyclic group as defined herein having two single bonds as points of attachment to other groups.
Where at least one carbon atom in a cycloalkyl group is replaced with a heteroatom, the resultant ring is referred to herein as "heterocycloalkyl" or "heterocyclyl".
The terms "heterocyclyl", "heterocycloalkyl" or "heterocyclo" as used herein by itself or as part of another group refer to non-aromatic, fully saturated or partially unsaturated cyclic groups (for example, 3 to 7 member monocyclic, 7 to 11 member bicyclic, or containing a total of 3 to 10 ring atoms) which have at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and/or sulfur atoms, where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. Any of the carbon atoms of the heterocyclic group may be substituted by oxo (for example piperidone, pyrrolidinone).The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system, where valence allows. The rings of multi-ring heterocycles may be fused, bridged
and/or joined through one or more spiro atoms. Non limiting exemplary heterocyclic groups include oxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinyl imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, 3H- indolyl, indolinyl, isoindolinyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl, 2- pyrazolinyl, 3-pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro- 2H-pyranyl, 3-dioxolanyl, 1 ,4-dioxanyl, 2,5-dioximidazolidinyl, 2-oxopiperidinyl, 2- oxopyrrolodinyl, indolinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolin- 1 -y 1 , tetr ahy droiso quino lin-2-yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-y 1 , t h i o m o rp h o l i n-4-yl, thiomorpholin-4-ylsulfoxide, thiomorpholin-4-ylsulfone, 1, 3-dioxolanyl, 1 ,4-oxathianyl, lH-pyrrolizinyl, tetr ahy dro- 1,1- dioxothiophenyl, N- formylpiperazinyl, and morpholin-4-yl.
The ring atoms of heterocyclyl and heterocyclylene moieties are numbered based on scheme below
piperidinyl tetrahydropyranyl piperazinyl morpholinyl The term "aryl" as used herein refers to a polyunsaturated, aromatic hydrocarbyl group having a single ring (i.e. phenyl) or multiple aromatic rings fused together (e.g. naphtyl) or linked covalently, typically containing 5 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic. The aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocyclyl or heteroaryl) fused thereto. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems
enumerated herein. Non-limiting examples of aryl comprise phenyl, biphenylyl, biphenylenyl, 5- or 6-tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1- 2-, 3-, 4- or 5-acenaphtylenyl, 3-, 4- or 5-acenaphtenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl, 1-, 2-, 3-, 4- or 5- pyrenyl.
The term "arylene" as used herein is intended to include divalent carbocyclic aromatic ring systems such as phenylene, biphenylylene, naphthylene, indenylene, pentalenylene, azulenylene and the like. Arylene is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthylene, 1,4- dihydronaphthylene and the like.
Where at least one carbon atom in an aryl group is replaced with a heteroatom, the resultant ring is referred to herein as a heteroaryl ring.
The term "heteroaryl" as used herein by itself or as part of another group refers but is not limited to 5 to 12 carbon-atom aromatic rings or ring systems containing 1 to 2 rings which are fused together or linked covalently, typically containing 5 to 6 atoms; at least one of which is aromatic, in which one or more carbon atoms in one or more of these rings is replaced by oxygen, nitrogen and/or sulfur atoms where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. Such rings may be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl ring. Non-limiting examples of such heteroaryl, include: furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, imidazo[2,l-b][l,3]thiazolyl, thieno [3, 2-b] furanyl, thieno[3,2- b]thiophenyl, thieno[2,3-d][l,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[l,5- ajpyridinyl, indolyl, indolizinyl, isoindolyl, benzofuranyl, isobenzo furanyl, benzothiophenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2- benzisoxazolyl, 2,1-benzisoxazolyl, 1, 3 -benzo thiazolyl, 1,2-benzoisothiazolyl, 2,1- benzo isothiazolyl, benzotriazolyl, 1,2,3-benzoxadiazolyl, 2,1,3-benzoxadiazolyl, 1,2,3- benzo thiadiazolyl, 2, 1,3 -benzo thiadiazolyl, thienopyridinyl, purinyl, imidazo[l,2-
ajpyridinyl, 6-oxo-pyridazin-l(6H)-yl, 2-oxopyridin-l(2H)-yl, 6-oxo-pyridazin-l(6H)-yl, 2-oxopyridin-l(2H)-y 1 , 1 , 3-benzodioxolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl.
The term "heteroarylene" as used herein means divalent carbocyclic aromatic ring systems including pyridinylene and the like.
The ring atoms of heteroaryl or heteroarylene moieties are numbered on scheme below:
X is selected from: X is selected from: X is selected from: Y is selected from:
N. O or S N, O or S N. O or S C, N
Examples: Examples: Examples: Examples:
pyrrolyl imidazolyl pyrazolyl pyridyl
furanyl oxazolyl isooxazolyl pyrimidinyl
thiophenyl thiazolyl isothiazolyl
7 1 7 1
X is selected from: X is selected from:
N. O or S N, O or S
Examples: Examples:
indolyl benzimidazolyl
benzofuranyl benzoxazolyl
benzothiophenyl benzothiazolyl
The term "biaryl" as used herein designates two aryl moieties as defined herein linked via a single bond. Non-limiting examples of such biaryl moieties include biphenyl.
The term "heterobiaryl" as used herein designates two heteroaryl moieties as defined herein or a heteroaryl moiety and an aryl moity as defined herein linked via a single bond. Non-limiting examples of such heterobiaryl moieties include pyridinylphenyl which is meant to include (2-pyridinyl)phenyl, (3-pyridinyl)phenyl and (4-pyridinyl)phenyl, bipyridinyl.
(2-pyridinyl)phenyl (3-pyridinyl)phenyl (4-pyridinyl)phenyl
bipyridinyl
The term "alkylamino" as used herein means an amino group substituted with one or two alkyl groups. This includes monoalkylamino and dialkylamino groups. The compounds of Formula I and subformulae thereof contain at least one asymmetric center and thus may exist as different stereoisomeric forms. Accordingly, the present invention includes all possible stereoisomers and includes not only racemic compounds but the individual enantiomers and their non racemic mixtures as well. When a compound is desired as a single enantiomer, such may be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods as each are known in the art. Resolution of the final product, an
intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley- Interscience, 1994), incorporated by reference with regard to stereochemistry. The bonds from an asymmetric carbon in compounds of the present invention may be depicted herein using a solid line (— ), a zigzag line ( ■ww ), a solid wedge ( ), or a dotted wedge ( ). The use of a solid line to depict bonds from an asymmetric carbon atom is meant to indicate that all possible stereoisomers are meant to be included, unless it is clear from the context that a specific stereoisomer is intended. The use of either a solid or dotted wedge to depict bonds from an asymmetric carbon atom is meant to indicate that only the stereoisomer shown is meant to be included.
The compounds of the invention may also contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds from asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included, unless it is clear from the context that a specific stereoisomer is intended.
The compounds of the invention may be in the form of pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the compounds of formula I include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoro acetate and xinofoate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2- (diethylamino)ethanol, ethanolamine, morpholine, 4-(2-hydroxyethyl)morpholine and zinc
salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. Preferred, pharmaceutically acceptable salts include hydrochloride/chloride, hydrobromide/bromide, bisulphate/sulphate, nitrate, citrate, and acetate. When the compounds of the invention contain an acidic group as well as a basic group the compounds of the invention may also form internal salts, and such compounds are within the scope of the invention. When the compounds of the invention contain a hydrogen-donating heteroatom (e.g. NH, OH), the invention also covers salts and/or isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule.
Pharmaceutically acceptable salts of compounds of Formula I may be prepared by one or more of these methods:
(i) by reacting the compound of Formula I with the desired acid;
(ii) by reacting the compound of Formula I with the desired base; (iii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of Formula I or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid; or
(iv) by converting one salt of the compound of Formula I to another by reaction with an appropriate acid or by means of a suitable ion exchange column. All these reactions are typically carried out in solution. The salt, may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionization in the salt may vary from completely ionized to almost non-ionized.
The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
All references to compounds of formula I include references to salts, solvates, multi- component complexes and liquid crystals thereof.
The compounds of the invention include compounds of formula I as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) and iso topically- labeled compounds of formula I.
In addition, although generally, with respect to the salts of the compounds of the invention, pharmaceutically acceptable salts are preferred, it should be noted that the invention in its broadest sense also included non-pharmaceutically acceptable salts, which may for example be used in the isolation and/or purification of the compounds of the invention. For example, salts formed with optically active acids or bases may be used to form diastereo isomeric salts that can facilitate the separation of optically active isomers of the compounds of Formula I above.
The invention also generally covers all pharmaceutically acceptable predrugs and prodrugs of the compounds of Formula I.
The term "prodrug" as used herein means the pharmacologically acceptable derivatives of compounds of formula I such as esters whose in vivo biotransformation product is the active drug. Prodrugs are characterized by increased bio-availability and are readily metabolized into the active compounds in vivo. Suitable prodrugs for the purpose of the invention include carboxylic esters, in particular alkyl esters, aryl esters, acyloxyalkyl esters, and dioxolene carboxylic esters; ascorbic acid esters as well as compounds of formula I in which Z is a substituent selected from the table 2 below.
Table 2:
The term "predrug", as used herein, means any compound that will be modified to form a drug species, wherein the modification may take place either inside or outside of the body, and either before or after the predrug reaches the area of the body where administration of the drug is indicated.
The term "patient" refers to a warm-blooded animal, more preferably a human, who/which is awaiting or receiving medical care or is or will be the object of a medical procedure.
The term "human" refers to suject of both genders and at any stage of development (i.e. neonate, infant, juvenile, adolescent, adult).
The terms "treat", "treating" and "treatment, as used herein, are meant to include alleviating or abrogating a condition or disease and/or its attendant symptoms.
The terms "prevent", "preventing" and "prevention", as used herein, refer to a method of delaying or precluding the onset of a condition or disease and/or its attendant symptoms, barring a patient from acquiring a condition or disease, or reducing a patient's risk of acquiring a condition or disease.
The term "therapeutically effective amount" (or more simply an "effective
amount") as used herein means the amount of active agent or active ingredient (e. g. GPR43 agonist or partial agonist) which is sufficient to achieve the desired therapeutic or prophylactic effect in the individual to which it is administered.
The term "administration", or a variant thereof (e.g. 'administering"), means providing the active agent or active ingredient (e. g. a GPR43 agonist or partial agonist), alone or as part of a pharmaceutically acceptable composition, to the patient in whom/which the condition, symptom, or disease is to be treated or prevented.
By "pharmaceutically acceptable" is meant that the ingredients of a pharmaceutical composition are compatible with each other and not deleterious to the patient thereof.
The term "agonist" as used herein means a ligand that activates an intracellular response when it binds to a receptor. An agonist according to the invention may promote internalization of a cell surface receptor such that the cell surface concentration of a receptor is decreased or remove. The term "partial agonist" as used herein means an agonist which is unable to induce maximal activation of a receptor, regardless of the amount of compound applied on the receptor.
The term "pharmaceutical vehicle" as used herein means a carrier or inert medium used as solvent or diluent in which the pharmaceutically active agent is formulated and/or administered. Non-limiting examples of pharmaceutical vehicles include creams, gels, lotions, solutions, and liposomes.
As used herein the term "inflammatory disorders" are those pertaining to, characterized by, causing, resulting from or becoming affected by inflammation. Such inflammatory diseases include but are not limited to rheumatoid arthritis; inflammatory bowel disease (IBD) including but not limited to Crohn's disease, ulcerative colitis and colitis; Pagets disease; osteoporosis; multiple myeloma; uveitilis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; rheumatoid spondylitis, osteoarthritis; gouty arthritis and other arthritis conditions; gout; adult respiratory distress syndrome
(ARDS); chronic pulmonary inflammation diseases; silicosis; pulmonary sarcoidosis; psoriasis; allergic rhinitis; anaphylaxis; contact dermatitis; pancreatitis; non-alcoholic steatohepatitis (NASH); asthma; muscle degeneration; cachexia such as cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome; Reiter's syndrome; bone resorption disease; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; endotoxic shock; gram negative sepsis; fever and myalgias due to infection such as influenza; pyrosis.
As used herein the term "metabolic disorders" includes but is not limited to type I and type II diabetes, obesity, dyslipidemia such as mixed or diabetic dyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia hypertension, hyperlipoproteinemia, metabolic syndrome, syndrome X, thrombotic disorders, cardiovascular disease, atherosclerosis and its sequelae including angina, claudication, heart attack, stroke and others, kidney diseases, ketoacidosis, nephropathy, diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liver diseases such as steatosis or nonalcoholic steatohepatitis (NASH).
As used herein the term "gastrointestinal disorders" means diseases selected from the group consisting of gastrointestinal hypermotility disorders, including but not limited to any type of diarrhea, such as, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease and other types of diarrhea; Irritable Bowel Syndrome (IBS); intestinal injury disorders such as short-bowel syndrome; diseases involving intestinal barrier dysfunction such as pancreatitis, proctitis and pouchitis.
The present invention will be better understood with reference to the following examples. These examples are intended to represent specific embodiments of the invention, and are not intended to limit the scope of the invention.
CHEMISTRY EXAMPLES
All temperatures are expressed in °C and all reactions were carried out at room temperature (RT) unless otherwise stated.
Analytical thin layer chromatography (TLC) was used to monitor reactions, establish flash chromatography conditions and verify purity of intermediates or final products. TLC plates used were Merck TLC aluminium sheet silica gel 60 F254. TLC plates were revealed using ultraviolet irradiation (wavelength=254 nm) at RT or bromocresol green spray reagent at 0.1% in propan-2-ol or KMn04 revelator (KMn04, Na2C03, NaOH, H20) upon heating at 160°C. HPLC-MS spectra were obtained on Agilent LCMS using Electropsray ionization
(ESI). The Agilent instrument includes an Autosampler 1200, a binary pump 1100, a 5 wave length detector 1100 and a 6100 Single Quad. The column used was an XBridge CI 8. Eluent was a mixture of solution A (0.1% TFA in H20) and solution B (0.1% TFA in MeCN). Gradients used are as follows: gradient A (intermediates characterization): held the initial conditions of 5% solution B for 1 min, increased linearly to 95% solution B in 4 min, held at 95% during 1 min, returned to initial conditions in 0.5 min and maintained for 1 min; gradient B (examples characterization): held the initial conditions of 5% solution B for 1 min, increased linearly to 60% in 10 min, increased linearly to 95% in 0.5 min, held at 95% during 3 min, returned to initial conditions in 0.5 min and maintained for 1 min.
Determination of enantiomeric excess was performed on an Agilent 1100 (binary pump and 5 wavelengths detector) with manual or automatic (Autosampler 1100) injection. Columns used were CHIRALPAK IA CHIRALPAK IB or CHIRALPAK IC in isocratic mode. Mixtures of eluents were selected depending on the separation obtained of enantiomers or diastereosiomers. Usual mixtures were:
- Hexane and Ethano 1 (0.1 % TFA)
- Hexane and Propanol (0.1% TFA)
- Hexane and Ethyl acetate (0.1% TFA)
- Hexane and Dichloromethane (0.1% TFA)
- Hexane and tert-butyl methyl ether (0.1% TFA)
Preparative HPLC purifications were carried out on Fractionlynx instrument, from Waters. This instrument consists of a Fraction Collector, a 2767 Sample Manager, a pump control a module II, a 515 HPLC Pump, a 2525 Binary Gradient Module, a Switching Valve, a 2996 Photodiode Array Detector and a Micromass ZQ. The column used was a Waters Sunfire CI 8 Eluent was a mixture of solution A (0.1% TFA in H20) and solution B (0.1% TFA in MeCN). The gradient was adapted depending on impurities present in samples, to allow sufficient separation between impurities and target compound.
1H and 13C NMR spectra were recorded on a Bruker ARX 300MHz. Chemical shifts are expressed in parts per million, (ppm, δ units). Coupling constants are expressed in Hertz units (Hz). Splitting patterns describe apparent multiplicities and are described as s (singlet), d (doublet), t (triplet), q (quintet), m (multiplet), or br (broad).
Solvents, reagents and starting materials were purchased from well known chemical suppliers such as for example Sigma Aldrich, Acros Organics, VWR Int., Sopachem or Polymer labs and the following abbreviations are used:
Ac: Acetyl,
Bn: Benzyl,
BuLi: Butyllithium,
Cp: cyclopentadienyl,
DAST : Diethylaminosulfurtrifluoride,
DCM: Dichloro methane,
DCE: 1,2-Dichloroethane,
DIEA: N,N-diisopropylethylamine,
ee: Enantiomeric excess,
eq: Equivalent,
EtOAc: Ethyl acetate,
EtOH: Ethanol,
g: Grams,
Grubbs cat. : Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium,
h: Hours,
HATU: 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tretramethyluronium hexafluorophosphate , HMDS: Hexamethyldisilazane,
IPA: Isopropanol,
L: Liters,
MeCN: Acetonitrile,
MeOH: Methanol,
Me: Methyl,
μί: Microliters,
mg: Milligrams,
min: Minutes,
mL: Milliliters,
mmol: Millimoles,
mol: Moles,
MW: Molecular weight,
NMM: N-methylmorpholine,
NMO: N-methylmorpholine-N-oxide,
P: UV purity at 254nm determined by HPLC-MS,
PE: Petroleum ether,
rf: retention fraction
rm or RM: reaction mixture.
rt: Retention time,
RT: Room temperature,
SIBX: Stabilized 2-iodoxybenzoic acid,
tBu: tert-Butyl
TCT: 2,4,6-trichloro[l ,3,5]triazine,
TFA: Trifluoro acetic acid,
THF: Tetrahydrofuran,
TLC: Thin layer chromatography,
Y: Yield,
For clarity reasons the synthetic schemes below are exemplified with specific substituents and stereochemistry but they can indeed be adapted easily by those skilled in the art to
access compounds of the invention and are meant to be general methods.
General Synthetic Schemes
A general method for the synthesis of compounds of the invention containing ring I, ring V or ring VII is outlined in scheme 1.
1.7 1.8 1.9
Scheme 1: General synthetic route for the compounds containing ring I, ring V or ring VII
The general method depicted in scheme 1 enabled the synthesis of intermediates of formula A
A wherein,
Ra is chloro and Rb is isopropyl, isobutyl, cyclopropyl, cyclopentyl, tetrahydropyran-4-yl,
phenyl, or biphen-4-yl; or
Ra is 2-methoxypyridin-5-yl and Rb is isopropyl, cyclopentyl or phenyl; or
Ra is 2-methoxypyrazin-5-yl and Rb is isopropyl; or
Ra is 2-(2-oxopyrrolidin-l-yl)pyridin-5-yl and Rb is isopropyl, cyclopentyl or phenyl.
Selected methods to achieve ring substitutions for the compounds containg ring I, ring V or ring VII are shown below in Scheme 2.
2.1
(precursor to compound n°6) TFA/DCM TFA/DCM
ί ί
compound n°26 compound n°25
Scheme 2: Selected methods to achieve ring substitutions for the compounds containg ring
I, ring V or ring VII.
Suggested methods and known literature references to achieve other ring substitutions for the compounds containg ring I, ring V or ring VII are shown below in Scheme 3.
C. Fava et al., Tetrahedron: Asymmetry 1 (2003) 3697-3703
Scheme 3: Suggested methods to achieve ring substitutions for the compounds containg ring I, ring V or ring VII
A suggested method for the synthesis of compounds of the invention containing ring is outlined in scheme 4.
4.3 4.4
Scheme 4: Suggested synthetic route for the compounds containing ring II.
A suggested method for the synthesis of compounds of the invention containing ring III is outlined in scheme 5.
-78°C-0°C
5.1 5.2 5.3
5.6 compound n°68
Scheme 5: Suggested synthetic route for the compounds containing ring III.
A suggested general method for the synthesis of compounds of the invention containing ring IV is outlined in scheme 6.
6.4 6.5 compound n°69
Scheme 6: Suggested method for the preparation of the compounds of the invention containg ring IV.
A general method for the synthesis of compounds of the invention containing rings outlined in scheme 7.
7.1 7.2 7.3
R= Aryl, coupling, ref.: Tetrahedron Letters 46 (2005) 2997-3001
R=Alkyl, Reductive amination, ref.: Tetrahedron Letters 41 (2000) 8225-8230
7.6
7.5 R=Ph, compound n°19
R=cyclopentyl, compound n°32
Scheme 7: General method for the synthesis of compounds of the invention containing ring
VI.
The general method depicted in scheme 7 enabled the synthesis of intermediates of formula B
wherein,
Rc is chloro and Rd is cyclopentyl or phenyl; or
Rc is 2-methoxypyridin-5-yl and Rd is isopropyl or cyclopentyl.
A suggested general method for the synthesis of compounds of the invention containing ring VIII is outlined in scheme 8.
8.1 8.2 compound n°70
J. Org. Chem. 2002, 67, 6272-6274
Scheme 8: Suggested method for the preparation of the compounds of the invention containg ring VIII.
A suggested synthesis of compound n°28 is outlined in scheme 9.
9.4 9.5 compound n°28
Scheme 9: Suggested method for the preparation of compounds n°28.
General methods for the synthesis heterobiaryl amine intermediates
Biaryl- or heterobiaryl-thiazole amine intermediates were synthesized using Suzuki approach as shown in schemes 10 and 1 1. General scheme for the preparation of biaryl- or heterobiaryl-thiazole amine intermediates 10.3 using Suzuki approach (Scheme 10):
Scheme 10: General scheme for the preparation of biaryl- or heterobiaryl-thiazole amine intermediates 10.3 using Suzuki approach. Alternative general scheme for the preparation of biaryl- or heterobiaryl-thiazole amine intermediates 10.3 using Suzuki approach (Scheme 11):
10.1 11.1 10.3
Scheme 11: Alternative general scheme for the preparation of biaryl- or heterobiaryl- thiazole amine intermediates 10.3 using Suzuki approach.
Intermediates 10.1 and 12.4 can be made using Hantzsch-type synthetic methodology as shown in Scheme 12. Thus, halogenation of substituted acetophenones 12.1 (Larock, R. C. Comprehensive Org Transf 2nd Ed., Wiley, 1999, pp 709-719; White et al. J. Med. Chem. 1996, 39, 4382-95) and subsequent condensation with thiourea 12.3 (Swain et al. J. Med. Chem. 1991, 34, 140-151; Bartoli et al. J. Med. Chem. 1998, 41, 1855-68) will furnish 4-aryl-2-amino-thiazole intermediates.
use of microwave
1 0.1 (X=Br)
Scheme 12: General scheme for the preparation of 4-aryl-2-amino-thiazole intermediates using Hantzsch-type synthetic approach.
Alternatively, synthesis of intermediates 12.4 can be achieved through the method described by Rudolph (Rudolph, J. Tetrahedron 2000, 56, 3161)
Scheme 13: General scheme for the preparation of 4-aryl-2-amino-thiazole intermediates using Rudolph's synthetic approach.
Acetophenone intermediates 12.1 can be prepared as described in Scheme 14.
General synthetic scheme for the preparation of substituted acetophenone intermediates 12.1 through Weinreb amide approach (Scheme 14):
14.1 14.2 12.1
Scheme 14: General synthetic scheme for the preparation of substituted acetophenone intermediates 12.1 through Weinreb amide approach.
Thiourea intermediates 12.3 can be prepared as described in Scheme 15.
General synthetic scheme for the preparation of substituted thiourea intermediates 12.3
15.1 15.2 12.3
Scheme 15: General synthetic scheme for the preparation of substituted thiourea
intermediates 12.3.
General Method A: synthesis of succininic acid intermediates 1.5.
This general method is depicted with the synthesis of (2S,3S)-2-(2-(tert-butoxy)- 2-oxoethyl)-3-phenylhex-5-enoic acid, intermediate la.
Step 1 : synthesis of (S)-4-benzyl-3-cinnamoyloxazolidin-2-one.
(4S)-4-Benzyl-l,3-oxazolidinon-2-one (39 mmol, 6.9 g) was dissolved in distilled THF (100 mL) under Argon. A 2.5 M solution of nBuli in hexanes (39 mmol, 15.6 mL) was added dropwise at -78°C. After 20 min, a solution of cinnamoyl chloride (35.5 mmol, 5.9g) in THF was added dropwise at the same temperature. The reaction mixture was stirred for 30 min at -78 °C and then 1 h at 0°C. The mixture was quenched with a saturated aqueous solution of NH4C1, THF was removed under vacuum. Residue was taken up with EtOAc, washed twice with NaOH IN and once with brine. The organic layer was then dried over MgSC^, filtered and concentrated under reduced pressure. The resulting white solid was triturated in petrolum ether, filtered and dried. Y: 9.85 g (82%), P: >90%, rt=4.47 min (gradient A), (M+H)+=308 Step 2: synthesis of (S)-4-benzyl-3-((S)-3-phenylhex-5-enoyl)oxazolidin-2-one.
To a dry-oven schlenck protected from light with an aluminum foil and flushed with argon, was added copper (I) bromide DMS complex (9.27 mmol, 1.906 mL) in anhydrous THF (40 mL). To this slurry solution, was added dropwise a 1M solution of allylmagnesium bromide in Et20 (16.07 mmol, 16.07 mL) over 30 min at -78°C under argon and the
resulting solution was stirred at the same temperature for 1.5 h. A solution of (S)-4-benzyl- 3-cinnamoyloxazolidin-2-one (6.18 mmol, 1.9 g) in THF (60 mL) was added to the above solution at -78°C and stirring was continued 2.5 h. The reaction was then quenched at - 78°C by addition of a saturated aqueous solution of NH4C1 and the RM was allowed to reach RT, the mixture was extracted twice with EtOAc. Combinated organic layers were dried over MgS04, filtered and dried under vacuum. Crude was purified by flash chromatography (PE/EtOAc = 9/1) to yield title product as a colorless solid. Y: 1.6 g (76%), P>99%, rt=4.8 min (gradient A), (M+H)+ = 350. Step 3 : synthesis of (3S,4S)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3- carbonyl)-4-phenylhept-6-enoate.
In a round bottom flask was added (S)-4-benzyl-3-((S)-3-phenylhex-5-enoyl)oxazolidin- 2-one (4.58 mmol, 1.6 g) in THF (69 mL) under argon. The mixture was cooled down to -78°C and a 1M solution of NaHMDS in THF (5.95 mmol, 5.95 mL) was added over 5 min. The solution was stirred for 30 min, and tert-butyl bromoacetate (6.87 mmol, 1.015 mL) was added. The reaction was stirred at -78°C for 50 min. The reaction was quenched at -78°C by addition of a saturated aqueous solution of NH4C1 and extracted with EtOAc. The organic layer was dried over MgS04, filtered and concentrated to afford 2.39g of a yellow oil. The crude oil was purified on a silica gel column (PE/EtOAc = 9/1) to afford 1.8g of a colorless oil. Y: 1.8 g (83%), P>98%, rt=5.2 min (gradient A), (M+H-tBu)+ = 408.
Step 4: synthesis of (2S,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylhex-5-enoic acid, intermediate la.
Hydrogen peroxide (30%> in water, 15.5mmol, 1.6 mL) was added dropwise over 15 min to a stirred solution of (4S)-tert-butyl 3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-4- phenylhept-6-enoate (3.88 mmol, 1.8 g) in THF/water (4/1, 25 mL) at 0°C under a nitrogen atmosphere. Stirring was continued for 10 min then a solution of LiOH
(6.21mmol, 150mg) in water (20 mL) was added dropwise over 5 min. The mixture was allowed to warm to RT slowly. The mixture was cooled on ice and a solution of sodium sulfite (10.4 mmol, 1.31 g) in water (8 mL) was added dropwise, causing a small
exo therm. The bulk of THF was evaporated in vacuo to leave the aqueous layer (pH=12-13). The aqueous layer was washed with Et20 (3x100 mL) and then cooled on ice and acidified to pH 1-2 with a 6M aqueous HC1 solution, extracted with EtOAc (5x100 mL), dried (MgSC^) and evaporated in vacuo to yield intermediate la as a colorless oil. lg. Y: 1 g (85%), P>95%, rt=4.2 min (gradient A), (M+H-56)+ = 248.
General method A was used for the synthesis of the following intermediates:
intermediate lb: (2S,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylpent-4-enoic acid,
intermediate lc: (2S,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylpent-4-enoic acid,
intermediate Id: (2R,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylpent-4-enoic acid,
intermediate le: (2R,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylpent-4-enoic acid,
intermediate If: (2S,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-cyclopentylhex-5- enoic acid, was synthesized from (E)-3-cyclopentylacryloyl chloride which was obtained from cyclopentanecarbaldehyde: Step 1 : synthesis of (E)-methyl 3-cyclopentylacrylate.
To a solution of n-BuLi (2.5M in hexanes, 1.57mL) in anhydrous THF (4 mL), at 0°C under nitrogen, was added dropwise a solution of methylphosphonoacetate (715 mg) in anhydrous THF (2 mL). Reaction mixture was stirred for 10 min at 0°C and a solution of cyclopentanecarbaldehyde (351 mg) in anhydrous THF (2 mL) was added dropwise. The mixture was allowed to reach RT over 1 h. Reaction mixture was washed 4 x with an aqueous solution of NaHS03 (10%) and the organic layer was separated, dried over MgS04 and concentrated in vacuo. Crude was purified on silica gel (PE/EtOAc=99/l) (TLC: PE/EtOAc 96/4, rf=0.6) to yield title product in mixture with its Z isomer as a colorless oil. Y: 405 mg, P>90%.
Step 2: synthesis of (E)-3-cyclopentylacrylic acid.
To a solution of (E)-methyl 3-cyclopentylacrylate (400 mg, 2.6 mmol) in THF (5 mL),
was added NBu4OH (1.5M in THF, 3.45 mL) and the mixture was stirred at RT for 2h. 4 more equivalents of NBu4OH were added and reaction was complete after a further 2h at RT. The reaction mixture was washed twice with aqueous HCl (6N) and the organic layer was separated with EtOAc, dried over MgS04 and concentrated in vacuo to yield title product.
Another and preferred variant for the synthesis of (E)-3-cyclopentylacrylic acid is:
To a solution of (E)-methyl 3-cyclopentylacrylate (26g, 169 mmol) in THF/H20 (400 mL, 1/1), was added LiOH (16.2g, 675mmol) and the mixture was stirred at RT for 12h.. The reaction mixture was quenched with aqueous HCl (6N) and the organic layer was separated with EtOAc (2x), dried over MgS04 and concentrated in vacuo to yield title product Y=23g (97%)
Step 3 : synthesis of (E)-3-cyclopentylacryloyl chloride.
To a solution of (E)-3-cyclopentylacrylic acid (1.4 mmol, 20 mg,) in anhydrous THF (5 mL) under nitrogen at 0°C, was added Et3N (1.7 mmol, 228 μί) and the solution was cooled at -70°C. Pivaloyl chloride (1.6 mmol, 193 μί) was added and a thick suspension formed. After 15 min, the reaction mixture was warmed to and kept at 0°C for 40 min. The mixture was used as such for the next reaction with (S)-4- benzyloxazolidin-2-one. intermediate lg: (2S,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-(tetrahydro-2H- pyran-4-yl)hex-5-enoic acid was synthesized from tetrahydro-2H-pyran-4-carbaldehyde as described above for intermediate If,
intermediate lh: (2S,3S)-3-(biphenyl-4-yl)-2-(2-tert-butoxy-2-oxoethyl)hex-5- enoic acid,
intermediate li: (2S,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-isopropylhex-5-enoic acid,
intermediate lj : (2S,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-isobutylhex-5-enoic acid,
intermediate lk: (2S,3R)-2-(2-(tert-butoxy)-2-oxoethyl)-3-cyclopropylhex-5- enoic acid was synthesized from cyclopropanecarbaldehyde as described above for
intermediate If
General Method B: synthesis of 2-amino-4-arylthiazole intermediates 1.6. This general method is depicted with the synthesis of N-allyl-4-(2-chlorophenyl)thiazol- 2-amine, intermediate 2a.
A solution of 2-bromo-l-(2-chlorophenyl)ethanone (100 mmol, 23.35 g) was stirred in ethanol (300 mL) and allylthiourea (100 mmol, 11.62 g) was added. The mixture was heated to refiux for 2h then cooled to RT and most of the ethanol was removed by evaporation. This mixture was suspended in DCM and washed with saturated aqueous sodium hydrogen carbonate solution (2 x 900 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was added to a silica gel column and was eluted with PE/EtOAc = 98/2. (TLC: PE/EtOAc = 98/2: rf 0.15) to afford title product as a yellow solid. Y: 17.9 g (70%), P>99%, rt=3.2 min (gradient A), (M+H)+ = 251.
General method B was used for the synthesis of the following intermediates:
intermediate 2b: N-homoallyl-4-(2-chlorophenyl)thiazol-2-amine,
intermediate 2c: 4-(2-bromophenyl)-N-allylthiazol-2-amine,
intermediate 2e: N-allyl-4-(2,5-dichlorophenyl)thiazol-2-amine,
intermediate 2f: 4-(2-chlorophenyl)thiazol-2-amine,
intermediate 2h: N-allyl-4-phenylthiazol-2-amine,
intermediate 2i: 4-(2-fluorophenyl)thiazol-2-amine.
intermediate 2j : 4-(2-bromophenyl)thiazol-2-amine.
intermediate 2k: N-allyl-4-(2-(5 -methoxypyrazin-2-yl)phenyl)thiazo 1-2-amine
General Method C: synthesis of 2-amino-4-biarylaminothiazole and 2-amino-4- heterobiarylaminothiazole intermediates 1.6.
This general method is depicted with the synthesis of l-(5-(2-(2-(allylamino)thiazol-4- yl)phenyl)pyridin-2-yl)pyrrolidin-2-one, intermediate 2d.
Step 1 : synthesis of 2-(2-(allylamino)thiazol-4-yl)phenylboronic acid.
To a stirred solution of N-allyl-4-(2-bromophenyl)thiazol-2-amine (intermediate 2c) (1.2 g, 4 mmol) in THF (20 mL) at -78°C was added dropwise a 2.5M solution of nBuLi in hexanes (8.72 mmol, 3.49 mL). After 15 min, triisopropyl borate (12 mmol, 2.76 mL) was rapidly added. After a further hour at -78°C, the rm was warmed to RT and stirred for lh. The reaction mixture was evaporated to dryness and residue analyzed by LCMS showing title product to be 50% pure (rt = 2.8 min). The residue was dissolved in toluene (10 mL) thus obtaining a 0.2M solution of title product to be used as such in the next step.
Step 2: synthesis of l-(5-(2-(2-(allylamino)thiazol-4-yl)phenyl)pyridin-2- yl)pyrrolidin-2-one, intermediate 2d.
A solution of 2-(2-(allylamino)thiazol-4-yl)phenylboronic acid (0.5 g, 1.9 mmol), 2M solution of potassium carbonate in water (2.88 mmol, 1.4 mL) and l-(5- bromopyridin-2-yl)pyrrolidin-2-one (0.232 g, 0.961 mmol) in toluene (12 mL) was degassed (3 vacuum/N2 cycles and then Ar bubbling). Tetrakis(triphenyl- phosphine)palladium (0) (0.096 mmol, 0.11 g) was then added and the rm was heated at reflux overnight. The reaction mixture was cooled down to RT, diluted with EtOAc, washed with brine and concentrated in vacuo. Crude was purified by flash chromatography (PE/EtOAc = 95/5 -> 7/3), TLC: PE/EtOAc = 7/3, rf=0.2) to yield title product as brown powder. Y: 0.17 g (64%), P>99%, rt=3.2 min (gradient A), (M+H)+ = 377.
General Method C was also used for the synthesis of:
intermediate 2g: N-allyl-4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-amine, intermediate 21: 4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-amine from intermediate 2j.
General Method D: synthesis of compounds 1.9. (scheme 1)
This general method is depicted with the synthesis of
Example 1: compound n°6: 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid.
Step 1 : synthesis of (3S,4S)-tert-butyl 3-(allyl(4-(2-chlorophenyl)thiazol-2- yl)carbamoyl)-4-phenylhept-6-enoate.
To a solution of (2S,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-phenylhex-5-enoic acid (intermediate la) (1.04 mmol, 318 mg) in anhydrous MeCN (5 mL) was added HATU (1.04 mmol, 395 mg). After 5 min was added N-allyl-4-(2-chlorophenyl)thiazol-2-amine (intermediate 2a) (262 mg, 1.04 mmol) and DIE A (1.14 mmol, 199 μί). Reaction mixture was stirred overnight at 60°C. and then concentrated under vacuum. The residue was purified by flash chromatography (PE/EtOAc= 98/2, rf=0.27) to yield title compound. Y: 505 mg (90 %), P>95%, rt=5 min (gradient A), (M+H)+ =537.
Step 2: synthesis of tert-butyl 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2- oxo-4-phenyl-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetate.
To an oven dried-oven schlenck, under Argon pressure, was added 1st generation Grubbs' catalyst (Grubbs' cat.) (0.193 mmol, 159 mg) and anhydrous DCM (2 mL). To this purple mixture, was added a solution of (3S,4S)-tert-butyl 3-(allyl(4-(2- chlorophenyl)thiazol-2-yl)carbamoyl)-4-phenylhept-6-enoate (2.07 g, 3.85 mmol) in anhydrous DCM (220 mL). The mixture evolved from purple to brown during the addition. The mixture was heated at reflux until completion and cooled to RT, ethyl vinyl ether was added and the solution was stirred 30 minutes. The mixture was concentrated under vacuum and the residue was purified on silica gel column, eluted with PE/EtOAc = 98/2 (rf 0.2), to yield title product. Y: 1.83 g (93 %), P>99%, rt=5.9 min (gradient A), (M+H)+ =509.
Step 3: synthesis of 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-1,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid, compound n°6.
To a solution of (3S,4S)-tert-butyl 3-(allyl(4-(2-chlorophenyl)thiazol-2- yl)carbamoyl)-4-phenylhept-6-enoate (0.064 mmol, 100 mg) in DCM (1 mL) was added
TFA (0.3 mL). Reaction mixture was stirred at RT until completion of the reaction. Reaction mixture was then diluted with EtOAc and the organic layer was washed (5x10
mL) with an aqueous NaHS03 solution (10%), brine (2xl0mL) and water (2xl0mL), dried aver anhydrous magnesium sulfate and concentrated in vacuo to yield compound n°6. Y: 90 mg (88 %), P>99%, rt=4.98 min (gradient B), (M+H)+ =454. !HNMR (CDC13): 5=7.97 (d, 1H), 7.58 (s, 1H), [7.36 (d,), 7.3-7.1 (m), 7.09 (d), (10H)], 6.09- 5.83 (m, 3H), 4.68 (d, 1H), 3.99 (m, 1H), 3.15 (m, 1H), 2.73-2.6 (m, 2H), 2.33 (dd, 1H), 2.1 (m, 1H).
General Method E: synthesis of intermediates 7.4. (scheme 7) This general method is depicted with the synthesis of (R)-4-tert-butyl 1 -methyl 2-(N- cyclopentyl-4-oxobutanamido)succinate, intermediate 3a.
Step 1 : synthesis of (R)-4-(tert-butoxy)-2-(cyclopentylamino)-4-oxobutanoic acid
A mixture of (R)-2-amino-4-tert-butoxy-4-oxobutanoic acid (1.586 mmol, 300 mg) and cyclopentanone (3.17 mmol, 0.280 mL) was stirred under an atmosphere of hydrogen at room temperature in absolute ethanol (3 mL) in the presence of Pd(OH)2 on carbon (0.032 mmol, 44.5 mg). The RM was stirred overnight, then filtered over a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo to afford title product as a white solid which was used without further purification.
Step 2: synthesis of (R)-4-tert-butyl 1 -methyl 2-(cyclopentylamino)succinate. Preparation of the diazomethane solution: (Organic Syntheses, Coll. Vol. 2, p.165 (1943); Vol. 15, p.3 (1935))
In an appropriate beaker, were added diethyl ether (100 mL) and a freshly prepared solution of KOH (40% in water) (291 mmol, 29.1 mL). To this solution cooled to 0-5 °C was added portion-wise 1 -methyl- 1 -nitrosourea (97 mmol, 1 1.76 g). The ether phase became deep yellow. After complete addition, the organic layer was carefully transferred to another beaker containing KOH (pellets) in order to dry the diazomethane solution.
Esterification:
In a glass tube, containing a solution of (R)-4-tert-butoxy-2-(cyclopentylamino)-4-
oxobutanoic acid (1.516 mmol, 390 mg) in 10 mL of Et20, cooled to 0°C with an iced bath, was added dropwise under a N2 flow, the diazomethane solution (12.35 mmol, 19 mL) until complete conversion: a persistant yellow color was obtained. Reaction was stopped by addition of acetic acid (1 mL). The RM was diluted with EtOAc and washed with a saturated aqueous solution of NaHC03, dried over MgS04, filtered and concentrated in vacuo. The crude product was purified on silica gel column, eluted with (PE/EtOAc 98/2 -> 5/5), (TLC: PE/EtOAc = 9/1, rf= 0.3) to afford title product as a colorless oil. Y: 1.26 g, rt=4.5 min (gradient A). Step 3: synthesis of (R)-4-tert-butyl 1 -methyl 2-(N-cyclopentylpent-4- enamido)succinate.
To a solution of (R)-4-tert-butyl 1-methyl 2-(cyclopentylamino)succinate (1.776 mmol, 482 mg) in DCM (1.8 mL) at RT was added N-methylmorpholine (2.66 mmol, 293 μί). After stirring for 5 minutes, a solution of pent-4-enoyl chloride (8.88 mmol, 980 μί) in DCM (1 mL) was added dropwise at 0°C. The mixture was stirred for 30min and quenched with a saturated aqueous solution of NH4C1 and the organic layer was separated, dried over MgS04 and concentrated to give a yellow oil. Crude was purified on silica gel, (PE/EtOAc=9/l -> 85/15), (TLC: PE/EtOAc = 9/1, rf=0.24, KMn04 rev.) to afford title compound as a colorless oil. Y: 59%, rt=4.5 min (gradient A).
Step 4: synthesis of (R)-4-tert-butyl 1-methyl 2-(N-cyclopentyl-4- oxobutanamido)succinate, intermediate 3a.
To a solution of (R)-4-tert-butyl 1-methyl 2-(N-cyclopentylpent-4-enamido)succinate (0.965mmol, 341 mg) in THF/H20 (3/1, 8mL) was added a solution of 4 % of Os04 in water (0.096 mmol, 590μί) followed by NaI04 (2.89 mmol, 619 mg). The reaction mixture was stirred at RT for 2 h and then quenched with aqueous Na2S203 IN. The aqueous layer was extracted twice with EtOAc. Combined organic layers were washed with brine, dried over MgS04, filtered and concentrated under vaccum to afford 344 mg of crude product. The crude was purified on silica gel column (gradient: PE/EtOAc=9/l -> PE/EtOAc/DCM=5/4/l), (TLC: PE/EtOAc = 75/25, rf=0.15, KMn04 rev.), to afford title product as a colorless oil. Y: 83%, rt=3.8 min (gradient A), (M+H) =356.
General method E was also used for the synthesis of the following intermediates: intermediate 3b: 4-tert-butyl 1 -methyl 2-(4-oxo-N-phenylbutanamido)succinate which was obtained from (R)-4-tert-butoxy-4-oxo-2-(phenylamino)butanoic acid which was synthesized as follows from (R)-2-amino-4-tert-butoxy-4-oxobutanoic acid:
Bromobenzene (0.881 mmol, 0.093 mL), copper (I) iodide (0.176 mmol, 33.6 mg), (R)- 2-amino-4-tert-butoxy-4-oxobutanoic acid (1.321 mmol, 250 mg), tribasic potassium posphate (5.29 mmol, 1.12 g), N,N-dimethylethanolamine (2.64 mmol, 0.265 mL) and water (2.6 mL) were mixed in a carrousel tube with a magnetic stirbar. The flask was air purged and filled with nitrogen. The reaction mixture was vigorously stirred at 90°C for 46 h until almost all the bromobenzene was consumed, as determined by LC-MS. The flask was cooled to RT and rm was poured on ice. HC1 6N was added dropwise with stirring until precipitation was observed and the color changed from blue to green. The final pH of the solution was adjusted to pH = 4-5. The acidified solution was extracted with EtOAc (3x). The combined organics were washed with brine and water and the solvent was evaporated to yield title compound as a yellow oil. Y: 55 mg (24%), P=100%, rt=3.9 min (gradient A), (M+H)+=266. intermediate 3c: 3-(N-isopropyl-4-oxobutanamido)-4-methoxy-4-oxobutanoic acid which was obtained from (R)-2-amino-4-tert-butoxy-4-oxobutanoic acid and propan-2- one following general method E:
General Method F: synthesis of compounds 7.6. (scheme 7)
This general method is depicted with the synthesis of
Example 2: compound n°32 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,8- dioxo- 1 ,4-diazocan-2-yl)acetic acid.
Step 1 : synthesis of 4-tert-butyl 1 -methyl 2-(4-((4-(2-chlorophenyl)thiazol-2- yl)amino)-N-cyclopentylbutanamido)succinate.
To a solution of 4-tert-butyl 1 -methyl 2-(N-cyclopentyl-4-oxobutanamido)succinate,
intermediate 3a, (0.802 mmol, 0.285 g) in DCE (10 mL) and AcOH (3.41 mmol, 0.195 mL) was added 5-(2-chlorophenyl)thiazol-2-amine (intermediate 2f) (0.802 mmol, 0.169 g) followed by 4 A crushed molecular sieves and the resulting mixture was stirred at RT under nitrogen atmosphere for 7 h. NaBH(OAc)3 (2.406 mmol, 0.510 g,) was then added to the solution and the resulting suspension was stirred at RT overnight. The mixture was then quenched with a saturated aqueous solution of sodium bicarbonate (2 mL) and extracted with DCM (2 x 5 mL). The organics were combined, dried over sodium sulfate, filtered and then evaporated under vacuum. Crude was purified on silica gel, eluent (PE/EtOAc=9/l -> 1/1), (TLC: PE/EtOAc = 75/25, rf=0.14), to yield title product. Y: 168 mg (38%), P=100%, rt=4.2 min (gradient A), (M+H)+=550.
Step 2: synthesis of 4-(tert-butoxy)-2-(4-((4-(2-chlorophenyl)thiazol-2- yl)amino)-N-cyclopentylbutanamido)-4-oxobutanoic acid.
To a solution of 4-tert-butyl 1 -methyl 2-(4-((4-(2-chlorophenyl)thiazol-2-yl)amino)-N- cyclopentylbutanamido)succinate (0.044 mmol, 24 mg) in THF/wate r= 1/1 mixture, was added LiOH (0.175 mmol, 4.18 mg) in one portion. The reaction mixture was stirred at RT for 3h and then was acidified to pH = 1 with HC1 IN and the aqueous layer was extracted twice with EtOAc. Combined organics were dried over MgSC^, filtered and concentrated under vacuum to afford title product as a colorless solid. Y: 25 mg, P=95%, rt=4.04 min (gradient A), (M+H)+=536.
Step 3 : synthesis of tert-buty l 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l- cyclopentyl-3,8-dioxo-l,4-diazocan-2-yl)acetate.
To a solution of 4-tert-butoxy-2-(4-(4-(2-chlorophenyl)thiazol-2-ylamino)-N- cyclopentylbutanamido)-4-oxobutanoic acid (0.179 mmol, 96 mg) in CH3CN (2.5 mL),
HATU (0.269 mmol, 102 mg) was added. The mixture was stirred for 10 min, and then DIEA (0.215 mmol, 37.5 μί) was added. The mixture was heated at 45 °C for 4h. The RM was concentrated in vacuo, and the crude was purified on silica gel (PE/EtOAc=8/2), (TLC PE/EtOAc = 6/4, rf 0.5), to afford title product as a colorless oil. Y: 50 mg, P=95%, rt=5.23 min (gradient A), (M+H-tBu)+=462.
Step 4: synthesis of 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,8-
dioxo-l,4-diazocan-2-yl)acetic acid, compound n°32.
To a solution of tert-butyl 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,8- dioxo-l,4-diazocan-2-yl)acetate (0.131 mmol, 67.8 mg) in DCM (1.8mL) was added TFA (5.2 mmol, 403 μί). The rm was stirred at RT until reaction completion. The RM was diluted with EtOAc, and washed with aqueous NaHS03 10 % w/w (5 x 25 mL), brine (5 mL) and water (5 mL). The organic layer was dried over MgSC^ and concentrated under reduced pressure to yield title product which was lyophilised overnight. P=95%, rt=4.4 min (gradient B), (M+H)+=463. !HNMR (CDC13): 5=7.9 (d, 1H), 7.54 (s, 1H), 7.46 (d,), 7.33-7.25 (m, 3H), 5.48-5.3 (m, 2H), 4.16-3.97 (m, 1H), 3.65-3.47 (m, 2H), 3.05-2.75 (m, 2H), 2.25 (m, 1H), 2.1 (m, 2H), 1.9-1.6 (m, 4H), 1.6- 1.3 (m, 3H).
The following examples were synthesized from intermediates and using general methods described above.
Example 3: compound n°l : 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lb and 2a using general method D.
Example 4: compound n°2: 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lc and 2a using general method D.
Example 5: compound n°3: 2-((3R,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates Id and 2a using general method D.
Example 6: compound n°4: 2-((3R,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates le and 2a using general method D.
Example 7: compound n°5: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazepan-3-yl)acetic acid:
Compound n°l (0.034mmol, 15 mg) was dissolved in MeOH (0.5 mL) and 50% wt Pd/C (1.5mg, 10%owt) was added. The flask was filled with hydrogen and stirred at RT for 3 days. Only 45%> conversion occurred, another 1.5 mg of Pd/C was added and the flask refilled with hydrogen and the rm stirred at RT for another 2 days until complete conversion. The rm was diluted with MeOH and filtered through a pad of celite, then concentrated in vacuo. Crude was purified using a Biotage PEAX SPE cartridge to yield title product. Y: 12mg (80%), rt=4.7min (gradient B), (M+H)+ = 442.
Example 8: compound n°7: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2- oxo-4-phenylazocan-3-yl)acetic acid:
Step 1 : synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetate.
To a solution of compound n° 6 (44 mg) in Et20 (4 mL) at 0°C was added a 1M solution of borane.THF complex (346 μί). The mixture was allowed to warm to RT and stirred for 4h at RT. The reaction mixture was cooled again to 0°C and a solution of 50% H202 in water (2.64 mL) and 2M NaOH (1.32 mL) was added. After 30 min the rm was poured onto a saturated aqueous solution of NaHCOs and extracted with Et20. Combined organics were dried over MgS04 and concentrated in vacuo. Crude was purified by column chromatography (PE/EtOAc=9/l then DCM/EtOAc=99/l) to yield title product. Y: 24.2 mg (53%), P=98%, rt=5.2 min (gradient A), (M+H)+ =527. tert-butyl 2-((3S,4S)-l-(4-(2- chlorophenyl)thiazol-2-yl)-6-hydroxy-2-oxo-4-phenylazocan-3-yl)acetate was also recovered during the chromatography.
Step 2: synthesis of compound n°7.
Intermediate obtained in step 1 was treated with TFA and DCM, as described in step 3 of general method D and provided title compound upon flash chromatography purification (DCM/MeOH=99/l). Y: 6 mg (28%), P=90%, rt=4.3 min (gradient B), (M+H)+ =472.
Example 9: c o m p o u n d n ° 9 : 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2a using general method D.
Example 10: compound n°l l : 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenyl-2,3,4,5,8,9-hexahydro-lH-azonin-3-yl)acetic acid was synthesized from intermediates la and 2b using general method D.
Example 11: compound n°12: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid was synthesized from compound n°6 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 12: compound n°13: 2-((3S,4S,Z)-l-(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo- 4-phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates la and 2e using general method D.
Example 13: compound n°14: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2- oxo-4-phenylazepan-3-yl)acetic acid was synthesized from compound n°l using the hydroboration and TFA deprotection steps as described for the synthesis of compound n°7. 7¾rt-butyl 2-((3S,4S,5R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-5-hydroxy-2-oxo-4- phenylazepan-3-yl)acetate was also recovered during the chromatography.
Example 14: compound n°16: 2-((3S,4S)-l-(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid was synthesized from compound n°13 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 15: compound n°17: 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- (tetrahydro-2H-pyran-4-yl)-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized
from intermediates lg and 2a using general method D.
Example 16: compound n°18: 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- (tetrahydro-2H-pyran-4-yl)azocan-3-yl)acetic acid was synthesized from compound n°17 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 17: compound n°19: 2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-3,8-dioxo-l-phenyl- l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3b and 2f using general method F.
Example 18: compound n°20: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2- oxo-4-phenylazocan-3-yl)acetic acid:
tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2-oxo-4-phenylazocan- 3-yl)acetate which was obtained during step 1 of compound n°7's synthesis was reacted with TFA in DCM as described in step 2 of compound n°7's synthesis; which yielded title compound after flash chromatography purification (DCM/MeOH=99/l). Y: 18 mg (47%), P=96%, rt=3.4 min (gradient B), (M+H)+ =472.
Example 19: c omp ound n°21 : 2-((3S,4S,5R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-5- hydroxy-2-oxo-4-phenylazepan-3-yl)acetic acid:
tert-b u t y 1 2-((3S,4S,5R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-5-hydroxy-2-oxo-4- phenylazepan-3-yl)acetate which was obtained during step 1 of compound n°14's synthesis was reacted with TFA in DCM as described in step 2 of compound n°7's synthesis; this yielded title compound after flash chromatography purification (DCM/MeOH=95/5).
Example 20: compound n°22: 2-((3S,4S)-l-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol- 2-yl)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid was synthesized from intermediates lb and 2g using general method D.
Example 21: compound n°23: 2-((3S,4S)-l-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol- 2-yl)-2-oxo-4-phenylazepan-3-yl)acetic acid was synthesized from compound n°22 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 22: compound n°24: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-fluoro-2- oxo-4-phenylazocan-3-yl)acetic acid:
step 1 : synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-fluoro-2-oxo- 4-phenylazocan-3-yl)acetate
A solution of compound n° 7 (1 eq) in chloroform at -50°C was treated with DAST (2.2 eq). The RM was warmed to RT and stirred for 2 days. The rm was quenched with a saturated aqueous solution of NaHC03 and extracted (3 x) with DCM, combined organics were drid and concentrated in vacuo. Crude was purified by flash chromatography (PE/EtOAc) to yield title compound with the dehydrated side product; the mixture was used as such for the next step.
Step 2: synthesis of compound n°24
Intermediate obtained in step 1 was treated with TFA and DCM, as described in step 3 of general method D which provided crude title product. Crude was purified by preparative HPLC to yield title compound. Y: 2 mg, P>90%, rt=7.79 min (gradient B), (M+H)+ =474.
Example 23: compound n°25: 2-((3S,4S,6S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7- dihydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid and compound n°26: 2-((3S,4S,6S,7R)- l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid: A solution of 4-methylmorpholine (1.336 mmol, 135 mg) and a catalytic amount of a 4wt% solution osmium tetroxide in distilled water (0.039 mmol, 0.240 mL) in distilled water (0.3 M, 230 μί) at RT was added slowly to a solution of tert-butyl 2-((3S,4S,Z)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 1 ,2,3,4,5,8-hexahydroazocin-3- yl)acetate (compound n°6's precursor)(0.393 mmol, 200mg) in THF/acetone = 1/1 (4.4
mL, 0.1 M). After the addition, a brown color appeared and 2 min later a white suspension formed. After 2 hours at RT, the rm was quenched with Na2S203 sat. solution and extracted with EtOAc, washed with brine. The organic layer was separated, dried over MgS04, filtered and concentrated in vacuo. Crude product was then purified by chromatography on silica gel (eluent PE/EtOAc=8/2 -> 5/5) to yield:
1) tert-butyl 2-((3S,4S,6S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy-2-oxo- 4-phenylazocan-3-yl)acetate as a colorless solid. Y: 90 mg, rt=5.04min, (M+H)+=544. Treatment with HCl 4N in dioxane and sodium bisulfite work up yielded compound n°25. Y: 18 mg (84%).
2) tert-butyl 2-((3S,4S,6R,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy-2-oxo- 4-phenylazocan-3-yl)acetate as a colorless solid. Y: 70 mg, rt=4.76min, (M+H)+=544. Treatment with HCl 4N in dioxane, sodium bisulfite work up and Biotage PEAX SPE purification yielded compound n°26. Y: 19 mg (96%).
Example 24: c o m p o u n d n ° 2 7 : 2-((3S,4S,Z)-4-([l,l'-biphenyl]-4-yl)-l-(4-(2- chlorophenyl)thiazol-2-yl)-2-oxo- 1,2,3,4,5 , 8-hexahydroazocin-3 -y l) acetic acid was synthesized from intermediates lh and 2a using general method D. Example 25: compound n°29: 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2,7-dioxo- 4-phenylazocan-3-yl)acetic acid:
To a solution of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2- oxo-4-phenylazocan-3-yl)acetate (compound n°7's precursor) (0.095 mmol, 50 mg) in DCM (5 mL) was added pyridinium chlorochromate (0.237 mmol, 51.1 mg) in one portion. The rm was stirred at RT for 4 days. The rm was filtered over a celite pad.The filtrate was concentrated under vaccum. The residue was suspended in DCM, and then filtered on a celite pad and concentrated once again. Residue was disolved in EtOAc and washed with aqueous HCl IN, brine and a saturated aqueous solution of NaHC03. The organic layer was dried over MgSC^, and concentrated in vacuo to afford tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2,7-dioxo-4-phenylazocan-3-yl)acetate as a pale yellow oil . Y: 42 mg (84%), P=100%, rt=5.4 min, (M+H)+=525. The product
was treated with TFA in DCM and provided upon a soldium bisulfite work up compound n°29 as a colorless powder. Y: 6 mg (67%), P>80%.
Example 26: compound n°30: 2-((3S,4S,Z)-2-oxo-l-(4-(2-(6-(2-oxopyrrolidin-l- yl)pyridin-3-yl)phenyl)thiazol-2-yl)-4-phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates la and 2d using general method D.
Example 27: c omp o und n°31 : 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- (isopropylamino)-2-oxo-4-phenylazocan-3-yl)acetic acid:
step 1 : synthesis of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- (isopropylamino)-2-oxo-4-phenylazocan-3-yl)acetate
To a suspension of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2,7-dioxo- 4-phenylazocan-3-yl)acetate (compound n°29's precursor) (0.029 mmol, 15 mg), isopropylamine (0.031 mmol, 2.7 uL) and sodium triacetoxyborohydride (0.04 mmol, 8.5 mg) in DCE (1 mL) was added acetic acid (0.02 mmol, 1.2 μΐ,) and the resulting mixture was stirred at RT overnight. The reaction mixture was treated with aqueous saturated NaHC03, extracted with DCM, dried over MgSC^, filtered and concentrated in vacuo to give title product as a colorless oil. Y: 8 mg (49%), rt=4.5 and 5 min (gradient A), (M+H)+=568. step 2: synthesis of compound n°31
Intermediate obtained in step 1 was treated with TFA and DCM, as described in step 3 of general method D which provided title product. Y: 10 mg, P=100%, rt=4.1 min (gradient A), (M+H)+ =513.
Example 28: compound n° 33 : 2-((3S,4S,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid
Purification of tert-butyl 2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2- oxo-4-phenylazocan-3-yl)acetate (compound n°7's precursor) on silica gel with PE/EtOAc = 8/2, (TLC: PE/ EtOAc 7/3, rf=0.2), provided tert-butyl 2-((3S,4S,7S)-l-(4- (2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2-oxo-4-phenylazocan-3-yl)acetate. P= 100%, rt=5.17 min (gradient B). This product was treated with TFA and DCM, as described in
step 3 of general method D and provided compound n°33. Y: 30 mg (36%), P=100%>, rt=4.4 min (gradient B), (M+H)+ =472.
Example 29: compound n°34 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- isopropyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2a using general method D.
Example 30: compound n°36: 2-((3S,4S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-2-oxo-4-phenylazocan-3-yl)acetic acid was obtained using the same procedure as for compound n°33.
Example 31: compound n°37: 2-((3S,4R,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-7-hydroxy-2-oxoazocan-3-yl)acetic acid and compound n° 38 : 2- ((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7-hydroxy-2-oxoazocan- 3-yl)acetic acid were synthesized from compound n°9 using the methodology described for the synthesis of compound n°7.
Example 32: compound n°39 : 2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- isobutyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates lj and 2a using general method D.
Example 33: compound n°40 : 2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7- hydroxy-4-isopropyl-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°34 using the methodology described for the synthesis of compound n°7.
Example 34: compound n°41 : 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°9 using the hydrogenation procedure detailed for the synthesis of compound n°5. Example 35: compound n°42 : 2-((3S,4R,Z)-4-cyclopentyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid was synthesized from intermediates If and 2d using general method D.
Example 36: compound n°43: 2-((3S,4R)-4-cyclopentyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid was
synthesized from compound n°42 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 37: compound n°44: 2-((3S,4R,Z)-4-cyclopentyl-2-oxo-l-(4-phenylthiazol-2- yl)-l,2, 3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2h using general method D. Example 38: c omp ound n ° 45 : 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2- fluorophenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2i using general method D.
Example 39: compound n°46: 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-methoxypyridin- 3-yl)phenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates If and 2g using general method D.
Example 40: compound n°47: 2-((3S,4S)-7-(benzylamino)-l-(4-(2-chlorophenyl)thiazol-2- yl)-2-oxo-4-phenylazocan-3-yl)acetic acid was synthesized using the methodology used for the synthesis of compound n°31 , replacing isopropylamine with benzylamine.
Example 41: compound n°48: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2g using general method D.
Example 42: compound n°49 : 2-((3S,4R,Z)-4-isopropyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid was synthesized from intermediates li and 2d using general method D.
Example 43: compound n°50 : 2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopropyl-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates lk and 2a using general method D. Example 44: compound n° 62 : 2-((3S,4S,Z)-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-4-phenyl- 1 ,2,3 ,4,5 ,8-hexahydroazocin-3-y l)acetic acid was synthesized from intermediates la and 2g using general method D.
Example 45: compound n° 63 : 2-((3S,4R)-4-isopropyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid was synthesized from compound n°49 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 46: compound n°64: 2-((3S,4R)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°62 using the hydrogenation procedure detailed for the synthesis of compound n°5.
Example 47: c o m p o u n d n °116: 2-(l-isopropyl-4-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3c and 2g using general method F.
Example 48: compound n°117: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid was synthesized from intermediates li and 2k using general method D.
Example 49: compound n°118: 2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid was synthesized from compound n°l 17 using the hydrogenation procedure detailed for the synthesis of compound n°5. Example 50: c o m p o u n d n °119: 2-(l-cyclopentyl-4-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid was synthesized from intermediates 3a and 2g using general method F.
BIOLOGY EXAMPLES
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 represents the effect of compound 9 on GLP-1 release from rat lower intestinal GLP-1 secreting cells.
Figure 2 represents the inhibition of in-vitro TNFa release from LPS-stimulated PBMC following the activation by the compounds of the invention.
Figure 3 represents the inhibition of in-vivo lipolysis following the injection of compound 42 in mice.
Membrane binding assay: GTPyS binding assay.
The following assay can be used for determination of GPR43 activation. When a GPCR is in its active state, either as a result of ligand binding or constitutive activation, the receptor couples to a G protein and stimulates the release of GDP and subsequent binding of GTP to the G protein. The alpha subunit of the G protein-receptor complex acts as a GTPase and slowly hydrolyses the GTP to GDP, at which point the receptor normally is deactivated. Activated receptors continue to exchange GDP for GTP. The non- hydro lysable GTP analog, [35S]GTPyS, was used to demonstrate enhance binding of [35S]GTPyS to membranes expressing receptors. The assay uses the ability of GPCR to stimulate [35S]GTPyS binding to membranes expressing the relevant receptors. The assay can, therefore, be used in the direct identification method to screen candidate compounds to endogenous or not endogenous GPCR. Preparation of membrane extracts:
Membrane extracts were prepared from cells expressing the human GPR43 receptor (hGPR43) as follows: the medium was aspirated and the cells were scraped from the plates in Ca++ and Mg++-free Phosphate-buffered saline (PBS). The cells were then centrifuged for 3 min at 1500 g and the pellets were resuspended in buffer A (15 mM Tris-HCl pH 7.5, 2 mM MgCl2, 0.3 mM EDTA, 1 mM EGTA) and homogenized in a glass homogenizer. The crude membrane fraction was collected by two consecutive centrifugation steps at 40.000 x
g for 25 min separated by a washing step in buffer A. The final pellet was resuspended in 500 μΐ. of buffer B (75 mM Tris-HCl pH 7.5, 12.5 mM MgCl2, 0.3 mM EDTA, lmM EGTA, 250 mM sucrose) and flash frozen in liquid nitrogen. Protein content was assayed by the Folin method.
GTPyS assay (SPA method):
The assay was performed in the presence of SCFA, and was used to determine the activity of the compounds of the invention.
The [35S]GTPyS assay was incubated in 20 mM HEPES pH 7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μΜ of GDP, 5 μg membrane-expressing hGPR43, 250μg of wheatgerm agglutinin beads (Amersham, ref: RPNQ001), a range concentration of compounds of the invention (from 30 μΜ to 1 nM) in a final volume of 100 μί for 30 min at room temperature. The SCFA propionate was used at 1 mM final concentration as positive control. The plates were then centrifuged for 10 minutes at 2000 rpm, incubated for 2 hours at room temperature and counted for 1 min in a scintillation counter (TopCount, PerkinElmer). The results of the tested compounds are reported as the concentration of the compound required to reach 50% (EC50) of the maximum level of the activation induced by these compounds. When tested in the assay described above and by way of illustration the compounds in Table 3 activate GPR43 receptor with an EC50 ranging from 21 nM to 2930 nM.
Table 3 : EC50 values in GTPy S assay
50 124
62 151
63 1465
64 223
116 758
117 49
118 274
119 169
GLP-1 release assay.
Rat lower intestinal GLP-1 secreting cells were prepared from eight- week-old male Sprague-Dawley rat. Each well contained 5x 104 cells stimulated in assay buffer (DMEM- based medium) containing 5.6 mM glucose with increasing concentration of the compounds of the invention for 1 hour at 37°C in cell incubator. The supernatants were harvested and assessed for GLP-1 using an ELISA (Wako).
When tested in the GLP-1 release assay described above and by way of illustration the compound n° 9 induced a significant and dose-dependent release of GLP-1 from rat lower intestinal cells (Figure 1).
Oral Glucose Tolerance Test (OGTT).
Lean male C57BL/6J mice (7 weeks of age) were kept in a 12/12h light-dark cycle (light from 0600-1800 h) with controlled temperature conditions (22-24°C). At day -1 food was removed from all mice. The acute experiment was performed 17 hours later (day 1). Mice (n=6) were dosed per oral with vehicle (cyclodextin/NaclO.9%) or compounds of the invention (50 mg/kg). At time points -15 and 0 min, baseline blood glucose was measured through a tail bleeding (using a glucometer). Then glucose was administered by oral gavage (2g/kg glucose) and blood glucose was then measured at time points 15, 30, 60 and 120 minutes. The blood glucose area under the curve (AUC) between time t-15 min and time tl20 min was calculated (GraphPad Prism software). The percentages of AUC inhibition induced by the compounds of the invention were calculated following the formula below: % of AUC inhibition = [1- (AUC compound / AUC vehicle)] * 100.
When tested in the above-described assay, preferred compounds of the invention showed a
% of AUC inhibition > 13%, indicating that the compounds of invention are able to significantly reduce the level of blood glucose.
Cytokines release from Peripheral Blood Mononuclear Cell assay.
Peripheral blood mononuclear cells (PBMC) are purified from heparinised fresh blood sample on a Lymphoprep gradient. PBMC are plated in 96-well assay plate (2x106 cells/well) and stimulated with or without LPS (100 ng/ml) and increasing concentration of compounds of the invention for 3 hours at 37°C. Cell supernatants are recovered after centrifugation and human soluble TNFa .is quantified using ELISA assay (R&D system) according manufacturer's recommendation.
When tested in the cytokines release from PBMC assay described above and by way of illustration the compounds n° 9; 39 and 43 significantly inhibit the TNFa secretion from PBMC (Figure 2).
In vivo assay to assess compound anti-lipolytic activity in rodent model
Male C57BL/6N wild-type are housed one per cage in a room maintained on a 12h light/dark cycle under constant temperature (22-25°C) with ad libitum access to food and water. The anti-lipolytic effects of the compounds of the invention are studied in awake mice. Animals are fasted overnight before experimental use. On the day of the experiment, animals are put in metabolic cages and left undisturbed to acclimate to the environment for l-2h. Blood samples are taken at indicated time points from the intraorbital retrobulbar plexus. A 1% sodium citrate saline solution is used to flush the lines. A pre-treatment blood sample is obtained from each animal to determine baseline values for free fatty acids (FFA) and triglycerides (TG). Compounds of the invention are given via oral gavage, sc injection, iv injection or ip injection for each different series of experiments. Blood samples are collected into pre-cooled tubes pre-coated with heparin (200μί blood, Li-heparin, Sarstedt) for determination triglycerides and glycerol and in tri-potassium EDTA added sodium fluoride (200 blood, K3-EDTA, 1.6 mg/mL + 1% NaF, Sarstedt) for determination of plasma free fatty acids. The tubes are placed on wet ice pending processing. Blood samples will be centrifuged at 4000 x g, at 4°C, 15 min the resulting plasma will be transferred into non-coated tubes and stored at -80°C until analyses. The plasma is thawed at 4°C for determinations of FFA and TG using commercial kits (Wako Chemicals).
According to the method described above and by way of illustration the compound n° 42 administered orally, inhibit, 60 minutes following the dosing, in vivo FFA baseline at the concentration of 50mg/kg from normal diet fed mice in comparison to the vehicle (Figure 3).
While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation ant it is understood that various changes may be made without departing from the spirit and scope of the invention.
Claims
CLAIMS 1. A compound of formula I
Ar1— L1— R Ar2— Ar3
I and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein:
Ar1 is a C3-C6 alkyl, C3-C6 cycloalkyl, C4-C6 heterocyclyl, 6-membered aryl or 5 to 6- membered heteroaryl group, each of which being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl or haloalkoxy; L1 is a single bond, -CH2-, -CHCH3 or -C(CH3)2;
Ar2 is a 6-membered aryl group or a 5 to 6-membered heteroaryl group, each of which being optionally substituted by one or more halo or alkyl group(s);
Ar3 is a 5 to 6-membered aryl optionally substituted by one or more halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy or haloalkoxy group(s), by one aryl or heteoaryl group, each of said aryl or heteroaryl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxy, haloalkoxyalkoxy, amino, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N-(aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the aryl or heteroaryl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo or oxo group(s);
ring-l ring-l l ring-IV
ring-V ring-VI
ring-VI I ring-VI 11 wherein:
L1 is attached to the ring at position a and Ar2 is attached to the nitrogen atom at position b; the bonds represented by the dotted lines are independently a single bond, a double bond or a triple bond; at least one of the bonds represented by the dotted lines depicted as "c" and "d" in ring-VII is a single bond;
D is C=0;
when the dotted line in ring-I is a single bond, R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R2 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and R2 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R2 forms together with R2 a =CH2 or oxo moiety; when the dotted line in ring-I is a double bond R1 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is absent; R2 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R2 is absent; when the dotted line in ring-I is a triple bond R1, R1 , R2 and R2 are absent;
R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R3 forms together with R3 an oxo moiety;
when the dotted line in ring-II is a single bond, R4 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R5 forms together with R5 an oxo moiety; when the dotted line in ring-II is a double bond, R4 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R4 is absent; R5 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R5 is absent; when the dotted line in ring- II is a triple bond R4, R4', R5 and R5 are absent;
R6 and R6' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R7 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl, C1-C4 haloalkoxyalkyl, or R7 forms together with R7 an oxo moiety; R8 is H or C1-C4 alkyl;
R9 and R9 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R10 and R10' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in ring-V is a single bond, R11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci-
C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R12 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R12 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R12 forms together with R12 a =CH2 or oxo moiety; when the dotted line in ring-V is a double bond, R11 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is absent; R12 is H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R12 is absent when the dotted line in ring- V is a triple bond, R11, R11', R12, and R12' are absent;
R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R13 forms together with R13 an oxo moiety;
when the dotted line in ring- VI is a single bond, R is selected from H, fluoro, chloro, Ci- C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R15 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R15 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl or R15 forms together with R15 a =CH2 or oxo moiety; when the dotted line in ring- VI is a double bond, R14 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is absent; R15 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R15 is absent; when the dotted line in ring- VI is a triple bond, R14, R14', R15, and R15 are absent;
R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl,
C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R16 forms together with R16 an oxo moiety;
R17 and R17' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted lines depicted by "c" and "d" in ring- VII are both single bonds, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; one of R19 or R20 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and the other one is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R19 forms together with R19 a =CH2 or oxo moiety and R20 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl,
hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R20 forms together with R20 a =CH2 or oxo moiety and R19 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; when the dotted line depicted by a "c" in ring- VII is a single bond and the dotted line depicted by a "d" in ring- VII is a double bond, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19 and R20 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 and R20 are absent; when the dotted line depicted by a "c" in ring- VII is a single bond and the dotted line depicted by a "d" in ring- VII is a triple bond, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19, R19', R20 and R20' are absent; when the dotted line depicted by a "c" in ring- VII is a double bond and the dotted line depicted by a "d" in ring- VII is a single bond, R18 and R19 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 and R19 are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or Ci- C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; when the dotted line depicted by a "c" in ring- VII is a triple bond and the dotted line depicted by a "d" in ring- VII is a single bond, R18, R18', R19 and R19' are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4
alkoxyalkyl or C1-C4 haloalkoxyalky;
L3 is a single bond, or L3 is a C1-C3 alkylene optionally substituted by one or more group(s) selected from fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R21 forms together with R21 an oxo moiety; R22 and R22' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R23 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R23 forms together with R23 an oxo moiety;
R24 is H or Ci-C4 alkyl;
R25 and R25 are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
L2 is a C1-C2 alkylene optionally substituted by one or more methyl group(s);
2. The compound of claim 1 having formula Ia-1
Ia-1 and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein
R, Ar1, and Ar3 are as defined in claim 1 ; and
R26 is H, halo, cyano, hydroxyl, linear or branched Ci-C3 alkyl, Ci-C3 hydro xyalkyl, Ci-C3 haloalkyl.
3. The compound of claim 2 having formula Ia-2
Ia-2 and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R, Ar1 and R26 are as defined in claim 2;
R27 is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy,, haloalkoxy, phenyl, pyridinyl, pyridazinyl or pyrazinyl, each of said phenyl, pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxyalkoxy, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N- (aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo, or oxo group(s); R27' is H;
R28 is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, or haloalkoxy; R28 is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, or haloalkoxy; R29 is H, halo, cyano, alkyl, or alkoxy.
Ia-3 and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein
R, Ar1 and R26, R27', R28, R28 , and R29, are as defined in claim 3; R30 is H, halo, alkyl, haloalkyl, hydroxyl, alkoxy;
R31 is alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group haloalkoxyalkoxy, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N- (aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, each of said substituents may be substituted by one or more alkyl, halo, or oxo group(s), or R31 and R30 together form a heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system which may be substituted by one or more alkyl, halo, or oxo group(s);
X1 is N or C-R32 wherein R32 is H;
X2 is N or C-R32' wherein R32' is H or alkoxy.
5. The compound of claim 3 having formula Ia-4
6. The compound of claim 1 selected from the group consisting of formulae Id-l, Id-5, Id-6 and Id-7:
ld-6 |d_7 and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein
Ar1, Ar2, Ar3, L1, L2, D, and Z are as defined above in respect to formula I; the bonds represented by the dotted lines are independently either absent or present thus making the bonds represented by = independently a single bond or a double bond respectively; at least one of the bonds represented by the dotted lines depicted as "c" and "d" in formula Id-7 is a single bond;
when the dotted line in formula Id-1 is absent, R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R2 is H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino, heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alkyloxycarbonylamino , hetero cycly lo xycarbony lamino , arylo xycarbony lamino , hetero arylo xycarbonylamino , alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and R2 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R2 forms together with R2 a =CH2 or oxo moiety; when the dotted line in formula Id-1 is present, R1 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R1 is absent; R2 is H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, and R2 is absent;
R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R3 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R3 forms together with R3 an oxo moiety;
R10 and R10' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4
haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted line in formula Id-5 is absent, R is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R12 is H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino, heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alkyloxycarbonylamino , heterocyclyloxycarbony 1 amino , ary loxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R12 is selected from H, fluoro, chloro, Ci- C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R12 forms together with R12 a =CH2 or oxo moiety; when the dotted line in formula Id-5 is present, R11 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R11 is absent; R12 is H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R12 is absent
R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R13 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl,
C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R13 forms together with R13 an oxo moiety; when the dotted line in formula Id-6 is absent, R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Ci- C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R15 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, hetero arylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, hetero arylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , hetero aryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino; R15 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl or R15 forms together with R15 a =CH2 or oxo moiety; when the dotted line in formula Id-6 is present, R14 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R14 is absent; R15 is selected from H, fluoro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; and R15 is absent;
R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl;
R16 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R16 forms together with R16 an oxo moiety;
R17 and R17' are independently selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; when the dotted lines depicted by "c" and "d" in formula Id-7 are both absent, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; one of R19 or R20 is selected from H, fluoro, chloro, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy, heterocyclylalkyloxy, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, amino, alkylamino, cycloalkylamino, cycloalkylalkylamino, heterocyclylamino, heterocyclylalkylamino, arylamino, aralkylamino, heteroarylamino, heteroarylalkylamino, alkylcarbonylamino, cycloalkylcarbonylamino, heterocyclylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, cycloalkylsulfonylamino, heterocyclylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbamoylamino, cycloalkylcarbamoylamino, heterocyclylcarbamoylamino, arylcarbamoylamino , heteroarylcarbamoylamino , alkoxycarbonylamino , cyclo alky lo xycarbony lamino , hetero cyclylo xyc arbony lamino , arylo xycarbony lamino , heteroaryloxycarbonylamino, alkylsulfamoylamino, cycloalkylsulfamoylamino, heterocyclylsulfamoylamino, arylsulfamoylamino, heteroarylsulfamoylamino, and the other one is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R19 forms together with R19 a =CH2 or oxo moiety and R20 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl,
haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; or R20 forms together with R20 a =CH2 or oxo moiety and R19 is selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl; when the dotted line depicted by a "c" in formula Id-7 is absent and the dotted line depicted by a "d" in formula Id-7 is present, R18 is selected from H, fluoro, chloro, C1-C4 alkyl, Ci- C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R19 and are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R19 and R20 are absent; when the dotted line depicted by a "c" in formula Id-7 is present and the dotted line depicted by a "d" in formula Id-7 is absent, R18 and R19 are independently selected from H, C1-C4 alkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R18 and R19 are absent; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or Ci- C4 haloalkoxyalkyl; R20 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalky; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, hydroxy-Ci- C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl; R21 is selected from H, fluoro, chloro, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy-Ci-C4 alkyl, C1-C4 alkoxyalkyl or C1-C4 haloalkoxyalkyl, or R21 forms together with R21 an oxo moiety;
7. The compound of claim 6 selected from the group consisting of formulae
Ie-1, Ie-5, Ie-6 and Ie-7:
and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein
Ar1, Ar2, Ar3, R1, R1 , R2, R2 , R3, R3 , R10, R10 , R11, R11 , R12, R12 , R13, R13 , R14, R14 , R15, R15 , R16, R16', R17, R17', R18, R18 , R19, R19', R20, R20', R21, R21'and the dotted lines are as defined are as defined in claim 6.
8. The compound of claim 7 selected from the group consisting of Ig-1, Ig-5,
Ig-6 and Ig-7:
Ar1, Ar3, R1, R1 , R2, R2 , R3, R3 , R10, R10 , R11, R11 , R12, R12 , R13, R13 , R14, R14 , R15, R15 , R16, R16', R17, R17', R18, R18 , R19, R19', R20, R20', R21, R21', and the dotted lines are as defined above in claim 7; and
R26 is H, halo, cyano, hydro xyl, linear or branched C1-C3 alkyl, C1-C3 hydro xyalkyl, C1-C3 haloalkyl.
9. The compound of claim 8 selected from the group consisting of formulae Ih-l, Ih-5, Ih-6 and Ih-7:
. A Vr I 1. R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . RIV10. R IV10' . R IV11. R IV11' . R IV12. R IV12' . R IV13. R IV13' . R IV14. R IV14' . R IV15. R IV15' ,
R16, R16', R17, R17', R18, R18 , R19, R19', R20, R20', R21, R21', R26, and the dotted lines are as defined in claim 8;
R27 is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, haloalkoxy, phenyl, pyridinyl, pyridazinyl or pyrazinyl, each of said phenyl, pyridinyl, pyridazinyl or pyrazinyl group may be further substituted by one or more substituent(s) selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group, haloalkoxyalkoxy, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N- (aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, or fused to the pyridinyl or pyrazinyl group may be one heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system, each of said substituents may be substituted by one or more alkyl, halo, or oxo group(s); R27' is H;
R is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, or haloalkoxy;
R28 is H, halo, cyano, alkyl, haloalkyl, hydroxyl, alkoxy, or haloalkoxy; and
R29 is H, halo, cyano, alkyl, or alkoxy.
10. The compound of claim 9 selected from the group consisting of formulae Ii-1, Ii-5, Ii-6 and Ii-7:
. A Vr I 1. R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . RIV10. R IV10' . R IV11. R IV11' . R IV12. R IV12' . R IV13. R IV13' . R IV14. R IV14' . R IV15. R IV15' ,
R16, R16 , R17, R17 , R18, R18 , R19, R19 , R20, R20 , R21, R21 , R26, R27 , R28, R28 , R29, and the dotted lines are as defined in claim 9;
R30 is H, halo, alkyl, haloalkyl, hydroxyl, alkoxy;
R31 is alkoxy, cycloalkylalkyloxy, aralkyloxy, alkoxyalkoxy optionally substituted by an alkoxy group haloalkoxyalkoxy, alkylamino, N,N-(cycloalkyl)(alkyl)amino, N,N- (aralkyl)(alkyl)amino, heterocyclyl, heterocyclylcarbonyl, heteroaryl, each of said substituents may be substituted by one or more alkyl, halo, or oxo group(s), or R31 and R30 together form a heterocyclyl or heteroaryl ring, thus forming a fused bicyclic system which may be substituted by one or more alkyl, halo, or oxo group(s); X1 is N or C-R32 wherein R32 is H; and
X2 is N or C-R32' wherein R32' is H or alkoxy.
1 1. The compound of claim 9 selected from the group consisting of formulae Ij-1 , Ij-5, Ij-6 and Ij-7:
and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein
. A Vr I 1. R IV1. R IV1' , R IV2. R IV2' . R IV3. R IV3' . RIV10. R IV10' . R IV11. R IV11' . R IV12. R IV12' . R IV13. R IV13' . R IV14. R IV14' . R IV15. R IV15' ,
R16, R16', R17, R17', R18, R18 , R19, R19', R20, R20', R21, R21', R26, R27, R28' and the dotted lines are as defined in claim 9.
12. The compound of claim 1 selected from the group consisting of
1 2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4 , 7-tetrahy dro - 1 H-azepin-3 -y l)acetic acid;
2 2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4 , 7-tetrahy dro - 1 H-azepin-3 -y l)acetic acid;
3 2-((3R,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4 , 7-tetrahy dro - 1 H-azepin-3 -y l)acetic acid;
4 2-((3R,4R)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 2,3,4 , 7-tetrahy dro - 1 H-azepin-3 -y l)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazepan-3-yl)acetic acid;
2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3 S,4S)-7-amino- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-2- oxo-1,2,3,4,5,8 -hexahy droazocin-3 -y l)acetic acid;
2-((3 S,4R,Z)-4-benzyl- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-
1.2.3.4.5.8- hexahydroazocin-3-yl)acetic acid;
2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl-
2.3.4.5.8.9- hexahy dro - 1 H-azonin-3 -y l)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3S,4S,Z)- 1 -(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo-4-phenyl- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2-oxo-4- phenylazepan-3-yl)acetic acid;
2-((3S,4S,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-(hydroxymethyl)- 2-oxo-4-phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2,5-dichlorophenyl)thiazol-2-yl)-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3 S,4R,Z)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-(tetrahydro- 2H-pyran-4-yl)-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-2-oxo-4-(tetrahydro- 2H-pyran-4-yl)azocan-3-yl)acetic acid;
2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-3 ,8-dioxo- 1 -phenyl- 1 ,4- diazocan-2-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-6-hydroxy-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3 S,4S,5R)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-5-hydroxy-2-oxo- 4-phenylazepan-3-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-yl)-2- oxo-4-phenyl-2,3,4,7-tetrahydro-lH-azepin-3-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-yl)-2- oxo-4-phenylazepan-3-yl)acetic acid;
2-((3S,4S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-fluoro-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3S,4S,6S,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy- 2-oxo-4-phenylazocan-3-yl)acetic acid;
2-((3S,4S,6R,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-6,7-dihydroxy- 2-oxo-4-phenylazocan-3-yl)acetic acid;
2-((3S,4S,Z)-4-([l,r-biphenyl]-4-yl)-l-(4-(2-chlorophenyl)thiazol-2- yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4S,Z)-4-(2-chlorophenyl)- 1 -(2'-methoxy-[ 1 , 1 *-biphenyl]-4-yl)- 2-oxo-l, 2,3,4,5, 8-hexahy droazocin-3 -yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2,7-dioxo-4- phenylazocan-3-yl)acetic acid;
2-((3S,4S,Z)-2-oxo-l-(4-(2-(6-(2-oxopyrrolidin-l-yl)pyridin-3- yl)phenyl)thiazol-2-yl)-4-phenyl-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-7-(isopropylamino)-2- oxo-4-phenylazocan-3-yl)acetic acid;
2-(4-(4-(2-chlorophenyl)thiazol-2-yl)- 1 -cyclopentyl-3 ,8-dioxo- 1 ,4- diazocan-2-yl)acetic acid;
2-((3S,4S,7S)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2-oxo-4- phenylazocan-3-yl)acetic acid;
2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-isopropyl-2-oxo- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3 S,4S,7R)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-2-oxo- 4-phenylazocan-3-yl)acetic acid;
2-((3 S,4R,7S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7- hydroxy-2-oxoazocan-3-yl)acetic acid;
2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7- hydroxy-2-oxoazocan-3-yl)acetic acid;
2-((3S,4S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-isobutyl-2-oxo- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-7-hydroxy-4- isopropyl-2-oxoazocan-3 -yl)acetic acid;
2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-2- oxoazocan-3-yl)acetic acid;
2-((3 S,4R,Z)-4-cyclopentyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
2-((3 S,4R)-4-cyclopentyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid;
2-((3S,4R,Z)-4-cyclopentyl-2-oxo-l-(4-phenylthiazol-2-yl)- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-fluorophenyl)thiazol-2-yl)-2- oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
2-((3 S,4S)-7-(benzylamino)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2- oxo-4-phenylazocan-3-yl)acetic acid;
2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
2-((3 S,4R,Z)-4-isopropyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopropyl-2- oxo-1,2,3,4,5,8 -hexahy droazocin-3 -y l)acetic acid;
2-((3S,4R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclobutyl-2-oxo- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopropyl-2- oxoazocan-3-yl)acetic acid;
2-((3S,4R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclobutyl-2- oxoazocan-3-yl)acetic acid;
2-((6S,7S)-4-(4-(2-chlorophenyl)thiazol-2-yl)-2,5-dioxo-7-phenyl- 1 ,4-diazonan-6-yl)acetic acid;
2-((3 S,4S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-7-(hydroxymethyl)-2- oxo-4-phenylazocan-3-yl)acetic acid;
(R)-2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-cyclopentyl-3,7-dioxo- 1 ,4-diazepan-2-yl)acetic acid;
(R)-2-( 1 -cyclopentyl-4-(4-(2-(6-methoxypyridin-3 -yl)phenyl)thiazol-
2- yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid;
(R)-2-( 1 -cyclopentyl-3 , 8-dioxo-4-(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)- 1 ,4-diazocan-2-yl)acetic acid; (R)-2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-l-(cyclopentylmethyl)-3,8- dioxo- 1 ,4-diazocan-2-yl)acetic acid;
(R)-2-(4-(4-(2-chlorophenyl)thiazol-2-yl)- 1 -isobutyl-3 ,8-dioxo- 1 ,4- diazocan-2-yl)acetic acid;
(R)-2-(4-(4-(2-chlorophenyl)thiazol-2-yl)- 1 -isopropyl-3 ,8-dioxo- 1 ,4- diazocan-2-yl)acetic acid;
2-((3S,4S,Z)-l-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-yl)-2- oxo-4-phenyl-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid;
2-((3 S,4R)-4-isopropyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid;
2-((3S,4R)-4-isopropyl-l-(4-(2-(6-methoxypyridin-3- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
2-((3 S,4S,7R)-7-acetamido- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-2- oxo-4-phenylazocan-3-yl)acetic acid;
2-((3 S,4S,7R)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-7- (methylsulfonamido)-2-oxo-4-phenylazocan-3-yl)acetic acid;
2-((3S,4S,8S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-8- (hydroxymethyl)-2-oxo-4-phenyl-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
2-((6S,7S)-4-(4-(2-chlorophenyl)thiazol-2-yl)-5-oxo-7-phenyl-l,4- oxazepan-6-yl)acetic acid;
2-((5 S,6S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-3 ,7-dioxo-5-phenyl- 1 ,4-diazepan-6-yl)acetic acid;
2-(4-(4-(2-chlorophenyl)thiazol-2-yl)-2,5-dioxo-7-phenyl- 1 ,4- diazonan-6-yl)acetic acid;
2-((3 S,4R,Z)-4-benzyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
2-((3 S,4R)-4-benzyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 -yl)pyridin-
3- yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid;
2-((3S,4S,7S)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2,3,4,7-
tetrahydro-lH-azepin-3-yl)acetic acid;
74 2-((3 S,4R,7S)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo- 1 -(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl)thiazol-2-yl)azepan-3 - yl)acetic acid;
75 2-((3 S,4S,7R)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo- 1 -(4-(2-(6-(2- oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2, 3,4,7- tetrahydro-lH-azepin-3-yl)acetic acid;
76 2-((3S,4R,7R)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-l-(4-(2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl)thiazol-2-yl)azepan-3 - yl)acetic acid;
77 2-((3 S,4S)-4-(2-chlorophenyl)- 1 -(2'-methoxy-[ 1 , 1 '-biphenyl]-4-yl)-2- oxoazocan-3-yl)acetic acid;
78 2-((3 S,4R,Z)-4-cyclobutyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8-hexahydroazocin-3- yl)acetic acid;
79 2-((3 S,4R)-4-cyclobutyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid;
80 2-((3 S,4R)-4-cyclopropyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3-yl)acetic acid;
81 2-((3 S,4R,Z)-4-cyclopropyl-2-oxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
82 2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7- (hydroxymethyl)-2-oxoazocan-3-yl)acetic acid;
83 2-((3 S,4R,7S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7- (hydroxymethyl)-2-oxoazocan-3-yl)acetic acid;
84 2-((3S,4R,7R)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo-l-(4-(2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl)thiazol-2-yl)azocan-3 - yl)acetic acid;
85 2-((3 S,4R,7S)-4-cyclopentyl-7-(hydroxymethyl)-2-oxo- 1 -(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3- yl)acetic acid;
86 2-((3S,4R,7R)-7-acetamido-l-(4-(2-chlorophenyl)thiazol-2-yl)-4- cyclopentyl-2-oxoazocan-3-yl)acetic acid;
87 2-((3S,4R,7R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-7- (methylsulfonamido)-2-oxoazocan-3-yl)acetic acid;
88 2-((3S,4R,7R)-7-acetamido-4-cyclopentyl-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3- yl)acetic acid;
89 2-((3S,4R,7R)-4-cyclopentyl-7-(methylsulfonamido)-2-oxo-l-(4-(2- (6-(2-oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3- yl)acetic acid;
90 2-((3S,4R,8S,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-8- (hydroxymethyl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid;
91 2-((3S,4R,8S,Z)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-l-(4-(2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)- 1 ,2,3,4,5,8-
hexahydroazocin-3-yl)acetic acid;
92 2-((3S,4R,8R,Z)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-8- (hydroxymethyl)-2-oxo-l,2,3,4,5,8-hexahydroazocin-3-yl)acetic acid;
93 2-((3S,4R,8R,Z)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-l-(4-(2-(6- (2-oxopyrrolidin-l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-l,2,3,4,5,8- hexahydroazocin-3-yl)acetic acid;
94 2-((3 S,4R,8S)- 1 -(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-8- (hydroxymethyl)-2-oxoazocan-3-yl)acetic acid;
95 2-((3S,4R,8S)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-l-(4-(2-(6-(2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)azocan-3- yl)acetic acid;
96 2-((3S,4R,8R)-l-(4-(2-chlorophenyl)thiazol-2-yl)-4-cyclopentyl-8- (hydroxymethyl)-2-oxoazocan-3-yl)acetic acid;
97 2-((3S,4R,8R)-4-cyclopentyl-8-(hydroxymethyl)-2-oxo-l-(4-(2-(6- (2-oxopyrrolidin- 1 -yl)pyridin-3 -yl)phenyl)thiazol-2-yl)azocan-3 - yl)acetic acid;
98 2-((6S,7R)-7-cyclopentyl-5-oxo-4-(4-(2-(6-(2-oxopyrrolidin-l- yl)pyridin-3-yl)phenyl)thiazol-2-yl)- 1 ,4-oxazepan-6-yl)acetic acid;
99 2-((5R,6S)-5-cyclopentyl-3 ,7-dioxo- 1 -(4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)- 1 ,4-diazepan-6-yl)acetic acid;
100 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-((S)-3-methyl-2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxo- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
101 2-((3 S,4R,Z)-4-cyclopentyl- 1 -(4-(2-(6-((R)-3-methyl-2- oxopyrrolidin- 1 -yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxo- 1 ,2,3,4,5, 8-hexahydroazocin-3-yl)acetic acid;
102 2-((3S,4R)-4-cyclopentyl- 1 -(4-(2-(6-((S)-3-methyl-2-oxopyrrolidin- l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
103 2-((3 S,4R)-4-cyclopentyl- 1 -(4-(2-(6-((R)-3-methyl-2-oxopyrrolidin- l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
104 2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-((S)-3-fluoro-2-oxopyrrolidin- l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8- hexahydroazocin-3-yl)acetic acid;
105 2-((3S,4R,Z)-4-cyclopentyl- 1 -(4-(2-(6-((R)-3-fluoro-2-oxopyrrolidin- l-yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8- hexahydroazocin-3-yl)acetic acid;
106 2-((3S,4R)-4-cyclopentyl- 1 -(4-(2-(6-((S)-3-fluoro-2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
107 2-((3 S,4R)-4-cyclopentyl- 1 -(4-(2-(6-((R)-3-fluoro-2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
108 2-((3S,4R,Z)-4-cyclopentyl- 1 -(5-fluoro-4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxo-l,2,3,4,5,8- hexahydroazocin-3-yl)acetic acid;
109 2-((3S,4R)-4-cyclopentyl- 1 -(5-fluoro-4-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
2-((3 S,4R,Z)-4-cyclopentyl-2-oxo- 1 -(3-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)-l,2,4-thiadiazol-5-yl)-l, 2,3,4, 5,8- hexahydroazocin-3-yl)acetic acid;
2-((3S,4R)-4-cyclopentyl-2-oxo- 1 -(3-(2-(6-(2-oxopyrrolidin- 1 - yl)pyridin-3-yl)phenyl)- 1 ,2,4-thiadiazol-5-yl)azocan-3-yl)acetic acid;
2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
2-((3S,4R)-4-cyclopentyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
2-((3S,4R,Z)-4-cyclopentyl-l-(4-(2-(6-methoxypyridazin-3- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
2-((3S,4R)-4-cyclopentyl-l-(4-(2-(6-methoxypyridazin-3- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid;
2-(l-isopropyl-4-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2-yl)-
3,8-dioxo-l,4-diazocan-2-yl)acetic acid;
2-((3S,4R,Z)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxo-l, 2,3,4,5, 8-hexahydroazocin-3- yl)acetic acid;
2-((3S,4R)-4-isopropyl-l-(4-(2-(5-methoxypyrazin-2- yl)phenyl)thiazol-2-yl)-2-oxoazocan-3-yl)acetic acid; and
2-(l-cyclopentyl-4-(4-(2-(6-methoxypyridin-3-yl)phenyl)thiazol-2- yl)-3,8-dioxo-l,4-diazocan-2-yl)acetic acid. harmaceutically acceptable salts, solvates and prodrugs thereof.
13. A pharmaceutical composition comprising a compound according to any of Claims 1 to 12 or a pharmaceutically acceptable salt, solvate or prodrug thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.
14. Medicament comprising a compound according to any of Claims 1 to 12 or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a composition according to Claim 13.
15. A compound according to any of Claims 1 to 12 or a pharmaceutically acceptable salt, solvate or prodrug thereof for treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.
16. Use of a compound according to any of Claims 1 to 12 or a pharmaceutically acceptable salt, solvate or prodrug thereof as a modulator of GPR43 receptor activity.
17. Use according to Claim 16 wherein the compound is an agonist or partial agonist of GPR43 receptor activity.
18. A compound of formula A
wherein,
Ra is chloro and Rb is isopropyl, isobutyl, cyclopropyl, cyclopentyl, tetrahydropyran- phenyl, or biphen-4-yl; or
Ra is 2-methoxypyridin-5-yl and Rb is isopropyl, cyclopentyl or phenyl; or
Ra is 2-methoxypyrazin-5-yl and Rb is isopropyl; or
Ra is 2-(2-oxopyrrolidin-l-yl)pyridin-5-yl and Rb is isopropyl, cyclopentyl or phenyl.
Rc is 2-methoxypyridin-5-yl and Rd is isopropyl or cyclopentyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305600.8 | 2010-06-04 | ||
EP10305600 | 2010-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011151436A2 true WO2011151436A2 (en) | 2011-12-08 |
WO2011151436A3 WO2011151436A3 (en) | 2012-02-02 |
Family
ID=42734636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/059181 WO2011151436A2 (en) | 2010-06-04 | 2011-06-03 | Novel compounds, method for use them and pharmaceutical composition containing them |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011151436A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2015078949A1 (en) * | 2013-11-27 | 2015-06-04 | Euroscreen Sa | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2021018786A1 (en) | 2019-07-26 | 2021-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN114685374A (en) * | 2020-12-28 | 2022-07-01 | 山东道一医药科技有限公司 | Novel process for synthesizing olaparib |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4855777B2 (en) * | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | Phenylpropanoic acid derivatives |
US7442693B2 (en) * | 2004-05-28 | 2008-10-28 | Smithkline Beecham Corporation | Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors |
GB2418427A (en) * | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
US20060160869A1 (en) * | 2005-01-05 | 2006-07-20 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
US20100261708A1 (en) * | 2007-10-25 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Diazepane Compounds Which Modulate The CB2 Receptor |
-
2011
- 2011-06-03 WO PCT/EP2011/059181 patent/WO2011151436A2/en active Application Filing
Non-Patent Citations (17)
Title |
---|
AHREN BO, NATURE REVIEWS, vol. 8, 2009, pages 369 - 385 |
BARTOLI ET AL., J. MED. CHEM., vol. 41, 1998, pages 1855 - 68 |
COVINGTON ET AL., BIOCHEMICAL SOCIETY TRANSACTION, vol. 34, 2006, pages 770 - 773 |
E. L. ELIEL, S. H. WILEN, L. N. MANDER: "Stereochemistry of Organic Compounds", 1994, WILEY- INTERSCIENCE |
FUSS, CURR DRUG TARGETS INFLAMM ALLERGY, vol. 2, 2003, pages 101 - 112 |
GE ET AL., ENDOCRINOLOGY, vol. 149, 2008, pages 4519 - 4526 |
LAROCK, R. C.: "Comprehensive Org Transf", 1999, WILEY, pages: 709 - 719 |
LE POUL ET AL., J. BIOL CHEM., vol. 278, 2003, pages 25481 - 489 |
MASLOWSKI ET AL., NATURE, vol. 461, no. 7268, 2009, pages 1282 - 1286 |
MILLIGAN ET AL., BJP, vol. 158, 2009, pages 146 - 153 |
RAYASAM ET AL., EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 11, 2007, pages 661 - 671 |
REGARD ET AL., J. CLIN. INV., vol. 117, 2007, pages 4034 - 4043 |
RUDOLPH, J., TETRAHEDRON, vol. 56, 2000, pages 3161 |
SWAIN ET AL., J. MED. CHEM., vol. 34, 1991, pages 140 - 151 |
TEDELIND ET AL., WORLD J. GASTROENTEROL, vol. 13, no. 20, 2007, pages 2826 - 2832 |
TIWARI, CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 11, no. 4, 2010, pages 385 - 393 |
WHITE ET AL., J. MED. CHEM., vol. 39, 1996, pages 4382 - 95 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
EA032271B1 (en) * | 2013-11-27 | 2019-05-31 | Огеда Са | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
EP3610872A1 (en) | 2013-11-27 | 2020-02-19 | Epics Therapeutics | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
CN105916500A (en) * | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
JP2017503758A (en) * | 2013-11-27 | 2017-02-02 | オゲダ エス.エー. | Compounds, pharmaceutical compositions, and methods for use in the treatment of inflammatory diseases |
US9770435B2 (en) | 2013-11-27 | 2017-09-26 | Ogeda Sa | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
CN114773249A (en) * | 2013-11-27 | 2022-07-22 | 艾匹克治疗公司 | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases |
JP2019178152A (en) * | 2013-11-27 | 2019-10-17 | エピックス セラピューティクス | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
KR20160079907A (en) * | 2013-11-27 | 2016-07-06 | 유로 스크린 에스.에이. | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
KR102259934B1 (en) * | 2013-11-27 | 2021-06-03 | 에픽스 테라퓨틱스 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
WO2015078949A1 (en) * | 2013-11-27 | 2015-06-04 | Euroscreen Sa | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
CN114773249B (en) * | 2013-11-27 | 2024-08-16 | 艾匹克治疗公司 | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2021018786A1 (en) | 2019-07-26 | 2021-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection |
CN114685374A (en) * | 2020-12-28 | 2022-07-01 | 山东道一医药科技有限公司 | Novel process for synthesizing olaparib |
CN114685374B (en) * | 2020-12-28 | 2024-04-12 | 山东道合药业有限公司 | Novel process for synthesizing Olaparib |
Also Published As
Publication number | Publication date |
---|---|
WO2011151436A3 (en) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011151436A2 (en) | Novel compounds, method for use them and pharmaceutical composition containing them | |
US9242977B2 (en) | Trk-inhibiting compound | |
AU2014315109B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
CN112424201B (en) | Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death | |
AU2016340264A1 (en) | 2,4-dihydroxy-nicotinamides as APJ agonists | |
WO2006043490A1 (en) | Pyrimidine derivative fused with nonaromatic ring | |
AU2016270903A1 (en) | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders | |
WO2006040966A1 (en) | Aromatic-ring-fused pyrimidine derivative | |
AU2017237930A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
CN101874030A (en) | Pyrrolidines and piperidines as orexin receptor antagonists | |
AU2014356460B2 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
AU2015292833A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
EP2513053A1 (en) | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) | |
JP2011521888A (en) | N-phenylhydrazide derivatives as modulators of ghrelin receptors | |
DK3207039T3 (en) | Aldosterone synthase inhibitors | |
KR20200099557A (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1, as a Trk kinase inhibitor for treating cancer 5-a]pyrimidine derivatives and related compounds | |
US10947218B2 (en) | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | |
TW201217362A (en) | Heteroaryls and uses thereof | |
EP3512845A1 (en) | Hepatitis b core protein modulators | |
EP2089397A1 (en) | 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists | |
WO2016029454A1 (en) | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
WO2011076732A1 (en) | Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders | |
WO2011076734A1 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
WO2016123275A1 (en) | Aldosterone synthase inhibitors | |
WO2015009609A1 (en) | Inhibitors of leukotriene production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11725400 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11725400 Country of ref document: EP Kind code of ref document: A2 |